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Abstract  
Dr Deborah Kendall. The University of Manchester. MD thesis. 2011 
Title: Metformin in Obese Children and Adolescents (MOCA) Trial.  
Background and objective: Childhood obesity is a serious global health problem and it is associated with 
insulin resistance and significantly increased risk for development of type 2 diabetes and cardiovascular 
disease. Metformin reduces the risk of developing T2D in adult patients with obesity and insulin resistance. 
However there is limited and inconclusive data in obese non diabetic children and adolescents. The 
objective of the Metformin in Obese Children and Adolescents (MOCA trial) was to assess the effect of 
metformin on body composition, metabolic risk factors and adipokines.  
Design and methods: The MOCA trial was a six month multi-centre randomized, double-blind placebo-
controlled trial of metformin (1.5g daily) in children and adolescents (8-18 years) with insulin resistance 
and/or impaired glucose tolerance. Auxology, blood pressure measurement and fasting blood tests 
(insulin, glucose, fasting lipids, ALT, bilirubin, CRP, lactate, resistin, adiponectin, leptin) were performed at 
baseline, three and six months. A prolonged oral glucose tolerance test was performed at baseline and after 
six months. Measures of insulin resistance/sensitivity were calculated including HOMA-IR and the 
adiponectin: leptin (A/L) ratio.  
Results: 151 obese children participated in the trial (metformin:77, placebo:78). 102 (67.5%) female, 99 
(65.6%) post-pubertal, 115 (76.2%) White British and 36 (23.8%) British Asian or Afro-Caribbean. Mean 
age of participants was 13.7 ±2.3 year and mean BMI-SDS 3.4 (0.5). In regression analysis, controlling for 
baseline values, sex, ethnicity and pubertal status, metformin had a greater treatment effect over placebo 
for BMI at three months, that was sustained at six months (-0.25 kg/m2, p=0.01, 95% CI 0.29 to 1.86) and 
BMI-SDS (-0.1, p=0.01, 95% CI 0.02 to 0.19).  Fasting glucose reduced (-0.03 mmol/l, p=0.03) and A/L 
ratio increased at three months (+0.04, p=0.03), but the improvements were lost at six months. The other 
measures of insulin sensitivity, metabolic risk factors and concentrations of adipokines did not change with 
metformin treatment.  
Conclusions: Metformin therapy for obese children with abnormal insulin glucose status is safe, well 
tolerated and has a small beneficial treatment effect over placebo for BMI, BMI-SDS, fasting glucose and 
A/L ratio at three months, with the changes in body composition sustained at six months. A three month 
course of metformin should be considered by Paediatricians to halt the inexorable rise in BMI-SDS in 
these children, improve insulin glucose status and act as catalyst and support for more radical change in 
lifestyle in the individual. Trial register number: ISRCTN 19517475. 
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Chapter 1: Introduction 
 
Background 
The increased global prevalence of childhood obesity over the last two decades has led to the 
emergence of childhood type 2 diabetes(T2D) and insulin resistance syndrome (IRS), conditions 
previously only encountered in adult medicine. Insulin resistance (IR) leading to the development of 
impaired glucose tolerance (IGT) is the underlying metabolic abnormality in both these conditions 
and can be considered a pre-diabetic state. IRS and T2D in childhood are associated with significant 
future health problems such as premature cardiovascular disease and premature death. 
Paediatricians in the UK are now frequently referred obese children with IR and related disorders 
such as fatty liver, but the evidence to support the development of treatment guidelines, other than 
for T2D, is deficient. Early detection and treatment of IR in childhood may be beneficial to prevent 
deterioration and development of T2D early in life. In adults progression from IR to T2D can be 
reduced by lifestyle intervention or metformin treatment and evidence from large studies exists, 
with the subsequent development of treatment guidelines. Some relatively small studies have also 
shown this effect in adolescents, but there have been conflicting results and no large randomised 
controlled trials to date, hence the development of the Metformin in Obese Children and 
Adolescents Trial (MOCA Trial).  
 
Key message: Identification and treatment of the metabolic consequences of childhood obesity is 
essential, both to improve the immediate health of the child and to prevent future morbidity and 
premature mortality.  The evidence for treatment of insulin resistance and prevention of T2D is 
deficient in children. The MOCA trial aims to establish the role of metformin in the treatment of IR 
and IGT in obese children. 
 
Example Case Study 
It is useful to consider an individual case of childhood obesity to illustrate the clinical picture and 
treatment decisions faced by Paediatricians.  
Gemma was a thirteen year old girl who was referred to the Paediatric Endocrine clinic from her 
General Practitioner. Both she and her parents were concerned about her weight gain over the 
previous three years, which coincided with her entering puberty and subsequently achieving 
menarche at the age of 12 years. Gemma had attempted various diets, joined a slimming club and 
increased her exercise to swimming twice per week and walking around a mile to school each day. 
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Gemma‟s mother was obese and she was under investigation for abnormal glucose tolerance with her 
GP. She also had a history of gestational diabetes. The paternal grandmother developed T2D in her 
mid fifties and there was also a strong family history of coronary artery disease. 
Gemma weighed 97.5Kg and her height was 159.7cm. Her BMI was 38.2 kg/m2 and the BMI-SDS was 
3.62. Her waist circumference was 103.6 cm, hip circumference 121.5 cm and waist:hip ratio was 
0.85. On examination, Gemma had Acanthosis Nigricans in her axillae and around her neck. Her 
blood pressure was normal. 
 
 
Figure 1: Acanthosis Nigricans in axilla 
 
Gemma was investigated with fasting insulin and glucose, thyroid function, liver function tests and 
fasting lipids. The results showed normal fasting glucose, thyroid function and liver function tests. 
Her Cholesterol was raised at 5.3mmol/l and her fasting insulin was elevated at 40.9 mIU/l. 
She was subsequently further investigated with an oral glucose tolerance test which showed a 
significantly elevated insulin at 120 minutes of 119 mIU/l and a glucose of 8.1 mmol/l (impaired 
glucose tolerance). 
Gemma returned to the clinic three months after her first visit and the results were discussed with 
her and her family. It was explained to Gemma and her family that Gemma had hyperinsulinaemia 
and impaired glucose tolerance, which was not only detrimental to her current health but could 
potentially put her at risk of developing T2D in the future. Gemma was very keen to try 
pharmacological intervention and was first started on Orlistat, a lipase inhibitor. However she 
returned to clinic after six weeks complaining of abdominal discomfort and loose stools and the 
Orlistat was stopped. 
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Gemma was then started on metformin 500 mg once per day, increasing to twice per day after a 
week. Her lactate was checked prior to starting on metformin and the result was normal. Gemma 
also consulted the dietician and was given advice regarding increasing her exercise. 
Gemma returned to clinic nine months later, with an oral glucose tolerance test six weeks prior to 
the appointment. She reported some loose stools with the twice daily dose of metformin, but this 
settled after two weeks of taking the drug. She also reported that she felt her appetite was reduced 
on the metformin. The oral glucose tolerance test showed an improved fasting and 120 minute 
insulin (25 mIU/l and 88 mIU/l respectively) and her impaired glucose tolerance had reverted to 
normal. In addition she had lost 6.5 kg in weight. Her lactate remained normal. 
Gemma was pleased and encouraged by the improvement and the metformin was discontinued. On 
further review Gemma‟s weight stabilised and her insulin and glucose levels remained normal one 
year later when she was discharged from clinic. 
 
Key message: Gemma is one of a number of children who received metformin for hyperinsulinaemia 
and impaired glucose tolerance and achieved a positive outcome, both in terms of her weight loss 
and stabilisation and her insulin glucose status. A small audit of all the children in the Paediatric 
Endocrine clinic who were treated with metformin, showed similar results. Some patients 
discontinued the drug due to side effects of abdominal pain or loose stools and some decided to stop 
for other reasons. Individual cases such as Gemmas‟ and the results of this small audit in Manchester 
motivated the development of the protocol and bids for funding for the MOCA trial. The main 
objective of the MOCA trial was to establish firm evidence to support or refute the use of metformin 
in this category of patient. 
 
 
Childhood Obesity 
Definition  
Obesity in its simplest term means excess adiposity. In adults the body mass index (BMI: 
weight/height2) is used to define overweight and obesity with a cut off at 25 kg/m2 for overweight 
and 30kg/m2 for obesity1. However the BMI in childhood changes substantially with age and these 
adult cut-offs cannot be used. Therefore age and sex specific cut-off points have been developed. In 
the UK, the cut-offs for overweight and obesity in children are defined as 91st and 98th centiles on 
the 1990 sex and age specific BMI reference charts2. Epidemiological evidence relating to increased 
health risk supports the use of the cut-offs in adults3 and the corresponding centile cut-offs in 
children are also associated with increased morbidity4. 
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Prevalence 
Globally, the International Obesity Taskforce has stated that at least 155 million (10%) school age 
children are overweight or obese and 30-45 million (2-3%) are categorised as obese. In the United 
States (US), adult obesity prevalence was documented at 32.2% in men and 35.5% in women5.  In 
children from the US, the National Health and Nutrition Examination Study 2007-2008 reported 
obesity prevalence of 17% in twelve to nineteen year olds6. The Bogalusa Heart Study in Louisiana 
examined trends in childhood obesity in five to seventeen year olds over a thirty-five year period 
from 1973 to 2009. Overweight prevalence (including obesity) increased from 14.2% to 48.4% and 
obesity prevalence increased from 5.6% to 30.8% during that timeframe7. 
In the United Kingdom there have been several studies demonstrating markedly increased levels of 
obesity in children and adolescents over the last fifteen years. The Health Survey for England, based 
on national data, has published a report that documents significantly increased prevalence of 
obesity among adults and children aged two to fifteen years. Adult obesity prevalence increased 
from 13% to 24% in men and from 16% to 25% in women between 1993 and 2008. In children, 
between 1995 and 2008, prevalence of obesity increased from 11.1% to 16.8% in boys and from 12.2% 
to 15.2% in girls. Prevalence of overweight has remained unchanged at 14.6% in boys and 14% in girls 
in 20088. Overall, 30.3% of children in 2008 were overweight or obese. However the trend may 
suggest that the increase is flattening out, with a slight fall in obesity for girls from a peak in 2005 
and a stabilisation in boys to between 17-19% (figure 2). 
 
Figure 2: Obesity Prevalence of UK Children aged 2-15 years8 
 
 
In the North-West region of the UK the prevalence of obese pre-school children increased from 5.4% 
to 9.2% over a nine year period (1989 to 1998)9. Further data from the North West has been obtained 
from the National Child Measurement Scheme started in 2006, which measures children in reception 
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and year six. Obesity in the North-West varied between Primary Care Trust‟s from 10.89% in Leigh 
and Wigan to 17.87% in West Cheshire10.  Higher rates of obesity were observed in the areas with the 
highest deprivation score. 
Further support is needed to halt this rise in obesity and to develop evidence based treatment 
strategies for childhood obesity and this is emphasised by the Government‟s scientific experts 
committee FORESIGHT, that predicts 55% of boys and 70% of girls will be overweight or obese by 
205011. 
Aetiology 
The increased prevalence of childhood obesity is multi-factorial and includes both genetic and 
environmental factors, including reduced activity levels and a change in diet. Data suggests that 60-
80% of the variance in childhood body weight can be accounted for by genetic factors12 and yet the 
rapid rise in obesity over the last decade cannot be accounted for by a rapid change in the gene 
pool, but rather by a change in environmental factors resulting in a positive calorie balance and 
weight gain. Calorie consumption in excess of calories expended results in a positive energy balance 
and excess energy is stored as fat, with the end result of increased adiposity and weight gain.  
A „thrifty genotype‟ hypothesis has been proposed as an explanation for the rapid rise in obesity 
associated with IR and T2D13. This theory suggests that humans have evolved a genetic trait that 
enables us to preferentially store calories as fat and to have metabolic efficiency, so that we could 
survive periods of starvation. Natural selection then favoured genetic polymorphisms that 
predisposed humans to overeat whenever excessive energy was available, in order to lay down fat 
for future starvation periods. This genetic advantage that favoured human survival historically in 
times of food deficit is now a genetic disadvantage in times of food excess and leads to over-eating 
behaviours and obesity. 
The socio-cultural environment now plays a major role in determining who becomes obese. This has 
been termed the „obesogenic‟ environment. The factors that contribute towards this obesogenic 
environment are multi-factorial. Increased car and public transport use, television watching, 
computer games and internet use all contribute to reduced energy expenditure and this has been 
linked to weight gain in several childhood studies. Reduced activity in adolescence has been 
associated with increased prevalence of obesity. A longitudinal study in 2287 girls (ages 9-19 years) 
found that at age 18-19 years, the inactive girls BMI was 2-3kg/kg2 higher than that of the active 
girls14.   
Dietary factors include a trend towards use of convenience foods that contain high levels of fat and 
sugar and a move away from freshly prepared family meals. „Junk food‟ advertising during children‟s 
television programmes and branding of products with cartoon characters contribute to children‟s 
desire for these unhealthy foods.  
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Several steps have been embarked upon to try and reduce childhood obesity in the population. 
Public health programmes to improve diet exist in the UK and school meals have been scrutinised. 
There are now government led initiatives for the provision of healthy food in school (£2 million Food 
in Schools Programme). These include the free national school fruit scheme for primary children, 
minimum nutritional standards for school meals and removal of „junk food‟ from school vending 
machines15. 
Consequences of childhood obesity 
Evidence suggests that childhood obesity has both short and long term health consequences16. Short 
term problems include psychological conditions (low self-esteem, behavioural problems, eating 
disorders and depression), increased cardiovascular risk, respiratory problems (obstructive sleep 
apnoea, asthma), orthopaedic disorders (slipped upper femoral epiphysis, knee and joint problems 
causing difficulty with mobility), menstrual irregularity, polycystic ovarian syndrome (PCOS) and 
T2D. Longer term consequences of childhood obesity include social and economic disadvantage, 
increased risk of certain cancers including colon, breast, kidney, oesophagus and endometrium, 
persistence of obesity and co-morbidity into adulthood, increased cardiovascular disease and 
increased risk of premature mortality in adulthood.  
Once children and adolescents become obese the evidence suggests that they have a high risk of 
maintaining their obesity into adulthood. A US study found that 69% of children who were obese at 
6-9 years and 83% of adolescents, who were obese at 10-14 years, were also obese as adults17. In 
addition childhood obesity has a significant impact on adult health, even independently of adult 
weight18. 
 
Key Messages: Childhood obesity is defined using centiles on sex specific BMI charts. One third of 
UK children are overweight or obese and by 2050 this could have doubled. The causes of 
childhood obesity are multi-factorial. Childhood obesity is associated with both short and long 
term health problems that may significantly reduce an individual’s life expectancy.  
 
Insulin Resistance  
Insulin resistance (IR) means impairment in the metabolic actions of insulin and it is the underlying 
abnormality in both T2D and insulin resistance syndrome (IRS). In addition IR has been associated 
with obesity, IRS, hypertension and cardiovascular disease in adults. In children IR has similarly been 
related to obesity, IRS and cardiovascular abnormalities19. However there is a lack of clarity 
regarding assessment of IR in childhood and how it can be treated or prevented. 
The causes of IR are complex and involve multiple genetic, metabolic and environmental factors. 
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Genetic predisposition to IR is apparent with T2D more commonly diagnosed in certain ethnic 
populations, in subjects with a positive family history and concordance in monozygotic twins is 80-
100%, more than twice that in dizygotic twins20. However the rapid increase in the prevalence of 
T2D over the last ten years which mirrors the rise in obesity cannot be explained by changes in the 
gene pool, as these do not occur at such a rapid rate. As with obesity, environmental factors must 
play a large part and act upon a background of genetic predisposition.   
The foetal and early infant environment is important to consider and Barker‟s “fetal origins of adult 
disease hypothesis” or “thrifty phenotype hypothesis” also linked intrauterine growth retardation 
with IR and other major risk factors for cardiovascular disease in adults21. Barker developed this 
hypothesis to explain the association of low birth weight in the early decades of the twentieth 
century, with increased risk of cardiovascular disease in adults from this generation22. He proposed 
that if there are periods of under nutrition at critical periods of foetal and infant growth, nutrients 
are diverted preferentially to the developing central nervous system and away from other organs. 
This may then lead to permanent structural and metabolic changes in these organs and predispose 
an individual to coronary heart disease. These changes include skeletal underdevelopment, vascular 
abnormalities and reduced β-cell mass in the pancreas. Subsequent excess weight gain in childhood 
was identified as an additional risk factor, with the highest risk of glucose intolerance in subjects 
having the lowest birth weights who subsequently developed obesity. 
IR is defined as the decreased tissue response to insulin-mediated actions within cells. It is the 
inverse of insulin sensitivity. IR refers to the whole body reduced uptake of glucose in response to 
insulin and resultant changes in glucose and insulin levels. The cellular mechanisms of IR are 
complex and understanding of normal glucose-insulin homeostasis is required.  
The metabolic actions of insulin include: 
1. reduction of glucose production from the liver; 
2. stimulation of glucose uptake in muscle, liver and adipose tissue;  
3. promotion of glucose storage as glycogen;  
4. reduction of adipocyte lipolysis;  
5. inhibition of ketogenesis;  
6. regulation of protein turnover and  
7. effects on electrolytes. 
Blood glucose regulation depends on the balance between insulin secretion from pancreatic β-cells 
and insulin action in peripheral tissues. Insulin is released from pancreatic β-cells in response to a 
rise in blood glucose and its actions are mediated via insulin receptors.   Insulin receptors are 
present in the membrane of almost all cells in the human body, with the main targets for insulin 
action being hepatocytes, skeletal myocytes and adipocytes. 
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Understanding of insulin signalling pathways has progressed in recent years. There are two main 
pathways activated by insulin binding to its receptor, the phosphatidylinositol-3‟-kinase (P13K) 
pathway and the mitogen-activated protein (MAP) kinase pathway. The P13K pathway mediates the 
metabolic effects of insulin and the MAP kinase pathway is associated with cell growth and 
proliferation and pro-coagulant effects23. 
The insulin receptor is a heterotetrameric structure comprised of two extracellular α sub-units and 
two membrane spanning sub-units, linked together by disulphide bonds. The α sub-unit has an 
inhibitory effect on autophosphorylation, which is released when insulin binds to it. This 
autophosphorylation at tyrosine sites within the β subunit is a key feature in insulin signalling and 
activates a cascade of post-receptor signalling events, involving the insulin receptor substrate (irs) 
family of proteins. Phosphorylation of irs leads to formation of docking sites for proteins including 
P13K and growth factor receptor-binding protein 2 (Grb2). Further phosphorylation 
/dephosphorylation cascades lead to translocation of glucose transporters (GLUT-4) to the cell 
membrane and subsequent transport of glucose into the cell with activation of glycogen synthase 
(GS). 
Insulin resistance may result from one of two main mechanisms: 
1. Receptor defects: There a number of inherited severe receptor defects including type A 
insulin resistance, Rabson-Mendenhall syndrome and Leprechaunism.  
2. Post-binding defects: Defects in signalling pathways, down-stream of insulin binding at the 
insulin receptor, may account for the insulin resistance in T2D. 
Obesity is a significant risk factor for IR, although not all obese children are insulin resistant and IR 
can occur in non-obese children and adults24,25,26,27. IR can also occur in normal physiological 
conditions such as puberty and pregnancy. However most children with T2D are severely obese and 
the mechanisms underlying the role of adipose tissues and how increased adiposity is linked with 
insulin resistance and IGT are beginning to emerge. Accumulation of visceral fat is a critical factor, 
possibly due to increased delivery of fat directly to the liver via the portal circulation. A strong 
relationship between IR and visceral fat has been demonstrated in obese children28. Growth of 
visceral fat in childhood is associated with rising fasting insulin concentrations, demonstrated by a 
study that reported a 5% annual increase in fasting insulin with each 1cm2 increase in visceral fat29. 
Additionally IR in both adults and children has been associated with accumulation of 
intramyocellular lipid within muscles and this is believed to be involved in mediating peripheral IR 
30. 
Clinical expression of the T2D phenotype is characterised by three basic defects of insulin 
metabolism which evolve over time:  
1. Peripheral insulin resistance in skeletal muscle and adipose tissue 
2. Compensatory rise in insulin levels (hyperinsulinaemia) 
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3. Gradual β-cell failure with reduced insulin secretion, increased hepatic glucose production 
and hyperglycaemia31. Post-prandial hyperglycaemia (IGT) is often the first glucose 
abnormality to become apparent, usually well before the development of fasting 
hyperglycaemia.  
In adults the decline in β-cell function with development of T2D occurs over five to ten years, 
depending on the population studied32. Longitudinal data in adults indicates that progression from 
IGT to T2D occurs in this time-frame in one third of subjects, one third remain IGT and one third 
revert to normal glucose tolerance (NGT). In obese children, a study in one hundred and seventeen 
adolescents over a two year period, found that approximately 10% of subjects initially classified as 
NGT developed IGT and T2D developed in 24% of children initially classified as IGT. Severe obesity, 
IGT and African-American ethnicity were the best predictors of developing T2D. Transition from IGT 
to NGT occurred in 32.3% and this was associated with the least amount of weight gain. The authors 
concluded that in children the tempo of progression may be quicker than in adults, with more rapid 
deterioration of IGT to T2D33. The increased speed of deterioration in glucose tolerance in 
childhood, also seen in the experience in a UK clinic (chapter 2), supports the requirement for 
evidence to support treatment options for IR and IGT such as metformin. 
Longitudinal studies including a prospective study of Pima Indians documented that insulin resistance 
was the strongest single predictive factor for development of T2D34. A twenty-five year study that 
followed one hundred and fifty-five children of couples who both had T2D, found that subjects who 
developed T2D had insulin resistance for more than ten years before development of overt 
diabetes35. Identification of IR in children may thus provide a window of opportunity for appropriate 
intervention to prevent the progression to T2D. 
The cellular mechanisms for IR are under investigation worldwide. Euglycaemic hyperinsulinaemic 
clamp studies show that over 75% of infused glucose is taken up by skeletal muscle tissue and so it is 
evident that IR is primarily determined by the change in response of skeletal muscle36. Magnetic 
resonance spectroscopy has been used to show that decreased insulin-stimulated muscle glycogen 
synthesis, due to a defect in insulin-stimulated glucose transport activity, is a major factor in the 
pathogenesis of T2D37 and fat-induced IR.  In skeletal muscle, increases in intramyocellular lipid 
metabolites such as fatty acyl coA‟s and diacylglycerol activate a serine/threonine kinase cascade, 
thus leading to defects in insulin signalling through Serine/Threonine (Ser/Thr) phosphorylation of 
IRS-1 (see figure 3). A similar mechanism exists in the liver where increases in hepatocellular 
diacylglycerol activate Protein Kinase C (PKC), leading to reduced insulin-stimulated tyrosine 
phosphorylation of IRS-2. Furthermore this study also showed reduced mitochondrial function in lean 
IR offspring of parents with T2D, which may predispose these individuals to intramyocellular lipid 
accumulation and IR. 
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Figure 3: The mechanism of fat-induced IR in skeletal muscle 
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Adiposity leads to increases in intramyocellular long chain fatty acyl CoA‟s (LCFA-CoA) and diacylglycerol (DAG) due to 
increased delivery from plasma and/or reduced β-oxidation due to mitochondrial dysfunction. This activates serine/threonine 
kinases such as protein kinase (PKC), leading to phosphorylation of serine residues on IRS-1, inhibiting insulin induced P13-
kinase activity, resulting in reduced insulin-induced AKT2 activity. Reduced AKT2 activity fails to activate GLUT4 
translocation and other AKT2 dependent downstream events such as Glycogen Synthetase (GS) activity.  
The final result of increased fatty acid delivery to the cell is reduced insulin-induced glucose uptake.  
 
Diagnostic standards for IR in children are currently unstandardised and variable. Research in this 
area has been with small cohort sizes and so the normal distribution for fasting insulin and measures 
of IR have not been established. In addition the prevalence of IR in the childhood population is 
unknown, variable methods have been used to measure IR and long term studies where IR in 
childhood is related to outcome are few in number. Fasting insulin as an index of IR has been used in 
many studies, as it is an easy to use measurement. However it is not optimal for assessing peripheral 
insulin sensitivity, rather the compensatory rise in insulin. Furthermore fasting insulin is not always 
well correlated with measures of IR in children38 and separate standards need to be developed to 
account for the other factors that influence insulin concentrations in childhood: ethnicity, sex and 
pubertal status. The screening of children for IR is a contentious subject and a recent consensus 
statement did not support screening for IR even in obesity, suggesting that the mere presence of 
obesity itself should stimulate the need for intervention to lower weight and consequently improve 
insulin levels39. 
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Key Messages: Insulin resistance is the underlying metabolic abnormality in T2D. Progression 
from insulin resistance and impaired glucose tolerance to T2D may occur more quickly in 
childhood. Obesity is the single most important modifiable risk factor for insulin resistance and 
prevention of T2D. Treatment of obesity to lower weight and reduce insulin resistance is 
important in an individual to prevent/delay onset of T2D. 
 
Sequelae of Insulin Resistance 
Insulin Resistance Syndrome (IRS) 
Gerald Reaven first described IRS in his 1998 Banting lecture to the American Diabetes Association. 
He proposed that „resistance to insulin-stimulated glucose disposal is the fundamental defect 
responsible for the clustering of a number of risk factors for atheromatous cardiovascular disease‟40. 
Reaven used the term „Syndrome X‟ and more recently the terms „metabolic syndrome‟ or „IRS‟ have 
been introduced.  
IRS consists of a range of disorders that have central adiposity as the fundamental abnormality. The 
disorders include dyslipidaemia, atherosclerosis, decreased fibrinolysis, hypertension, acanthosis 
nigricans, polycystic ovarian syndrome, hyperuricaemia and disturbances of insulin-glucose 
homeostasis ranging from IGT to overt T2D. 
There are several definitions of IRS in adults including the World Health Organisation41 (WHO), and 
the National Cholesterol Education Programme42(NCEP), but there is no agreed consensus in children 
and adolescents.  
The NCEP guidelines have been modified for adolescents aged 12-19 years and require three of five 
characteristics: 
1. Abdominal obesity: Waist circumference ≥ 90% of the population of same sex and 
age (in adults > 102 cm in men and > 88cm in women) 
2. Hypertriglyceridaemia ≥ 1.2 mmol/l (in adults ≥ 1.7 mmol/l) 
3. Abnormal cholesterol profile with HDL cholesterol ≤ 1mmol/l (in adults < 1 
mmol/l in men and < 1.3 mmol/l in women) 
4. Blood pressure ≥ 90% population of same sex and age (in adults BP ≥ 130/85 
mm/hg) 
5. Impaired fasting glucose (≥ 5.5 mmol/l 
 
The WHO guidelines differ by requiring impaired fasting glucose and impaired glucose tolerance or 
T2D, on oral glucose tolerance testing (OGTT). Viner et al adapted the WHO guidelines further for 
use in their study of the prevalence of insulin resistance syndrome in obese children, with IRS 
diagnosed in individuals with ≥ three out of a possible eight components (table 1)43.  
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Table 1: Definition of Components of the IRS. IRS defined as ≥ 3/8 components 
IRS Component Definition 
Obesity Body Mass Index (BMI) ≥ 95th centile for age 
Abnormal glucose 
homeostasis 
Any of the following: 
1. Fasting hyperinsulinaemia* 
2. Impaired fasting glucose (≥6.1 mmol/l) 
3. Impaired glucose tolerance: glucose at 120 mins ≥7.8 mmol/l 
but <11.1 mmol/l 
Hypertension Systolic blood pressure ≥ 95th centile for age and sex 
Dyslipidaemia Any of the following: 
1. High triglycerides (≥1.75 mmol/l) 
2. Low HDL (<0.9mmol/l) 
3. High total cholesterol (≥ 95th centile) 
 
*Fasting hyperinsulinism has a variable definition according to pubertal stage44 (pre-pubertal ≥ 
15 mU/l and mid-puberty stages 2-4 ≥ 30 mU/l). Post-puberty hyperinsulinism is defined by 
WHO guidelines as ≥ 20mU/l. 
 
The relationship between obesity and disordered insulin-glucose metabolism in the form of IRS has 
been demonstrated in childhood.  A UK study of one hundred and three obese children aged two to 
eighteen years years (58% white, 9% black, 29% South Asian and 4% mixed ethnicity) reported that 
one third had IRS using their definition (see table 1) and abnormal glucose homeostasis was 
identified in 46% (hyperinsulinism in 40%, impaired fasting glucose in 0.8%, IGT in 11%)42. There were 
no cases of T2D in this cohort and there was a trend for IRS to be more common in white (37%) than 
black (13%) or Asian (22%) children. Dyslipidaemia was identified in 30% and hypertension in 32%.  A 
study from the South-West of England of one hundred and twenty-six obese children (one hundred 
and twenty white Caucasian) reported that 13% had IGT45. Twenty-five percent (n=75) had ≥ three 
components of the Insulin Resistant Syndrome. No cases of T2D were reported and no sex differences 
were found. The only other large study in European obese children (seven hundred and ten Italian 
children aged six to eighteen years) reports a lower incidence of IGT at 4.5% with only one case of 
T2D46.  
Epidemiological data from the US suggests a higher incidence of both IRS and T2D. One study 
reported a 25% rate of IGT in fifty five obese children aged four to ten years, and in one hundred 
and twelve children aged 11-18 yrs, 21% had IGT and 4% had previously undiagnosed T2D47. A more 
recent study of four hundred and thirty-nine obese young people aged four to twenty years reported 
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that the prevalence of metabolic syndrome increased with the severity of obesity and reached 50% 
in those considered severely obese (BMI-SDS above 2.5)48. Risk of metabolic syndrome significantly 
increased with every 0.5 unit increase in the BMI (odds ratio 1.55, 95% confidence interval 1.16-
2.08). The Bogalusa Heart Study has shown that the IRS components track strongly from childhood 
into adulthood49.  
Genetic factors, lifestyle and dietary habits may account for the difference in results between 
countries. However the evidence suggests that childhood obesity is associated with IRS and as a 
possible prelude to the development of T2D it is an important condition to consider treating. 
Type 2 Diabetes Mellitus (T2D) 
Previously regarded as a disease of overweight, middle-aged and elderly people, T2D in childhood is 
now reported in a number of countries including the UK, the US, Japan, India and 
Australia50,51,52,53,54,55,56. 
In the UK childhood T2D has been reported in both ethnic minorities and white Caucasians49,50. A UK 
study in year 2000 to estimate prevalence of T2D found that children under sixteen years still had a 
low prevalence at 0.21/100,000 with South Asian children at increased risk (relative risk 13.7) 
compared to white British children51.  
In the US an epidemiological review52 documented the T2D accounted for 33% of diabetes among 
African–Americans and whites aged 10-19 years. Prevalence increased six-fold in Pima Indian 
adolescents over a twenty year period (1967-1976 to 1987-1996). The children with T2D were more 
likely to be obese, have a family history of T2D, presence of acanthosis nigricans, belong to minority 
populations and to be female. 
The largest study documenting the increased incidence of T2D in children is from Japan53. T2D is 
more common than T1DM and accounts for 80% of childhood diabetes. Approximately seven million 
young people were studied between 1976 and 1997 with initial urine glucose dipstick and blood 
testing in those with glycosuria. Over the twenty year study period the incidence of T2D in children 
aged six to twelve years increased ten-fold from 0.2 per 100,000 per year during the years 1976-1980 
to 2 per 100,000 per year during the years 1991-1995.  Over the same time period, T2D incidence 
doubled in children aged thirteen to fifteen years from 7.3 to 13.9 per 100,000 per year.  
There are several risk factors identified in these papers for the development of T2D including family 
history, ethnicity, onset of puberty, female sex, small for gestational age and PCOS. However the 
single most important modifiable risk factor is obesity. The Nurses‟ Health Study prospectively 
followed 17,000 adult women for sixteen years and the risk of developing T2D was forty-fold higher 
in those with the highest BMI57.  
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Cardiovascular Risk 
Many cross-sectional studies have shown an association between IR and atherosclerosis, with obesity 
and IR associated with arterial wall stiffness, endothelial dysfunction and increased left ventricular 
mass58, 59. Hyperinsulinaemia has been reported as an independent risk factor for ischemic heart 
disease and it can cause hypertension by several different mechanisms; increasing renal sodium 
absorption, activation of the sympathetic nervous system, FFA-induced sensitivity to adrenergic 
stimuli and by reducing nitric oxide vasodilation60.  
Hyperlipidaemia 
The normal action of insulin is to inhibit lipolysis of triglycerides (TG‟s) to free fatty acids (FFA‟s). In 
the IR state this inhibition is reduced, rates of lipolysis increase, FFA‟s circulate in increased 
amounts and triglyceride clearance is reduced, contributing to the dyslipidaemia found in 
association with IR and T2D. The raised level of FFA‟s in skeletal muscle further contributes to IR as 
described previously (see figure 3). 
Inflammation 
Markers of inflammation such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and 
tissue necrosis factor-α (TNF-α) are increased in IRS and T2D. CRP is an acute phase reactant 
produced and released by the liver under stimulation of cytokines including interleukin-1, 
interleukin-6, and TNF-α. It is recognised as a general and non-specific marker of inflammation. In 
adults, chronic low grade elevations within the normal range are independently predictive of future 
cardiovascular morbidity61 and development of T2D62. Cross-sectional studies in adults have shown 
that elevated CRP levels significantly correlate with components of the IRS63 and increased visceral 
and subcutaneous fat on CT64.  The six year Mexico City diabetes study65 (five hundred and fifteen 
men and seven hundred and twenty-nine women) found that women with CRP in the highest tertile 
had increased relative risk of developing IRS by four. However CRP in men was not predictive of IRS. 
The Diabetes Prevention Program66 studied the effect of metformin and lifestyle intervention on CRP 
in 3234 adults with IGT. The changes in CRP from baseline to one year were metformin: -7% in men 
and -14% in women, lifestyle intervention: -33% in men and -29% in women, placebo: +5% in men and 
0% in women. In summary, lifestyle intervention was more effective than metformin or placebo in 
reducing CRP. 
Evidence for low grade inflammation in children and adolescents with metabolic syndrome is now 
being published. In the US a study of 1366 adolescents aged twelve to seventeen years found that 
mean and median CRP concentrations were higher in those with the metabolic syndrome67. Elevated 
CRP concentrations >3mg/l were found in 38.4% of those with the metabolic syndrome and 10.3% of 
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those without the syndrome (p=0.007).  Abdominal obesity was the only component of the metabolic 
syndrome to be associated significantly and independently with elevated CRP. 
Non-alcoholic Steatohepatitis (NASH) 
Non-alcoholic steatohepatitis or fatty liver disease is recognised in association with childhood 
obesity. Prevalence varies between 10 – 25% with male predominance. Risk factors include obesity, 
insulin resistance and hypertriglyceridaemia. Fatty liver disease has potentially serious sequelae: 
hepatitis, cirrhosis, end stage liver failure and hepatocellular carcinoma68.  There is currently a trial 
on-going in the US (TONIC trial) investigating the treatment of children with NASH using Metformin 
and Vitamin E vs. placebo69. 
 
Key Messages: There is a range of disorders that are associated with childhood obesity and 
insulin resistance. Awareness, diagnosis and treatment of these disorders in childhood is 
essential to prevent further deterioration and persistence into adulthood. 
 
Energy Homeostasis and the AMPK system 
Understanding of the regulation of energy homeostasis in childhood is essential when considering 
treatment strategies for childhood obesity and IR related conditions.  
AMP-activated protein kinase (AMPK) 
AMP-activated protein kinase (AMPK) is now recognized as a key regulator of energy homeostasis 
both within cells and in the human body as a whole. It is activated at a cellular level by metabolic 
stressors that increase the cellular AMP: ATP ratio such as hypoglycaemia, hypoxia, ischemia and 
exercise. Once activated, it stimulates catabolic pathways that produce ATP such as fatty acid 
oxidation and glycolysis and it switches off ATP consuming processes such as cell growth, 
gluconeogenesis, glycogenesis and lipid synthesis. Activation of AMPK also enhances both the 
transcription and translocation of GLUT4, resulting in an increase in insulin-stimulated glucose 
uptake to cells70.  Although the AMPK system is likely to have developed in cells as a response to 
cellular stressors, due to the interaction of hormones (insulin) and cytokines (adiponectin and leptin) 
with AMPK, it is now also thought to be a regulator of whole body energy status. It is also considered 
to be a key therapeutic target for the treatment of obesity and T2D and it is the site of action for 
Metformin. 
Hormonal Regulation 
Over recent years a new wave of gut-adipose tissue-brain signalling peptides have also been 
identified and act to regulate food intake and energy balance. Rodent models have been used to 
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study the feedback mechanisms and demonstrate that hormones produced in adipose tissue (leptin, 
resistin, adiponectin, visfatin, retinol-binding protein 4), appetite regulating hormones produced in 
the gut (ghrelin, peptide tyrosine-tyrosine, glucagon-like peptide 1, oxyntomodulin, cholecystokinin) 
and pancreatic hormones (insulin, pancreatic polypeptide, amylin) are afferent signals that feedback 
to the hypothalamus and brainstem. Long term regulators are thought to be the adipose tissue 
hormones with the gut and pancreatic hormones acting in the shorter term71,72,73,74,75. 
Adipose tissue 
Adipose tissue is no longer considered to be simply a store of fat. It is known to secrete a number of 
products including hormones and cytokines (adipokines) that are implicated in the pathogenesis of 
obesity related diseases such as IR and atherosclerosis. These adipocyte products are involved in 
linking energy homeostasis with neuro-endocrine pathways, regulating weight gain change and are 
cited as the possible link between IR and obesity.  
These adipokines include leptin, resistin, adiponectin, plasminogen activator-inhibitor-1, interleukin 
6 and tumour necrosis factor-α. The first three will be considered in more detail below. 
Leptin 
The protein product of the ob gene discovered in 199470, leptin, is secreted by adipocytes and binds 
to receptors in the hypothalamus to indicate the size of energy stores, signal satiety, regulate 
feeding and whole body energy balance. Production is stimulated by insulin and glucocorticoids. Its 
effect is anorexogenic and when it is given to mice that have a mutation in the gene and are leptin 
deficient, it increases energy expenditure, decreases body weight, normalises hyperglycaemia, 
insulin resistance and hyperinsulinaemia76. Leptin exerts its effects in the hypothalamus, brainstem 
and key regions of the brain that control feeding, metabolism and neuroendocrine systems, via the 
long leptin receptor, the LRb receptor. Binding of leptin to LRb activates the Janus family of 
tyrosine kinases (JAK), activates transcription signalling (STAT) and induces proopiomelanocortin 
(POMC), leading to inhibition of feeding, stimulation of thermogenesis, fatty acid oxidation and 
increased peripheral insulin sensitivity. 
Recombinant human leptin is now available as a daily subcutaneous injection and trials are 
underway to determine if it can reduce obesity in humans as it does in mice. Congenital leptin 
deficiency in humans has been identified and treatment of these individuals with leptin has 
produced dramatic weight loss and reduction of hyperphagia77.  
However most obese individuals are not deficient in leptin and multiple studies have shown that 
leptin levels correlate positively with obesity and amount of adipose tissue78. High leptin levels in 
obese individuals may indicate resistance to the biological actions of leptin and reduced leptin 
signalling in the brain.  This resistance may lead to ineffective reduction in appetite and result in 
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weight gain. Leptin levels have been shown to reduce after successful weight loss79,80. Treatment 
with metformin has also been shown to reduce serum leptin levels in obese adolescents79.  
Resistin  
Discovered in 200181, resistin is a peptide secreted by adipose tissue and named for its ability to 
induce insulin resistance. The function of resistin in humans has not been fully evaluated, but it is 
thought to modulate glucose tolerance and lipid metabolism and has been proposed as a link 
between T2D and obesity82. Obese diabetic mice were found to have elevated levels of resistin and 
levels were reduced after administration of antidiabetic agents (rosiglitazone) and prolonged 
fasting83. Clinical studies in man have not proved conclusively any substantial correlation between 
resistin and body weight, insulin sensitivity or type 2 diabetes84,85,86. In children resistin levels did 
not change significantly after weight loss and there were no differences between lean and obese 
children87. 
Adiponectin  
Adiponectin was discovered in 1995 and it exists as homotrimers that form low molecular weight 
hexamers and high molecular weight complexes88. It is the product of the apM1 gene and is produced 
and secreted exclusively by adipocytes. It is a 244 amino acid protein with structural similarity to 
collagen VIII, X, complement C1q and TNF.  Two adiponectin receptors have been indentified: 
Adipo-R 1 and Adipo-R-289. The receptors are expressed in peripheral tissues and the brain.  
Unlike leptin, Adiponectin levels are reduced in obesity. Adiponectin deficiency in obesity is 
associated with insulin resistance, glucose intolerance, atherosclerosis and dyslipidaemia. 
Adiponectin reverses these abnormalities by stimulating fatty acid oxidation, reducing 
gluconeogenesis and suppressing inflammation.  
In a study of Japanese adults, reduced adiponectin levels were associated with obesity, T2D and 
cardiovascular disease90. In obese children (n=42) adiponectin levels were inversely correlated with 
age, body fat and insulin resistance91. Adiponectin levels increased with significant weight loss and 
were associated with an improvement of insulin resistance. A further study in children found clear 
links between adiponectin and features of the metabolic syndrome92. In a study of 115 obese 
children, increased HOMA-IR correlated with adiponectin (r = -0.40, P =0.0007). Furthermore, after a 
one year follow up and lifestyle intervention in sixty-two children, adiponectin levels were 
significantly reduced in twenty-nine children with >0.5 BMI-SDS reduction (p<0.5)93. 
Production of adiponectin is known to be influenced by other cytokines and the inverse relationship 
between adiponectin and obesity may be partly explained by the antagonistic action of tumour 
necrosis factor-α (TNF-α) to adiponectin94. The insulin-sensitising mechanism of adiponectin is via 
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phosphorylation and activation of adenosine monophosphate-activated protein kinase (AMPK) and 
activation of PPAR-α in liver and skeletal muscle93.  
The anti-atherosclerotic action of adiponectin results from: 
a. Suppression of inflammatory cytokines (eg. intracellular adhesion molecule-1, vascular 
cellular adhesion molecule-1, E-selectin and TNF- α- induced nuclear factor-k-B) 
b. Suppression of cholesterol uptake by inhibiting scavenger macrophages 
c. Protective role against intimal thickening in response to injury (adiponectin knockout mice 
develop severe vascular alterations in arteries after injury compared with wild-type mice). 
In summary, Adiponectin exerts anti-inflammatory effects, appetite-restraining effects and reduces 
insulin resistance, thereby perhaps offering protection against the development of both T2D and 
cardiovascular disease. 
Adiponectin: leptin Ratio 
The adiponectin/leptin ratio (ALR) has been proposed as a useful parameter of insulin resistance. 
The level of leptin increases with obesity and IR whereas the level of adiponectin decreases, thus 
leading to a decrease in the A/L ratio with increasing obesity and IR.  In adults with and without 
T2D, the A/L ratio was a more sensitive measure of IR than adiponectin or leptin alone and a more 
reliable measure of IR than HOMA-IR as glucose levels increased95,96. Furthermore the A/L ratio has 
been reported to negatively correlate with number of components of metabolic syndrome97. In 
children, the A/L ratio has been proposed as a tool to distinguish between type 1 diabetes and T2D. 
A striking difference was reported in the A/L ratio between forty-one children with type 1 diabetes 
(6.3), compared with seventeen children with T2D (0.3) (p<0.001)98. In this study the A/L ratio was 
also reported in forty-three age-matched non-diabetic children and this was significantly higher at 
20.2.  
 
Key message: Investigation of these adipocyte cytokines at baseline and after treatment with 
metformin in the MOCA study is novel and may help to clarify the role of metformin in treating 
IR and prevention of progression to T2D. 
 
Treatment of IRS and Prevention of T2D with Lifestyle Intervention 
Prevention or delay of T2D onset in those who are at increased risk has been demonstrated in adults. 
There are three major RCT‟s confirming that effective lifestyle intervention can prevent or delay 
progression to T2D in obese adults with IGT99, 100, 101. 
The Da Quing study of five hundred and seventy-seven subjects with IGT in which participants were 
randomised to diet alone, exercise alone, diet and exercise combined or no intervention, 
demonstrated that diet/and or exercise reduced the risk of T2D by 39% over six years98. A twenty 
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year follow up of the cohort found that the incidence of T2D was persistently lower in the combined 
diet/exercise group compared to the control. 
The Finnish Diabetes Prevention Study of lifestyle modification in five hundred and twenty-two 
patients with IGT resulted in a 58% reduction in the risk of T2D99. After four years intervention the 
insulin sensitivity was higher in the intervention group and there was a strong correlation between 
increased insulin sensitivity and weight loss. Even those who lost weight in the control group were 
protected against development of T2D. This study concluded that weight loss was significantly 
associated with improved insulin sensitivity and reduced incidence of T2D. 
The Diabetes Prevention Program (DPP) Research Group in the US has shown a reduction in the 
incidence of type 2 diabetes with lifestyle intervention and metformin100. The subjects were 3234 
non-diabetic adults with elevated fasting glucose and IGT, 68% women and 14% from ethnic minority 
groups. The mean age was fifty-one years and the mean BMI was 34kg/m2. They were randomised to 
placebo, metformin (850mg Bd) or a lifestyle modification programme with a target of 7% weight 
loss and one hundred and fifty minutes of physical activity per week with a mean follow up of 2.8 
years. There was a 58% reduction in incidence of T2D with lifestyle intervention and a 31% reduction 
with metformin treatment (see figure 4). A further paper from the DPP summarized the results of 
the trial and looked at the cost effectiveness of the interventions102. Although both metformin and 
lifestyle intervention are more expensive than placebo, they both increase Quality Adjusted Life 
Years (QALY): metformin by 0.12 and lifestyle by 0.36. The distinction between delaying the 
development of diabetes versus actual prevention of diabetes is important to consider. True 
prevention can only be assessed at a point in time when the entire cohort has died and when 
differential development of diabetes before death would then reflect true prevention. In this trial, 
computer modeling was used to project the cohort out thirty years beyond the diagnosis of IGT. The 
incident rates of diabetes observed during the 2.8 years were extended over a lifetime and the 
results suggested that over 80% of the placebo group would develop diabetes before dying of any 
other cause. Metformin treatment was found to have an absolute risk reduction of 7.9%, whereas 
lifestyle intervention had an absolute risk reduction of 20.2% compared with placebo. Furthermore 
the potential in delaying the onset of diabetes was assessed. The duration of time after 
identification of IGT for 50% of the cohort to develop diabetes was calculated. Conversion from IGT 
to diabetes in 50% of the placebo group occurred after 6.6 years. This conversion was delayed by 3.4 
years with metformin therapy and by 11.1 years with lifestyle intervention. The authors concluded 
that these results support the hypothesis that T2D can be prevented or delayed in adults with 
increased risk.  
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Figure 4: Cumulative risk of diabetes and the effect of interventions: placebo, metformin and intensive 
lifestyle modification in the Diabetes Prevention Program 
 
 
Due to the relatively recent emergence of T2D in children and adolescents there are very few 
studies of treatment options for obesity or T2D preventative strategies in this age group. Current 
approaches with lifestyle intervention strategies such as dietary modification and exercise alone can 
be unsuccessful in children due to poor compliance. However there are now lifestyle interventions 
with additional psychological support, including mentoring and family therapy that are currently 
being developed and evaluated. 
A number of systematic reviews have been carried out regarding the treatment of paediatric 
obesity. Speiser at al reviewed the evidence and „The Consensus Development: Childhood Obesity‟103 
concluded that longer term clinical trials with larger numbers of children are needed before drug 
treatment (orlistat, metformin) can routinely be employed in obese children. A Cochrane review104 
of eighteen randomised controlled trials of lifestyle intervention lasting longer than six months in 
obese children (n=975) concluded that most of the studies were too small. The trials did not use the 
same outcomes and therefore the data were of limited quality. The recent consensus statement 
published in 2010 regarding insulin resistance in children concluded that lifestyle intervention 
strategies should be started early and treatment with metformin should be restricted to selected 
cases38. An NHS review of the evidence on treating childhood obesity also concluded that future 
research must involve larger numbers and be of longer duration and intensity105.  
 
Key Message: Lifestyle interventions and treatment with metformin are successful in adults to 
prevent T2D. Further evidence in children is needed for both lifestyle intervention and 
pharmacological treatments, hence the development of the MOCA trial. 
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Metformin 
Metformin is a biguanide compound that has been in use for the treatment of T2D for many decades.  
It is derived from guanidine, the active ingredient of French lilac that was used to treat diabetes in 
medieval Europe. Despite the age of the drug, the mechanism of action at the molecular level has 
only begun to be comprehensively investigated and established in more recent years.  
The majority of studies have shown that metformin has a primary action in the liver to increase 
glucose uptake, decrease gluconeogenesis and reduce hepatic glucose output (the major 
determinant of fasting glucose levels)106 (see figure 5). Other studies have demonstrated that 
metformin has an insulin-sensitising effect in peripheral tissues such as skeletal muscle to increase 
insulin stimulated glucose uptake107.  In vivo studies have shown that metformin corrects defects in 
post receptor insulin signalling, with activation of insulin receptor substrates and 
phosphatidylinositol kinase activity108. However the effect has not yet been replicated in muscle 
from diabetic human subjects.  
Metformin has been demonstrated to target the liver enzyme AMPK (adenosine monophosphate-
activated protein kinase). As described earlier, the AMPK system acts as a cellular sensor of energy 
status and may play a role in total body energy status. In hepatocytes of rats metformin normalised 
hepatic output of glucose and increased basal liver AMPK levels109. Activation of AMPK by metformin 
increases the expression of small heterodomer partner (SHP), which in turn inhibits the expression of 
the hepatic gluconeogenic genes, Phosphoenolpyruvate carboxykinase and Glucose-6-phospahtase110. 
Furthermore, activation of the AMPK cascade also induces muscles to take up glucose from the blood 
stream and increased levels of AMPK were found in skeletal muscle of T2D adults treated for four 
weeks with metformin111.  
Figure 5: Mechanism of Metformin action 
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The safety and efficacy of metformin in adults both with T2D and IGT has been extensively 
documented. The effects of metformin on cardiovascular risk factors include reduction in 
hyperglycaemia, reduction in insulin levels, reduced IR, reduced blood pressure, improvements in 
dyslipidaemia (reduced triglyceride and total cholesterol concentrations), reduced plasminogen 
activator inhibitor-1 levels and reduction in body weight. In the UKPDS study overweight patients 
newly diagnosed with T2D were treated with diet vs sulphonylureas, metformin or insulin. In 
comparison to diet alone the metformin group showed a 42% reduction in diabetes-related deaths, 
39% reduction in myocardial infarction, 34% reduction in overall mortality and 32% reduction in 
diabetes-related end-points112. These beneficial cardiovascular effects were not entirely explained 
by improvements in glycaemic control and decreased fibrinolysis was proposed as a mechanism due 
to reduced plasminogen activator inhibitor-1 levels. 
The most commonly reported side effects are gastro-intestinal disturbances and the most serious 
side effect is lactic acidosis (3/100,000 patient years of exposure). Lactic acidosis occurs in patients 
with liver disease, renal insufficiency, pulmonary disease and congestive heart failure and its use is 
contra-indicated in these patients. 
There have been several studies of metformin in obese non diabetic adolescents. The first study 
(n=29) in adolescents aged twelve to nineteen years, reported a reduction in BMI-SDS over a six 
month treatment period (3.6% relative to placebo controls)113. All the participants had a BMI>30 
kg/m2, a raised fasting insulin>15 IU/l and at least one first or second degree relative with T2D. The 
metformin group showed a reduction in BMI-SDS by 0.12 and a reduction in fasting glucose (-0.54 
mmol/l) and insulin levels (-12 mU/l). In contrast the placebo group showed a rise in BMI-SDS by 0.23 
and a rise in fasting glucose levels. The fasting insulin levels did not change in the placebo group. 
Insulin sensitivity (reduction in HOMA-IR and increase in QUICKI) in the metformin group increased 
slightly. The study concluded that metformin moderates weight gain and reduces fasting insulin and 
glucose concentrations in obese adolescents, and therefore may be used as an adjunct to diet and 
exercise to reduce risk of T2D in this group. 
In a study of twenty-four obese children metformin was combined with a low calorie diet over an 
eight week period114. Metformin reduced weight by 2.7% relative to controls and reduced plasma 
leptin, insulin, glucose cholesterol and triglyceride concentrations. Body fat was assessed using bio-
impedence and there was a reduction of -6kg body fat in the treated group compared with -2.7 kg in 
controls.  
One study took place in Australia and was designed as a randomised, double blind crossover trial in 
twenty-eight obese adolescents aged nine to eighteen years. Metformin treatment was reported to 
improve weight loss (-4.35kg, p=0.02), reduce BMI (-1.26kg/m2, p=0.02), reduce waist circumference 
(-2.8cm, p=0.003), reduce subcutaneous abdominal adipose tissue (-52.5cm2, p=0.002) and reduce 
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fasting insulin (-2.2 mU/l, p=0.001)115. However there was no significant change in insulin sensitivity, 
as measured by minimal model analysis (p=0.21). 
Another study evaluated whether metformin in addition to personal goal setting improved weight 
loss in eighty-five insulin resistant adolescents with a mean BMI of 39.7kg/m2 (71% female, 58% 
Hispanic and 34% African-American). The trial design was a randomised controlled trial with 70% of 
patients receiving metformin. Metformin was found to significantly increase weight loss in the 
female group and weight loss was predicted by adherence to metformin therapy116. 
Another randomised controlled trial took place in Germany with a cohort of sixty-seven obese 
children with insulin resistance and/or impaired glucose tolerance, using a treatment dose of 500mg 
BD for six months117. There were no significant differences in all parameters of body composition and 
glucose/insulin metabolism at the end of the trial. The conclusion was that metformin treatment 
could not be recommended. 
The largest trial to date of metformin treatment in obese adolescents, aged nine to seventeen years 
with hyperinsulinemia, took place in Turkey118. The metformin group (n = 90) received 500mg twice 
daily and the placebo group (n = 30) received placebo twice daily. Both groups also received 
individually tailored diet, exercise and behavioral therapy. Hyperinsulinism and insulin sensitivity 
indices were defined from fasting samples only. Metformin treatment was associated with a 
significant reduction in body mass index from 28.5(3.4) to 26.7 (4) kg/m2 (p < 0.001), fasting insulin 
from 19.2(10.4) to 11.1(6.1) mIU/ml (p < 0.001) and 120 min insulin levels from 103.7(73.8) to 
49.8(30.9) mIU/ml (p < 0.001). HOMA-IR was reduced from 4.95(3.34) to 2.6(1.6) (p < 0.001) and 
QUICKI significantly increased from 0.31(0.02) to 0.34(0.03) (p < 0.001) in the metformin group. The 
authors suggest that metformin treatment is effective in reducing insulin resistance in obese 
adolescents with hyperinsulinemia. 
A systematic review and meta-analysis of randomized controlled trials of ≥ six months duration in 
obese children or adolescents aged ≤ nineteen years without diabetes found five trials for inclusion 
in the analysis(n=320) 112,114,115,116,119. The review found that metformin appeared to be moderately 
effective over the shorter term in reducing BMI by 1.42 kg/m2 (95% CI 0.83 – 2.02) and HOMA-IR by 
2.01 (95% CI 0.75 – 3.26)120. 
Although there are now papers published regarding several trials of metformin in obese children, 
there are conflicting reports of its efficacy and there is still no conclusive evidence supporting its 
use. Many of the studies use BMI or weight alone, rather than the age and sex adjusted BMI-SDS. The 
studies to date have reported changes in fasting values of insulin and glucose and indices based upon 
fasting values as measure of insulin sensitivity, rather than indices that correlate better with the 
gold standard for measuring insulin sensitivity such as the WBISI. In addition, the mechanism of 
action for metformin to reduce body weight and BMI has not been fully investigated.  
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Key Message: Metformin has been used for many years in the treatment of T2D and there is 
evidence that its use can prevent progression from IR and IGT to T2D in obese adults. Metformin 
is increasingly used in adults for this purpose and the MOCA trial is designed to contribute to the 
evidence in evaluating its use in obese children and adolescents with IR and or IGT.   
 
The Metformin in Obese Children and Adolescents Trial (MOCA) 
The evidence outlined in this introduction clearly demonstrates that the prevalence of childhood 
obesity has increased rapidly and is associated with the conditions IRS and T2D. IR is the underlying 
metabolic mechanism for many of the abnormalities associated with obesity. There are many studies 
in adults with IR related conditions, but understanding of mechanisms and treatment options in 
children is an emerging field in Paediatric Endocrinology. Metformin is currently being used „ad hoc‟ 
by Paediatric Endocrinologists for the treatment of obese insulin resistant children, but its use is not 
evidence based and there are no robust guidelines for dose, length of treatment or monitoring of 
effect. 
 The clinical effects of Metformin treatment in obese children with insulin resistance and IRS have 
not been studied in detail and the likely significant benefits of reduction in BMI-SDS and 
improvements in cardiovascular and inflammatory risk factors have not been comprehensively 
demonstrated in childhood, leading to the development of the MOCA trial.  
The MOCA trial was a six month double blind randomised placebo controlled trial of metformin 
compared to placebo in obese children and adolescents aged eight to eighteen years with IR and/or 
IGT. 
 
The hypotheses to be tested in the trial were: 
A. Primary hypothesis:                                                                                                                                                        
Metformin, at a dose of 1.5 g per day for six months, is more effective than placebo in reducing BMI 
Standard Deviation Scores (BMI-SDS) in obese children with abnormal insulin glucose status. 
B. Secondary hypothesis:  
Metformin, at a dose of 1.5g per day for six months, is more effective than placebo in improving 
secondary outcomes including BMI, waist: hip ratio and cardiovascular and inflammatory risk 
markers: fasting and 2 hr insulin and glucose levels on OGTT, measures of insulin resistance (HOMA-
IR, QUICKI and WBISI), fasting lipids, CRP, adiponectin, leptin, resistin, adiponectin: leptin ratio and 
blood pressure. 
Metformin, at a dose of 1.5 g per day for three months (at visit two) is more effective than placebo 
for BMI-SDS, BMI, waist: hip ratio and cardiovascular and inflammatory risk markers: fasting and 2 hr 
insulin and glucose levels on OGTT, measures of insulin resistance (HOMA-IR, QUICKI and WBISI), 
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fasting lipids, CRP, adiponectin, leptin, resistin, adiponectin: leptin ratio and blood pressure. 
Outcomes: 
1. The primary outcome is BMI-SDS at six months; 
2. The secondary outcomes are:  
 BMI-SDS at three months; 
 BMI and waist:hip ratio at three and six months; and 
 Cardiovascular and inflammatory risk markers: fasting and 2 hr insulin and glucose levels on 
OGTT, measures of insulin resistance (HOMA-IR, QUICKI and WBISI), fasting lipids, CRP, 
adiponectin, leptin, resistin, adiponectin: leptin ratio, diastolic and systolic blood pressure 
at three and six months 
 
Key Message: The MOCA trial is a six month double-blind randomized controlled trial that aims to 
examine the effects of metformin treatment on body composition and metabolic and 
cardiovascular risk factors for T2D in obese children and adolescents with IR and/or IGT. 
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Chapter 2:  
Abnormalities of Insulin Glucose Status in Childhood Obesity: 
Experience in a UK Specialist Paediatric Endocrine Clinic  
 
 
Introduction 
As a prelude to the MOCA trial, the objectives of this preliminary study were to determine the 
prevalence of abnormalities and to assess the changes over time in insulin glucose status (IGS), in a 
cohort of severely obese children originating from the North-West of England. 
 
Methods 
 A retrospective case note review was performed of one hundred and nine obese children (defined 
by body mass index [BMI] >98th percentile of the United Kingdom 1990 reference charts for age and 
sex2). The cohort was aged 3.1 -19.1 years (median 13.4 years) and originated from the North West 
region of England. They were referred to the endocrine unit by General Practitioner‟s and District 
General Hospital Paediatricians between 2002 and 2007 for baseline investigation of their obesity, 
and were investigated with an oral glucose tolerance test (OGTT). Fifty-six subjects were followed 
up over a period of one to four years, during which time they had at least two OGTT‟s. Longitudinal 
auxological and laboratory data were also collected in these patients. 
Clinical information on weight, height, blood pressure (measured using an oscillometric method with 
a Dinamap), ethnic background, family history of diabetes, pubertal status (according to the criteria 
of Tanner and Whitehouse) and presence of acanthosis nigrans (AN) was obtained. The children were 
grouped according to Tanner pubertal stage121: Tanner breast stage 1 and 2 in girls and Tanner 
genitalia stages 1 and 2 in boys were classed as pre-pubertal and Tanner stages 3, 4, 5 were classed 
as pubertal in both sexes. Insulin resistance increases during puberty and peaks at Tanner stage 3 in 
both sexes, returning to pre-pubertal levels at Tanner stage 5. This grouping of pubertal stage into 
two groups was done to allow analysis of the effect of puberty as a categorical variable. 
A standard protocol was used for the OGTT‟s. The patient was fasted overnight for 10-14 hours, a 
venous sample for fasting glucose and insulin taken, a glucose load of 1.76 g/kg of anhydrous glucose 
(maximum dose 75g) dissolved in 100-200ml of water was given to the subject and a further venous 
sample taken at 120 minutes for glucose and insulin measurements. Insulin samples were stored in 
ice, centrifuged immediately and frozen at -80C before analysis. Insulin was measured by a two-site 
immunoassay with fluorescent detection (Delfia - Perkin Elmer, Cambridge UK). Glucose was 
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measured by a glucose oxidase method on a Hitachi 911 analyser (Roche Diagnostics, Lewes, E 
Sussex) up to September 2004, and a hexokinase method on an Integra 800 analyser thereafter). 
The glucose results were categorized according to the WHO criteria as normal, impaired glucose 
tolerance (IGT), or diabetic40. Insulin resistance (IR) was assessed with fasting insulin (FI) > 26mIU/L, 
120 minute insulin (HI) ≥ 95 mIU/l (reference range based on local paediatric population) and 
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR: fasting insulin x fasting glucose/22.5, 
abnormal >2.5).  
The fifty-six follow up subjects were categorised according to their insulin glucose results on OGTT 
as normal insulin glucose status (NIGS) and abnormal insulin glucose status (AIGS).  
AIGS was defined as patients with one or more of the following: 
1. Fasting glucose 6.1≥ mmol/l; 
2. 120 min glucose ≥7.8 mmol/l ≤ 11.1 mmol/l; 
3. Fasting insulin >26 mIU/l;  
4. 120 min insulin >89 mIU/l. 
 
Adapted WHO guidelines were used to define IRS: ≥ 3 of the components (see table 1). 
Statistical analysis was performed using SPSS 15.0 for windows. Standard statistical tests were used 
throughout. Non-normally distributed data were log transformed. Differences between groups 
(comparison of means) were assessed using the student t tests and differences between proportions 
using chi-square tests. Pearson correlation was used to study relationships between continuous 
variables and logistic linear regression used to study independent effects of variables. A cox model 
was used to predict risk of IGT and risk of IRS. An alpha value of < 0.05 was used to determine 
significance. 
 
Results  
Study Population 
All the one hundred and nine subjects were obese with a BMI > 98th percentile for age with a median 
BMI-SDS of +6.3 (range +2.2 to +14.8). Most of the cohort were severely obese and 89.9% had a BMI-
SDS ≥ 3. Seventy-two (66%) were female. Pubertal stage was recorded: thirty-seven (37%) were 
Tanner stage (TS) 1-2 and sixty-four (63%) were TS 3, 4, or 5. Family history of T2D was recorded as 
positive in forty-two (41.6%). Acanthosis Nigricans was present in thirty-nine (38.6%). Data on 
ethnicity was available for all of the subjects: eighty-three (76%) British White (BW), twenty-five 
(22.9%) British Asian (BA) and one (0.9%) Afro-Caribbean (AC). 
Sex and ethnic differences in clinical and biochemical characteristics were assessed (Tables 2 and 3). 
In this cohort there were significantly more girls than boys, p=0.001. The proportion of BA children 
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in this cohort (22.9%) was in excess of that expected as the BA community comprises 3.4% North 
West UK population (2001 census data). 
 
Table 2: Clinical and Biochemical Characteristics in Childhood Obesity according to Sex 
 
Characteristic 
 
Male 
N=37 
 
Female 
N=72 
 
Significance 
Age (years), Mean (SE)  
 
12.2 (0.7) 
 
12.4 (0.4) 
 
NS 
BMI-SDS, Mean (SE) 6.4 (0.4) 
 
6.2 (0.3) 
 
NS 
Pubertal Status: N (%) 
  pre-pubertal  
  pubertal  
 
 
18 (56) 
14 (38) 
 
 
20 (32) 
42 (58) 
 
 
 
P=0.02 
Family history of T2D: N (%)                
   
15 (40) 
 
31 (43) 
 
NS 
Acanthosis Nigricans: N (%) 19 (51) 
 
25 (35) 
 
NS 
Ethnicity:  N (%)  
  British White 
  British Asian/AC 
 
 
25 (68) 
12 (32) 
 
58 (81) 
14 (19) 
 
NS 
Fasting insulin, mean (SD) mIU/l (n=107) 
 
24.6 (21) 
 
30.6 (21) 
 
NS 
120 min insulin, mean (SD) mIU/l (n=79) 
 
130.3 (118) 
 
173.5 (137) 
 
NS 
Fasting glucose, mean (SD) mmol/l (n=107) 
 
5.0 (0.5) 5.1 (1.1) NS 
120 minute glucose, mean (SD) mmol/l (n=83) 
 
6.7 (1.5) 6.5 (1.3) NS 
HOMA-IR, mean (SD) (n=106) 
 
5.6 (5.6) 7.3 (6.5) NS 
Fasting Hyperinsulinism: N (%) 
 
13 (35) 
 
33 (47) 
 
NS 
120 minute Hyperinsulinism: N (%)  11 (38) 
 
31 (62) 
 
P=0.04 
Impaired fasting glucose: N (%) 
 
2 (5.4) 
 
2 (2.8) 
 
NS 
Impaired glucose tolerance: N (%)  
 
4 (13) 
 
10 (19) 
 
NS 
T2D: N (%) 
 
0 
 
4 (5.5) 
 
P<0.001 
Raised HOMA-IR: N (%) 
 
26 (70) 59 (86) P=0.05 
NS=not significant 
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Table 3: Clinical and Biochemical Characteristics in Childhood Obesity according to Ethnicity 
 
Characteristic 
 
British White 
N=83 
 
British Asian 
N=26 
 
Significance 
Age (years), Mean (SE)  
 
12.7 (0.4) 11.1 (0.7) NS 
BMI-SDS, Mean (SE) 6.4 (0.3) 
 
5.8 (0.4) 
 
NS 
Pubertal Status: N (%) 
  pre-pubertal  
  pubertal  
 
 
25 (34) 
49 (66) 
 
13 (65) 
7 (35) 
 
 
P=0.01 
Family history of T2D: N (%)                32 (40) 14 (54) 
 
NS 
Acanthosis Nigricans: N (%) 28 (34) 
 
16 (62) P=0.009 
Fasting insulin, mean (SD) (mIU/l) (n=107) 
 
28 (21) 40 (22) P=0.05 
120 min insulin, mean (SD) (mIU/l) (n=79) 
 
151 (135) 
 
175 (121) 
 
NS 
Fasting glucose, mean (SD) mmol/l (n=107) 
 
5.6 (1.1) 4.9 (0.5) NS 
120 minute glucose, mean (SD) mmol/l (n=83) 
 
6.5 (1.4) 6.8 (1.6) NS 
HOMA-IR, mean (SD) 
 
6.6 (6.5) 7.1 (5) NS 
Fasting Hyperinsulinism: N (%) 
 
33 (40) 
 
13 (52) 
 
NS 
120 minute Hyperinsulinism: N (%) (n=79) 
 
28 (48) 
 
14 (67) 
 
NS 
Impaired fasting glucose: N (%)  
 
4 (4.9) 
 
0 NS 
Impaired glucose tolerance: N (%)  
 
11 (17.7) 
 
3 (14.3) 
 
NS 
T2D: N (%) 
 
3 (3.6) 
 
1 (3.8) 
 
NS 
Raised HOMA-IR: N (%) 
 
65 (80) 20 (80) 
 
NS 
 
Abnormalities of insulin glucose status  
Twenty-four (22%) of the subjects had normal insulin glucose status (NIGS) and eighty-five (78%) had 
abnormal insulin glucose status (AIGS). 
Abnormalities in glucose status were found in twenty-one (19.3%) of children at baseline: Impaired 
fasting glucose (IFG) (n=107) in four (3.7%): two male and two female, IGT (n=83) in fourteen 
(12.8%): four male and ten female, T2D in four females (3.7%), no males (Table 2). Only one child 
with IGT was identified by IFG. Children with IGT after a glucose load, were more insulin resistant 
  
 
44 
 
prior to the glucose load with a higher HOMA-IR of 8 (4.1) compared with 5.4 (3.7) in those with 
normal glucose tolerance (NGT) (p=0.04, 95% CI -5.1 to -0.01). Ten (77%) of the children with IGT 
had a family history of T2D compared with 27 (41%) of children with normal glucose tolerance.  
Baseline abnormalities of insulin status were found in the majority. HOMA-IR was raised in eighty-
five (78%). Fasting hyperinsulinism (n=107) was found in forty-six (42%): thirteen males and thirty-
three females. 120 minute hyperinsulinism (n=79) was found in forty-two (38%): eleven males, 
thirty-one females (Table 2). Fasting insulin positively correlated with 120minute insulin (r=0.6, 
p<0.005) and 120 minute glucose (r=0.3, p=0.002). Acanthosis nigricans was found in forty-four 
children (40%).  
In the cohort of fifty-six patients with follow up data, at baseline, twenty-seven children had NIGS 
and twenty-nine had AIGS (26 with raised FI, 18 with 120 minute hyperinsulinism and 2 with IGT), of 
which one was newly diagnosed T2D.  AIGS was associated with greater age (13.4yrs vs 10.2yrs, 
p=0.001) and advanced pubertal status (64% post-pubertal vs 36% pre-pubertal p=0.03). On follow 
up, 9/27 (33%) of NIGS changed to AIGS (6 with raised FI and 3 with raised 120 minute insulin) and 
13/28 (46%) AIGS changed to NIGS (see figure 6). In comparing those who changed from NIGS to 
AIGS, with those who changed from AIGS to NIGS, there was significant increase in the BMI (mean 
change BMI=+5.8 kg/m2vs +0.45 kg/m2, p=0.008) in the former group.  
 
Figure 6: Insulin Glucose status in Childhood Obesity, Longitudinal Follow up Data 
 
 
 
NIGS = Normal Insulin Glucose Status AIGS = Abnormal Insulin Glucose Status T2D = Type 2 Diabetes 
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Sex Differences  
All four subjects with T2D were female (p<0.001). HOMA-IR was raised in fifty-nine (86%) females 
compared with twenty-six (70%) males (χ2=4.2, p=0.05). 120 minute hyperinsulinism was present in 
thirty-one (62%) females compared with eleven (38%) males (χ2=4.3, p=0.04) (Table 2). Within the 
BA group, mean FI (SD) was higher in females at 42.1 (24) mIU/l than males at 22.4 (15) mIU/l 
(p=0.02, 95% CI 3.1 to 36) and HOMA-IR was raised in females at 9.0 (5.5) compared with males at 5 
(3.6) (p=0.05, 95% CI 0.1 to 7.8). Ten females (31%) were diagnosed with IRS compared with three 
(16%) males. 
Ethnic differences  
Acanthosis nigricans was present in twenty-eight (62%) BA compared with sixteen (34%) BW (χ2=9.5, 
p=0.009). Mean (SD) FI was higher in BA, 40 (23) mIU/l than in BW, 28 (18) mIU/l (p=0.05, 95% CI -
15.6 to 4.7) (Table 3). Within the female group, FI was higher in BA at 42.1 (24) mIU/l than in BW at 
27.9 (20.1) mIU/l (p=0.05, 95% CI -29.4 to 1). 
Insulin Resistance Syndrome 
Fifty children (thirty-two female, eighteen male) had ≥ 3 investigations necessary for the diagnosis 
of insulin resistance syndrome. Of these twelve (24%) had obesity alone, twenty-five (50%) had two 
components and thirteen (26%): three male and ten female, had ≥ three components. 
Twenty-four children had blood pressure recorded and thirteen (54%) were hypertensive. Systolic 
blood pressure was positively correlated with BMI (r=4.1, p=0.05) (see figure 7). 
Figure 7: Correlation of BMI and systolic blood pressure 
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Fasting lipids were measured in forty-two children. Raised cholesterol was detected in four (9.5%), 
raised triglycerides in eleven (24%) and low HDL in two (4.8%). 
Fasting insulin predicted risk of IRS (3.5% increased risk for 1 mIU/l rise in fasting insulin (95%CI 1.6-
5.4, p<0.005) having adjusted for age, sex, ethnicity and pubertal stage. Fasting insulin was divided 
into tertiles (<16, 16 to <28 and ≥ 28 mIU/l) and a higher fasting insulin tertile was associated with 
an increased number of IRS components (Figure 8). 
 
Figure 8: Number of components of IRS according to Fasting Insulin Tertile in Childhood Obesity 
 
 
Characteristics of children with T2D 
All four of the patients with T2D were female with a mean age 13.6 (SD 1.8) years (range 11.1-15.18 
years). Three were BW, three had AN, three had a family history of T2DM and all were post-
pubertal. The BMI-SDS ranged from +2.35 to +12.08, mean 6.75 (SD 4.6) and this is not significantly 
different to the BMI-SDS of the children who did not have T2D (p=0.89, 95% CI -6.8 to 7.78). The 
children with T2D were more IR and this was especially evident in the fasting values: Mean FI 67.7 
(SD 11.1) vs 28.5 (21) mIU/l (p=0.001, 95% CI 15.5 to 65.0) and mean HOMA-IR 28.7(8.5) vs 6.1 (4.9) 
(p=0.04, 95% CI 1.7 to 43.5). All children with T2D were identified with raised fasting glucose values. 
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Discussion 
This preliminary study characterises some of the abnormalities associated with childhood obesity and 
demonstrates that there may be a role for monitoring insulin glucose status in obese children, as the 
rate of abnormality detection was high.  Further increases in BMI, a family history of T2D, female 
sex and Asian ethnicity all increased the risk of finding abnormalities in this cohort. 
In this study, the incidence of IGT (12.8%) and T2D (4%) are higher than previously documented in 
the UK42,44,50 or Europe45. The incidence of IGT remains lower than that reported in the US but the 
incidence of T2D is similar46,47,52. Twenty-six percent of those studied in our cohort had IRS. This is 
equivalent to that previously reported in the UK, but lower than in the US.  
Sex differences in insulin resistance have been documented the UK in the EarlyBird study of pre-
pubertal white British children (non-obese) with five year old girls being more insulin resistant than 
boys122. In this cohort, many of the insulin glucose parameters were higher in girls than boys, 
although not all achieved statistical significance.  
Several studies in children have documented ethnic differences in insulin resistance. In the Ten 
Town‟s Heart Health studies of UK children aged 8-11 years, the South Asian children were found to 
be more insulin resistant (as measured by fasting and post-glucose load insulin levels) than British 
white children123. A study of 129 healthy South Asian and white European children with BMI-SDS well 
within the normal range (equal sex and ethnic distribution), found that South Asian children were 
less insulin sensitive (p=<0.05), had more body fat (p=0.005 girls, p=0.001 boys) and more central fat 
(p=<0.001) than white European children124. The data from this cohort supports these previous 
studies in normal weight children and provides evidence that severely obese British Asian children 
are more insulin resistant and may thus be at higher risk of sequelae than obese British White 
children.   
Clinical progression from NIGS to AIGS evolves over time, with insulin resistance as the first 
detectable abnormality. In adults, development of T2D occurs in one third of subjects over 5-10 
years 31. In a study of one hundred and seventeen obese adolescents over a two year period, 
approximately 10% of subjects initially classified as NGT developed IGT and T2D developed in 24% of 
children initially classified as IGT32. Severe obesity, IGT and African-American ethnicity were the 
best predictors for developing T2D. In this UK cohort, who were followed up for between one and 
four years, 33% of children with NIGS progressed to AIGS. Data on change in pubertal status was 
incomplete over the same time period. Clearly the change in IGS could be associated with advancing 
pubertal stage, however in population studies of normal weight children, the highest mean insulin at 
Tanner stage 3 was found to be 15 mIU/l. In this study our definition of fasting hyperinsulinism was 
>26 mIU/l, therefore even if there was a deterioration in IGS due to change in pubertal stage, it still 
resulted in an abnormal elevation of insulin compared with the usual level of insulin resistance found 
in puberty. The deterioration in IGS was significantly associated with further increases in BMI. The 
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changes we found over this time period of 1-4 years suggests that the progression from NIGS to AIGS 
in adolescents may take place over a shorter time period than in adults. This faster progression of 
change is most likely to be related to relatively fast increases in BMI over this time period together 
with the physiological pubertal insulin resistance associated with peak growth velocity. 
Identification of obese children with abnormal insulin glucose status is required to allow targeted 
intervention with weight control programmes and possibly pharmacological intervention with drugs 
such as metformin. Fasting insulin was significantly associated with risk for IRS and thus may be used 
to determine the children who need further definitive investigation for all the components of IRS. 
Trials such at the MOCA trial have been developed to increase our understanding of the treatment 
options that are available for obese children and adolescents, with the aim to prevent the 
progression from normal glucose tolerance to T2D. 
 
Key message: The association between childhood obesity, abnormal insulin glucose status and 
persistence into adulthood is now well established. This study provides cross-sectional evidence 
from the UK that obese children are at risk of significant associated co-morbidity including IRS 
and T2D.  The obese children of today are likely to become obese adults in the future and the 
health and socio-economic consequences will be significant. The direct costs of obesity and 
related morbidities are currently estimated to be £4.2 billion and Foresight  have forecasted 
that this will more than double by 2050 if nothing changes. However there are also costs to the 
wider economy (e.g. sickness absence) in the region of £16 billion, and that this will rise to £50 
billion per year by 2050 if left unchecked11. 
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Chapter 3: MOCA Trial Methods 
 
Objectives 
To investigate the effect of metformin on body composition, metabolic risk factors and adipokines in 
obese children and adolescents. 
 
Hypothesis 
A. Primary hypothesis:                                                                                                                                                        
Metformin, at a dose of 1.5 g per day for six months, is more effective than placebo in reducing BMI 
Standard Deviation Scores (BMI-SDS) in obese children with abnormal insulin glucose status. Over this 
time-scale, a reduction of BMI-SDS of -1 to -2 SD would be considered an effective decrease. 
B. Secondary hypothesis:  
Metformin, at a dose of 1.5g per day for six months, is more effective than placebo in improving 
secondary outcomes including BMI, waist: hip ratio and cardiovascular and inflammatory risk 
markers: fasting and 2 hr insulin and glucose levels on OGTT, measures of insulin resistance (HOMA-
IR, QUICKI and WBISI), fasting lipids, CRP, adiponectin, leptin, resistin, adiponectin: leptin ratio and 
blood pressure. 
Metformin, at a dose of 1.5 g per day for three months (at visit two) is more effective than placebo 
for BMI-SDS, BMI, waist: hip ratio and cardiovascular and inflammatory risk markers: fasting and 2 hr 
insulin and glucose levels on OGTT, measures of insulin resistance (HOMA-IR, QUICKI and WBISI), 
fasting lipids, CRP, adiponectin, leptin, resistin, adiponectin: leptin ratio and blood pressure. 
 
MOCA Trial Design 
The MOCA trial was a two arm parallel, randomised double-blind placebo controlled superiority trial 
of metformin in children and adolescents (8-18 years) with insulin resistance and/or impaired 
glucose tolerance, over an intervention period of six months. MOCA was a multi-centre trial with six 
UK centres including the Manchester Wellcome Trust Clinical Research Facility, Sheffield Children‟s 
Hospital, the James Cook University Hospital Middlesborough, Hull Royal Infirmary, University 
Hospital Coventry and Warwickshire and Birmingham Children‟s Hospital. 
The trial registration number was ISRCTN 19517475. 
The trial comprised of three visits over six months and an outline of the trial pathway is shown 
below in Figure 9. 
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Ethics 
Ethical approval was obtained from the Salford and Trafford Research Ethics Committee on 13th 
September 2004. REC reference no: 04/Q1404/65.  
 
Funding 
Several research grant proposals were submitted and funding was secured from the Child Growth 
Foundation and Manchester University Hospital NHS Foundation Trust. 
 
Management of the MOCA trial 
The MOCA trial started in May 2005 and ended in July 2010. The trial was managed primarily by 
myself including protocol development, administration, ethics applications, funding applications, 
recruitment, liaison with other centres and reviewing the Manchester patients. 
A trial management group was organized and chaired by myself with regular bi-monthly meetings.  
A trial steering committee (TSC) and data monitoring committee (DMC) were set up by the sponsor, 
the Central Manchester and Manchester Children‟s NHS Foundation Trust, chaired by Professor Henry 
Kitchener. Other members of these committees included Dr Catherine Hall (PI), Dr Neil Wright (CI 
Sheffield), Steve Roberts (statistician), Dr Julian Davis (adult Endocrinologist, MRI), myself and 
Lynne Webster (see appendix 7 for minutes of a TSC).  
The trial was subject to a Medicines and Healthcare products Regulatory Agency (MHRA) inspection 
and new recruitment to the trial was subsequently stopped for eight months in 2006/07 (patients 
already on the trial were allowed to continue), due to incorrect placebo documentation (marketing 
authorization) with respect to regulation 13 (Supply of investigational medicinal products for the 
purpose of clinical trials, Regulation 13, prohibits anyone from selling or supplying an investigational 
medicinal product (IMP), i.e. a medicinal product to be used or tested in a clinical trial 
(or a placebo), to those involved in a clinical trial unless certain conditions are met). The trial was 
subsequently re-started as soon as the documents were in place (see appendix 8 for e-mail from 
MHRA).  
The trial was both extended and the target number of patients to be recruited was increased to one 
hundred and sixty-five, to account for the slow recruitment and the relatively high loss to follow up 
(decisions by TSC). Substantial amendments were made to account for these changes in the trial 
length and structure. 
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Figure 9: MOCA Trial Pathway 
 
 
 Power calculation 
Initially the target recruitment was one hundred and forty patients, with seventy in each group. This 
power calculation was based on the results of a previous pilot study in twenty-nine patients112. This 
study demonstrated a reduction in BMI (-0.12) and fasting insulin with metformin treatment. Using 
the standard power calculation to compare the means of a normally distributed outcome (reduction 
in BMI-SDS of 0.3 SDS), seventy in each group gave a statistical power of 80% to test for significance 
at the 5% level. This number of patients should also detect a 27% change in fasting insulin levels. 
Mean and standard deviations of fasting insulin levels are taken from a Finnish study of 3,486 
Patients screened with standard OGTT and auxology 
Eligible patients invited to enter trial: 
 BMI > 98th centile on UK BMI centile charts 
 Raised fasting insulin/120 min insulin 
AND/OR 
 Impaired glucose tolerance 
Patients recruited, consented and randomised  
Trial starts - Visit one: 
Fasting bloods, Prolonged OGTT and auxology 
Diet and exercise advice given 
Visit two @ three months: 
Fasting bloods and auxology 
Trial ends - Visit three @ six months: 
Fasting bloods, Prolonged OGTT and auxology 
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children125. However as the trial progressed it became clear that there was a withdrawal rate of 
between 15-20% and for this reason the target recruitment number was increased by the trial 
steering committee to one hundred and sixty-five to aim for one hundred and forty patients to 
complete the trial to the end. 
 
Recruitment 
 The patients for the trial were identified from obese children and adolescents aged eight to 
eighteen years, referred to each centre for investigation and management of their obesity by 
General Practitioners or General Paediatricians. These children were screened with a standard 120 
minute oral glucose tolerance test (OGTT) with insulin and glucose measures at baseline and after 
120 minutes.  
Patients for inclusion in the trial were selected from the results of the OGTT according to the 
criteria below. 
Inclusion Criteria: 
1. BMI > 98th centile on UK BMI centile charts  
AND 
2. Pubertal and post-pubertal children : Fasting insulin > 26 mIU/l 
3. Pre-pubertal children: Fasting insulin > 15 mIU/l  
 
AND/OR 
 
4. 120 minute insulin > 89 mIu/l  
 
AND/OR 
 
5. Impaired glucose tolerance i.e. OGTT 2hr plasma glucose value ≥ 7.8 to ≤11.1 
mmol/l (+/- impaired fasting glucose ≥  6.1 to ≤ 7.0 mmol/l) 
 
Exclusion Criteria:  Glycosuria, ketonuria, other chronic illness or chromosomal abnormality or 
syndrome e.g. Prader-Willi, renal insufficiency, hepatic dysfunction (raised ALT >2 SDS above mean), 
chronic diarrhoea, previous episode of lactic acidosis. 
Parents/guardians of the children eligible for the trial were then sent a letter of invitation (see 
appendix 1), parent information sheet and child age appropriate information sheets: 8-12 years and 
13-18 years (see appendix 2). They were asked to return a slip with a decision about taking part in 
the trial or not. If there was no reply within two weeks telephone contact was made with the family 
to ensure that they had received the letter and to ask if they had made a decision or needed further 
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information. 
Consent from the parents was then obtained during the first visit after checking understanding and 
assent from the child, using a standard consent form (see appendix 3). 
Randomisation 
The subjects were randomised into two groups via a computer-generated randomised numbers table: 
1. Metformin plus standardised diet and exercise advice         
2. Placebo plus standardised diet and exercise advice 
There was further stratified randomisation within each group for age and sex to minimize any bias in 
the final samples: male 8-13yrs, female 8-13 yrs, male 14-18yrs and female 14-18 yrs. The age 
groupings were to try and ensure an equal spread of ages within each treatment group. 
 
Randomisation procedure: 
The pharmacy department at each site was asked to access www.randomization.com and print out 
four randomisation lists, one for each stratification group. They were advised to use a small block 
size (four or six) depending on expected levels of recruitment. The Pharmacist then transcribed this 
into a pharmacy specific randomisation list i.e. allocated the treatments to patient numbers 
according to the lists according to that department‟s standard practice and this was re-checked by a 
second member of staff. When a MOCA prescription was received by the pharmacy department, the 
age and gender of the patient was checked and the patient‟s name written against the next 
unallocated number of that stratification group on the randomisation list. This randomisation was 
always incorporated in the prescription checking procedure. The principal investigator at each site 
had the authorisation to break the code in the case of an emergency. 
 
Trial Visits 
Following recruitment and consent to take part in the trial the patients were required to attend for 
an initial visit and then two further visits at three month intervals (table 4). 
Visit one: 
Every child had a medical history taken including documentation of a family history of T2D, birth 
weight and ethnicity. A full medical examination was performed by a Paediatrician with pubertal 
assessment according to Tanner stages121, documentation of presence of acanthosis nigricans, 
measurement of blood pressure (BP) and accurate anthropometry including height, weight, waist and 
hip measurement.  
Other investigations included: Prolonged OGTT with insulin and glucose levels at thirty minute 
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intervals for one hundred and eighty minutes (see appendix 3), leptin, resistin, adiponectin, lactate 
(due to small risk of lactic acidosis with metformin treatment), liver function tests (LFTs), CRP, 
cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. 
On completion of the above tests the participant was discharged home with a coded vial of pills 
containing either metformin (500mg) or placebo. Patients were instructed to take one pill with 
breakfast for one week, then one pill with breakfast and tea the next week and then two pills with 
breakfast and one pill with tea thereafter (1.5g per day). Written instructions were given to each 
participant (see appendix 5). 
The metformin used throughout the MOCA trial was the generic brand Glucophage and the placebo 
tablet was lactose and manufactured by University College London Hospitals Pharmaceutical 
Production Unit in accordance with MHRA specifications. 
Patients were also issued with a medication diary (see appendix 6). 
Visit two - three Month Assessment 
Patients returned to outpatients for: measurement of BP and accurate anthropometry including 
height, weight, waist and hip measurement.  
Three months investigation list (all fasting blood samples): 
 Serum glucose, insulin, leptin, resistin, adiponectin, lactate, LFT‟s, CRP, cholesterol, LDL, HDL and 
triglycerides. 
Patients were asked questions regarding compliance with medication and the medication diary was 
reviewed.  
Visit three - six Month Assessment 
The patients attended as day cases for measurement of BP and accurate anthropometry including 
height, weight, waist and hip measurement.  
Six month investigations list: 
Prolonged OGTT with insulin and glucose levels at thirty minute intervals for one hundred and eighty 
minutes.  
Fasting bloods for: serum leptin, resistin, adiponectin, lactate, LFTs, CRP, cholesterol, LDL, HDL and 
triglycerides. 
Medication diaries were collected. 
All visits were recorded in a standard Case Record File (CRF). 
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Table 4: Summary of Investigations at each visit 
Investigation 
Visit one 
Baseline 
Visit two  
3 months 
Visit three 
6 months 
Height and weight X x x 
Waist and hip circumference X x x 
Blood Pressure X x x 
Prolonged OGTT X   x 
Fasting bloods* X x x 
*Fasting Bloods: Insulin, glucose, LFT's, fasting lipids, adiponectin, leptin, 
resistin, CRP, lactate 
Discussion of drug dose and length of treatment 
The most effective dose of metformin in IGT is unknown. Clearly the balance between effectiveness 
and potential side effects has to be considered. Gastro-intestinal side effects are minimised if the 
dose is increased gradually and as hypoglycaemia is rare, higher doses can be considered. The dose 
of 1.5g per day is based on previous studies in children with IGT (500mg bd112 and 850mg bd113). Size 
of tablets for children and frequency of administration can effect compliance in children. In order to 
maximise compliance in this study, metformin was taken twice a day with the larger dose of 1g 
taken in the morning with food (to minimise gastrointestinal side effects and risk of hypoglycaemia) 
and 500 mg in the evening.  
The length of treatment in children with IGT is also unknown. Adults are treated indefinitely but this 
may not be practical or beneficial in children. Six months treatment has been used in the previous 
studies and this length of treatment should therefore be sufficient to detect changes in BMI-SDS and 
other variables (see table 84).  
Discussion of diet and exercise advice given in MOCA 
All of the children in the trial were provided with standardised lifestyle advice regarding a healthy 
diet and increasing levels of exercise to 30 minutes per day (see appendices 9 and 10). This advice 
was given at the start of the trial during a one to one session and a leaflet was also provided. It is 
not anticipated that this lifestyle advice will have a significant impact. A dedicated lifestyle 
intervention arm was not included in this study. 
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Auxological Methods 
Measurement of Height. 
The children were measured using a Harpenden stadiometer according to a standard operating 
procedure and good clinical practice126. The procedure was first explained to the child and the 
child's shoes and socks were removed. The child's body was positioned with their feet together, flat 
on the ground and heels touching the footboard.  The child‟s head was positioned with the lower 
margins of the orbit in the same horizontal plane as the external auditory meati, i.e. the corner of 
the eyes horizontal to the middle of the ear. The headboard of the apparatus was placed carefully 
on the child‟s head and the measurer placed their hands on the child‟s mastoid processes. The child 
was asked to breathe in normally and as they inhaled light pressure was maintained on the mastoids. 
The child was asked to breathe out normally and gentle upward pressure was exerted on their 
mastoid processes.  Once the child had fully exhaled the measurement was recorded to the last 
complete millimetre with the instrument read at eye level.  The height was then recorded in the 
CRF. 
Measurement of Weight 
The children were weighed using Seca 954 scales. The scales were placed on a firm and level surface 
and the procedure was explained to the child and parent. The scale's display was turned on as a 
check for the operational function and it was ensured that they were in kilogram (kg) mode. The 
child was asked to remove their shoes and all heavy clothing. The child was asked to sit on the 
scales, as still as possible. The display showed a fixed reading and the weight was then recorded in 
kgs to two decimal places, in the CRF. 
Calculation of Body Mass Index and BMI-SDS 
Body mass index at each visit was calculated using the formula: 
Weight (kg)/height(m)2  = BMI kg/m2 
BMI-SDS were then derived from 1990 UK growth data. 
Measurement of Waist circumference 
Waist circumference was measured using a self regulating spring loaded tape measure, with subjects 
in the standing position. Measurements were taken midway between the inferior margin of the last 
rib and the crest of the ilium, in a horizontal plane. Each landmark was palpated and marked and 
the midpoint determined by tape measure. Subjects were asked to breathe normally and at the time 
of the measurements, and asked to breathe out gently. This prevents the subject from contracting 
  
 
57 
 
their muscles or from holding their breath. Measurements were made in duplicate to the nearest 0.1 
cm.  
Measurement of Hip circumference 
Hip circumference was measured using a self regulating spring loaded tape measure, with subjects in 
the standing position. The observer sat in front of the subject and fitted the tape round the widest 
part of the buttocks. Subjects were asked to breathe normally and at the time of the measurements, 
and asked to breathe out gently as with waist measurements. Measurements were made in duplicate 
to the nearest 0.1 cm.  
Auxological Methods: Body Mass Index and waist circumference as a measurement of fatness 
 In the UK cut-offs for overweight and obesity in children are defined as 91st and 98th centiles on the 
1990 sex and age specific BMI reference charts2. Epidemiological evidence supports these cut-offs 
with the risk of eventual morbidity significantly rising with a BMI above the 95th centile. BMI alone as 
an indicator of adiposity in children is limited as it does not reflect body composition, but it is a 
useful tool to diagnose obesity and monitor change. However more accurate techniques to measure 
body composition using DEXA, MRI and CT are costly, invasive and have limited availability.  
Waist circumference as a proxy bedside measure of visceral adipose tissue is now in clinical use. A 
waist circumference in adult men and women >100cm is a good surrogate for a visceral adipose 
tissue depot>130cm127. Furthermore, a study in 2746 Swedish adults aged eighteen to seventy-two 
years concluded that waist circumference is an independent risk factor for cardiovascular disease 
and is a good predictor of insulin sensitivity in both sexes (<100cm excludes insulin resistance)128. 
The cut offs for cardiovascular disease were 102 cm and 88cm in men and women respectively.  
Waist circumference percentile charts for British children are available129. There is no consensus 
about how to define paediatric obesity using waist measurement, but the 99.6th or 98th centiles are 
suggested for obesity and 91st centile for overweight. An association between waist circumference 
and adverse atherogenic profile was documented in children in the Bogalusa heart study130. In a 
study of five hundred and eighty children, the 80th percentile for waist circumference correctly 
identified almost 90 % of children with high trunk fat mass measured by DEXA (sensitivity) and over 
90% of children with low fat mass (specificity)131.  
Accurate anthropometry with measurement of waist circumference, hip circumference and BMI are 
simple non-invasive methods used in MOCA to assess abdominal adiposity and overall adiposity 
respectively, at baseline and to monitor changes over time with treatment.  
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Blood Pressure Measurement 
Blood pressure was measured using the Critikon Dinamap Pro 400. The correct cuff size was selected 
for the size of the participant's limb. The participant's brachial artery was palpated and the cuff was 
placed so that the patient's artery was aligned with cuff arrow marked "artery". The cuff was 
wrapped snugly around the participant's limb. The BP was recorded by pressing the start/stop 
button. Heart rate was also recorded. 
 
Statistical Analysis 
Data Validation 
The date were validated using a number of methods including: 
1. Allocation sequence checking  
2. Date sequence checking 
3. Range checks on continuous variable e.g. minimum and maximum values 
4. Frequency checks on categorical variables 
5. Compatibility checks in cross tabulation 
Analysis 
SPSS software v 16 for windows was used to analyse the results. All values are expressed as mean 
±SD. Variables that were not normally distributed were log-transformed for analysis. However, for 
clarity of interpretation, results are usually expressed as untransformed values. All ratios and 
concentration values were also log transformed.  
The first analysis was to describe the demographic and clinical baseline characteristics of the two 
groups (metformin and placebo). Differences in the means of continuous variables were tested by 
student t-tests. Non-parametric statistics were applied in the analysis of data that had a skewed 
distribution. Correlations between variables and baseline were examined using Spearmans 
Correlation coefficient. 
The primary outcome of difference in BMI-SDS between the groups at six months was analysed using 
an ANCOVA test (adjusted for baseline BMI-SDS). Potential small amounts of effect modification 
and/or confounding factors due to sex, pubertal status and ethnicity that might remain after 
randomisation were minimised via multivariate regression analysis. The secondary outcomes were 
also analysed using an ANCOVA test (adjusting for the same baseline value). 
All analyses were performed on an intention to treat (ITT) basis132. ITT in the MOCA trial has been 
interpreted to mean that once randomised the participant is included in the primary analysis 
regardless of what occurs post-randomisation.  In MOCA, this included making all reasonable efforts 
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to obtain follow-up data on all randomised participants, including those who did not receive any 
study medication.  Results were reported according to the CONSORT guidelines133. 
 
Laboratory Investigations Methods 
 
The bloods collected from the subjects during the three visits were analysed in the laboratory 
according to specific standard operating procedures. An outline of each method is given below. 
 Insulin 
The Delfia 04 Insulin commercial assay kit was used to measure insulin in the MOCA trial. The Delfia 
Insulin assay is a solid-phase two-site Fluoroimmunometric assay, in which Insulin in the sample 
reacts with an immobilised monoclonal antibody specific for one site on the insulin molecule and a 
Europium labeled monoclonal antibody specific for a different site on the insulin molecule. 
Enhancement solution is used to dissociate the Europium ions into solution where they form highly 
fluorescent chelates. The resulting fluorescence is directly proportional to the concentration of 
insulin in the sample and measured using the AutoDELFIA automatic immunoassay system. 
The fasting reference range quoted by Perkin Elmer is 2.3 - 26mIU/l (n=150 healthy fasted adults). 
Results were reported to the nearest 0.1mIU/l, between 1mIU/l and 10mIU/l and reported to the 
nearest 1 above 10mIU/l. The assay typically has an intra-assay coefficient of variation (CV) of 3% 
and an inter-assay CV of 3.5%. 
Fasting insulin as a measure of whole body insulin sensitivity has been found to be disappointingly 
inaccurate in an individual child. Correlation analyses with the euglycaemic clamp, frequently 
sampled intravenous glucose tolerance test (FSIVGTT) and the steady-state plasma glucose (SSPG) 
have been low134. The correlations reported vary between 0.42-0.92 for fasting insulin and clamp135, 
136 and from 0.18 to 0.8 for fasting insulin and the FSIVGTT137,138,139,140. In the largest of these studies, 
the correlation between fasting insulin and clamp was 0.42 at a mean age of 13 yrs (n=3230) and 
0.29 at a mean age of 15 yrs (n=300), although correlations were slightly higher in obese children. 
Measurements of Insulin Sensitivity 
The gold standard for measurement of insulin sensitivity is the hyperinsulinaemic-euglycaemic 
clamp. Other valid measurements are the FSIVGTT or SSPG. However these tests are time-
consuming, labour intensive, invasive and technically difficult in obese children.  
The oral glucose tolerance test (OGTT) is a safe and relatively simple test that involves an oral 
glucose load and measurement of basal and 120 minute insulin and glucose levels.  It allows 
calculation of various indices of insulin sensitivity from mathematical modeling of insulin and glucose 
values including:   
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1. The homeostasis model assessment insulin resistance index:  
HOMA-IR = fasting insulin x fasting glucose/22.5)141,142. Low values <2.5 indicate greater insulin 
sensitivity and higher values >2.5 indicate insulin resistance. 
2. The quantitative insulin sensitivity check index: 
QUICKI = 1 / (log fasting insulin + log fasting glucose)143. Higher values indicate greater insulin 
sensitivity. In a sample of two hundred and fifty-three healthy adults the cut off for insulin 
resistance was 0.33144. This is in agreement with the results of a further study in 65 subjects where a 
value of 0.33 was at the 25th percentile, 0.34 the 50th percentile, 0.36 the 75th percentile and 0.38 
the 90th percentile145. 
3. The whole body insulin sensitivity index: 
WBISI = 10,000 / √ (fasting glucose x fasting insulin) X (mean glucose x mean insulin during 
pOGTT)146. The higher the WBISI value, the greater the insulin sensitivity. The threshold value for 
adult subjects who do not have insulin resistance is 3 or higher, although another study used 2.5 as 
the cut off to find adult subjects with insulin resistance in the US. There are no population studies in 
children. A prolonged OGTT (pOGTT) that continues until 180 minutes is used for this calculation.  
These indices have been validated in both adults and children and adolescents and HOMA-IR and 
QUICKI have been widely used in adults and children to quantify IR. In adult studies comparing the 
OGTT to the euglycaemic clamp, high correlations have been reported147. 
The first two indexes used in the MOCA trial are based on fasting measurements of insulin and 
glucose, whereas the IR associated with obesity is mainly due to an impairment of insulin action in 
response to a glucose challenge or meal. It could be argued that HOMA-IR and QUICKI may 
underestimate obesity associated IR.  Fasting insulin is highly variable (53-fold variation) and as 
described earlier is not a good measure of peripheral IR. The addition of fasting glucose into the 
calculation of these indices is now thought not to improve the accuracy of insulin alone as there is a 
very small variation in fasting glucose values even amongst those with obesity or abnormal glucose 
tolerance148,149. 
Small studies have shown a good correlation for these indices with gold standards for the 
measurement of IR, but larger studies may be needed before the indices can be adopted for clinical 
use in individual children. In a study of eighteen obese children  HOMA-IR, QUICKI and fasting insulin 
correlated strongly with insulin sensitivity as measured by the FSIVGTT (r=-0.9, p=<0.01 and r=0.9, 
p<0.1 respectively)150. In another study of eighteen black and white children with NGT, QUICKI 
correlated best with insulin sensitivity measured by the euglycaemic clamps (r=0.69, p<0.05)151.  In 
the MOCA study we have used these indices as measurements of IR due to the difficulty in obtaining 
full pOGTT samples in obese children. 
WBISI represents a measure of whole body insulin sensitivity and includes insulin sensitivity in the 
basal state and after ingestion of a glucose load (mean insulin and glucose during a frequently 
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sampled 180 minute OGTT). This index correlated very strongly with insulin sensitivity derived from 
euglycaemic clamps in 153 adults with varying degrees of glucose tolerance (r=0.73, p<0.0001). In 
children aged 8-18 years with NGT and IGT, the WBISI represented a good estimate for insulin 
sensitivity derived from euglycaemic clamp studies (r=0.78, p<0.0005)152. In addition this study 
demonstrated that using the WBISI it is possible to construct feedback relationship curves that relate 
insulin sensitivity with β-cell function. The WBISI was also found to correlate with a marker of 
peripheral IR, intramyocellular lipid content (r=-0.74, p<0.0001). 
Indices of insulin sensitivity derived from fasting values (HOMA-IR and QUICKI) appear to correlate 
with the gold standard methods of measuring insulin sensitivity in some smaller studies and are far 
easier and more practical to obtain than other methods. WBISI offers a method of assessing insulin 
sensitivity in response to a glucose challenge and may therefore be a better measure of IR in the 
obese child. These indices were used to measure insulin resistance/sensitivity in the MOCA trial at 
baseline, three and six months. 
Glucose 
Glucose was measured using the Roche COBA INTEGRA Glucose HK Liquid cassette which was used 
with the COBAS INTEGRA systems. This was an enzymatic reference method using hexokinase to 
catalyse the phosphorylation of glucose to from glucose-6-phosphate (G6P) and ADP. A second 
enzyme, glucose-6-phosphate dehydrogenase (G6PDH) was then used to catalyse oxidation of G6P by 
NAD+ to form NADH. The concentration of the NADH formed was directly proportional to the glucose 
concentration and was determined by measuring the increase in absorbance at 340nm. The test 
range was 0.11-40 mmol/L. The normal values for both fasting glucose and 120 minute glucose after 
an OGTT have been quoted previously. The intra-assay CV is 1.6 to 1.8% and the inter-assay CV is 2 -
2.1%. 
Leptin 
 The „Quantikine‟ Human Leptin Immunoassy was used in the MOCA trial. This assay used a 
quantitative sandwich enzyme immunoassay technique. The assay microplates were pre-coated with 
a monoclonal antibody specific for Leptin. Standards and blood samples were pipetted into the wells 
and any Leptin present was bound by the immobilized antibody. The unbound substances were 
washed away and an enzyme-linked monoclonal antibody specific for Leptin was added. Following a 
further wash to remove any unbound antibody-enzyme reagent, a substrate solution was added to 
the wells and colour developed in proportion to the amount of Leptin bound in the initial step. The 
intensity of the colour was measured. The range of values from normal healthy volunteers: Male 
Serum (n = 16) Range 2.2 – 11.1 µg/l, mean 4.7 µg/l and female serum (n = 36) range 3.9 - 77 µg/l, 
mean 20.7 µg/l. The assay has an inter-assay CV of 4.37%.  
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 Resistin 
The „Quantikine‟ human Resistin Immunoassay was used in the MOCA trial. This assay also used a 
quantitative sandwich enzyme immunoassay technique. The assay microplates were pre-coated with 
a monoclonal antibody specific for Resistin. Standards and blood samples were pipetted into the 
wells and any Resistin present was bound by the immobilized antibody. The unbound substances 
were washed away and an enzyme-linked monoclonal antibody specific for Resistin was added. 
Following a further wash to remove any unbound antibody-enzyme reagent, a substrate solution was 
added to the wells and colour developed in proportion to the amount of Resistin bound in the initial 
step and the intensity of the colour was measured. The units of measurement are mg/l. The intra-
assay CV was 4.7% and the inter-assay CV was 5.6%. 
Adiponectin 
The „Quantikine‟ Human Total Adiponectin/Acrp30 Immunoassay was used in the trial. This assay is 
very similar to that used for the Leptin and Resistin and used a quantitative sandwich enzyme 
immunoassay technique. The assay microplates were pre-coated with a monoclonal antibody specific 
for Adiponectin globular domain. Standards and blood samples were pipetted into the wells and any 
Adiponectin present was bound by the immobilized antibody. The unbound substances were washed 
away and an enzyme-linked monoclonal antibody specific for Adiponectin was added. Following a 
further wash to remove any unbound antibody-enzyme reagent, a substrate solution was added to 
the wells and colour developed in proportion to the amount of Adiponectin bound in the initial step 
and the intensity of the colour was measured. The units of measurement are mg/l. The intra-assay 
CV was 3.5% and the inter-assay CV was 6.5%. 
Lactate 
The Roche COBAS INTEGRA lactate Gen.2 (LACT2) kit was used on the COBAS INTEGRA system. The 
method used an enzymatic reaction to convert lactate to pyruvate and the hydrogen peroxide 
produced by this reaction was then used in an enzymatic reaction to generate a coloured dye. The 
colour was directly proportional to the lactate concentration and was determined by measuring the 
increase in absorbance at 552 nm. Venous plasma normal values: 0.5-2.2 mmol/l. The inter-assay CV 
was 1.1% and the intra-assay CV was 0.7%. 
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Liver Function Tests:  
Alanine Amino Transferase (ALT) 
The COBAS INTEGRA 800 system analyser was used in the MOCA trial for the quantitative 
determination of the catalytic activity of Alanine amino transferase (ALT). ALT catalyses the 
reaction between L-alanine and 2-oxoglutarate and the pyruvate formed is reduced by NADH in a 
reaction catalysed by lactate dehydrogenase (LDH) to form L-lactate and NAD+ . Pyridoxal phosphate 
serves as a coenzyme in the amino transfer reaction. The rate of the NADH oxidation is directly 
proportional to the ALT activity. It is determined by measuring the decrease in absorbance at 
340nm. Test range 0-700U/l, lower detection limit is 1.0 U/l, reference range for a child < 45 U/l. 
The CV is 0.47-1% for intra-assay and 1.5-1.9% for inter-assay. 
Bilirubin 
Bilirubin was measured using the COBAS INTEGRA 800 analyser for the quantative determination of 
total bilirubin. Bilirubin is formed during degredation of aged red blood cells in the 
reticuloendothelial system. The heme portion is removed, metabolized to bilirubin, and transported 
as a complex with albumin to the liver where it is conjugated with glucuronic acid for transport 
through the bile duct and elimination through the gut. 
A colorimetric assay is used where bilirubin is coupled with a  diazonium ion in a strongly acidic 
medium forming azobilirubin. The colour intensity of the red azo-dye formed is directly proportional 
to the total bilirubin in the sample and can be measured photometrically. 
Expected values: up to 17µmol/l, Lower detection limit: 1.7µmol/l, Measuring range: 1.7 - 
650µmol/l. The method precision (CV%) is 0.6 to 3.1 % for intra-assay and 1.7 to 4.7% for inter-assay. 
C-Reactive Protein (CRP) 
CRP is an acute phase protein released in response to tissue-damaging processes such as infections, 
inflammation and malignant neoplasms. It is also related to the development of vascular disease and 
metabolic syndrome. High-sensitivity C-reactive protein (hs-CRP) is a marker of low-grade systemic 
inflammation and is reported as an independent risk factor of T2D and cardiovascular disease153. Hs-
CRP levels lower than 1 mg/L, between 1 mg/L and 3 mg/L, and higher than 3 mg/L are considered 
as low risk, intermediate risk, and high risk categories for cardiovascular disease in adults, 
respectively154. Hs- CRP was measured in the MOCA trial at the start, three and six months. 
In the MOCA trial the COBAS INTEGRA system was used to measure CRP. The principle of the test is 
CRP agglutinates with latex particles coated with mono-clonal anti-CRP antibodies. The precipitate 
is determined turbidimetrically at 552nm. Lower detection limit: 0.085mg/dl. Inter-assay CV is 2.7-
2.9% and intra-assay CV is 1.5-1.8%. 
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Fasting Lipids: Cholesterol, LDL, HDL and Triglycerides 
The Roche modular P analyser was used to analyse Cholesterol, Low density lipoprotein (LDL), high 
density lipoprotein (HDL) and triglycerides at baseline, three, and six months. This was an enzymatic 
colorimetric assay on an automated clinical chemistry analyser. 
The normal ranges in adults are: 
Total cholesterol: <5mmol/l, HDL >1mmol/l, LDL<3mmol/L, Triglycerides <1.7mmol/l. 
Thyroid Function Tests 
TSH and T4 are used to assess thyroid function in the MOCA trial at baseline and at 6 months. TSH is 
produced in the anterior pituitary and has a stimulating action in all stages of thyroid hormone 
formation and secretion. It is a sensitive measure of thyroid function. The thyroid hormone T4 has a 
major role in the regulation of metabolism. The majority of T4 is protein bound and it is the free T4 
(fT4) that is biologically active. A positive association has been reported between TSH in the normal 
range and BMI155.  Furthermore a study in over 1000 euthyroid adults reported that subject with TSH 
in the upper normal range (2.5-4.5 mU/l) were more obese, had higher triglycerides and were more 
likely to be diagnosed with the metabolic syndrome156. A TSH below 2.5 mU/l was associated with a 
better metabolic profile and the authors proposed that lowering TSH to below 2.5 mU/l may improve 
metabolism, but that further intervention trials were needed. In the MOCA trial the Roche E170 
analyser was used to measure thyroid function at baseline. This uses an electrochemiluminescence 
immunoassay (ELCIA) for the measurement of both TSH and fT4. The TSH assay is a sandwich assay 
and the fT4 assay is a competitive assay. The range for TSH is 0.005-100 IU/L and 0.3-100 pmol/L for 
fT4. 
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Chapter 4: Results of MOCA Trial Participants Characteristics 
 
 
Trial Participants 
Participants were assessed for eligibility to the trial according to the entry criteria.  
A total of two hundred and thirty-four patients were invited and screened for inclusion in the trial. 
Thirty-five participants were subsequently excluded as they did not meet the inclusion criteria and 
forty-four declined participation.  
A total of one hundred and fifty-five patients were randomised: seventy-seven (49.7%) to metformin, 
seventy-eight (50.3%) to placebo. However four did not start the trial (three metformin and one 
placebo) as they either did not attend the first visit or changed their mind due to personal 
circumstances.  
One hundred and fifty-one participants (metformin: seventy-four, placebo: seventy-seven) received 
treatment and participated in the study (see CONSORT diagram figure 10). 
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Figure 10: CONSORT Flow Diagram MOCA trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 234) 
Excluded (n= 79) 
   Not meeting inclusion criteria 
(n=35) 
   Declined to participate (n=44) 
   Other reasons (n= 0) 
Analysed (n=74) 
 Excluded from analysis (n=0) 
Lost to follow-up at 6 months (n=19) 
 
 
Allocated to metformin (n=77) 
 Received metformin (n=74) 
 Did not receive metformin (n=3) 
Lost to follow-up at 6 months (n=22) 
Allocated to placebo (n=78) 
 Received placebo (n=77) 
 Did not receive placebo (n=1) 
Analysed (n=77) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=155) 
Enrollment 
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Treatment Centre 
The participants attended six treatment centres with one hundred and six (70.2%) attending the 
Manchester centre (see table 5). 
Table 5: Participant numbers at each treatment centre 
Treatment Centre Metformin N Placebo N Total N (%) 
Manchester 52 54 106 (70.2) 
Sheffield 16 12 28 (18.5) 
Coventry 2 3 5 (3.3) 
Birmingham 2 2 4 (2.6) 
Hull 0 4 4 (2.6) 
Middlesborough 2 2 4 (2.6) 
 
Follow up data 
Follow up date were available at visit two (three months) for a total of one-hundred and twenty-four 
participants, as twenty-seven (18 %) participants did not attend (fifteen in the metformin group and 
twelve in the placebo group). 
At the final visit three (six months) follow up date were available for one-hundred and ten 
participants and a further ten participants in the placebo group and four in the metformin group did 
not attend, giving a total of forty-one (27%) lost to follow up: twenty-two (15%) in the placebo group 
and nineteen (12%) in the metformin group (see figure 11). 
In order to establish if the drop-out was related to either treatment group or starting BMI, a drop out 
analysis was performed, comparing those that did drop out at visit three with those that did not 
drop out. The drop-out analysis did not show any difference in the baseline BMI-SDS of those 
participants that did attend visit two or visit three compared to those that did not attend (see tables 
6 and 7). In addition there were no differences between the treatment groups in starting BMI-SDS, 
between those participants that did and did not attend at visit three (see figure 12). In summary the 
drop-out can be considered to be entirely random and unrelated to starting BMI-SDS or treatment 
allocation. 
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Figure 11: Follow up data MOCA trial 
 
Table 6: Baseline BMI-SDS in the participants that did and did not attend visit three 
 Follow up at visit three N Mean SD P value Difference  
(95% CI) 
BMI-SDS visit one Attended follow up  110 3.38 0.5 0.79 0.02  
(-0.22 to 0.17) Did not attend follow up  41 3.40 0.5 
T-test results 
 
Table 7: Baseline BMI-SDS in the participants that did and did not attend visit two 
 Follow up at visit two N Mean SD P value Difference  
(95% CI) 
BMI-SDS visit one Attended follow up  124 3.36 0.5 0.20 0.14 
(-0.36 to 0.08) Did not attend follow  27 3.50 0.5 
T-test results 
 
 
 
 
 
 
 
 
Placebo visit 1
77 participants
Placebo visit 2
65 participants,12 drop outs
Placebo visit 3
55 participants, 10 drop outs
TOTAL LOST TO FOLLOW UP: 22 (15%)
Metformin visit 1
74 participants
Metformin visit 2
59 participants, 15 drop outs
Metformin visit 3
55 participants, 4 dropouts
TOTAL LOST TO FOLLOW UP: 19 (12%)
TOTAL visit 1
151 participants
TOTAL visit 2
124 participants, 27 dropouts
TOTAL visit 3
110 participants, 14 dropouts
TOTAL LOST TO FOLLOW UP: 41 (27%)
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Figure 12: Drop out analysis showing the comparative distribution of BMI-SDS in the metformin and placebo 
groups between participants that did miss (Yes) and did not miss (No) visit three 
 
 
Baseline Clinical Characteristics of the Participants  
The mean age of the participants was 13.7 ± 2.3 years.  One hundred and two (67.5%) of the 
participants were female and ninety-nine (65.6%) were post-pubertal. One hundred and fifteen 
(76.2%) were White British participants, with thirty-four (22.5%) British Asian and two (1.3%) Afro-
Caribbean. 
A positive family history of T2D was noted in eighty-nine (58.9%) of the participants and seventy-
eight (51.7%) had evidence of acanthosis nigricans on examination.  
There were no differences in baseline clinical characteristics between the metformin and placebo 
groups (see table 8). 
However there were differences in the baseline characteristics according to ethnicity. The number 
of participants with AN was significantly higher in those participants from ethnic backgrounds: 
twenty-three (63.9%) in the British Asian/Afro-Caribbean (BA/AC) group compared with fifty-five 
(47.8%) in the White British group (WB), χ2 = 6 (p=0.02). In addition, participants with an ethnic 
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background were more likely to have a family history of T2D: twenty-six (72.2%) in the BA/AC group 
compared with sixty-three in the WB group (54.8%), χ2 =7.8 (p=0.05). 
Table 8: Baseline Clinical Characteristics of participants in the MOCA trial 
Characteristic Sub-group Metformin  Placebo   Total  
Age yrs (SD) Total group 13.68 (2.3) 13.64 (2.2) 
 
13.7 (2.3) 
Sex N (%) Male 25 24 49 (37.5) 
Female 49 53 102 (67.5) 
Ethnicity N (%) White British 59 56 115 (76.2) 
British Asian 14 20 34 (22.5) 
Afro-Caribbean 1 1 2 (1.3) 
Family History T2D  
N (%) 
Yes 47 42 89 (58.9) 
No 12 17 29 (19.2) 
Unknown 15 18 33 (21.9) 
Acanthosis Nigricans  
N (%) 
Yes 38 40 78 (51.7) 
No 18 16 34 (22.5) 
Unknown 18 21 39 (25.8) 
Pubertal Stage  
N (%) 
Pre-pubertal 13 14 27 (17.9) 
Pubertal/Post-
pubertal 
53 46 99 (65.6) 
Unknown 8 17 25 (16.6) 
 
Baseline Auxology and Blood Pressure   
The participants were obese with a mean BMI-SDS: +3.4 (0.5), BMI: 36.5 (6.3) kg/m2 and weight: 98.3 
(23) kg at baseline. There were no significant differences between the groups for any of the 
parameters measured (table 9). 
The baseline measures of auxology and blood pressure were normally distributed (see figure 13).  
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Figure 13: Normal distribution of baseline BMI-SDS 
 
 
Ethnic differences were found in the baseline auxology and blood pressure. The BMI-SDS in the WB 
group was significantly higher: +3.44 (SD 0.5) compared to those in the BA/AC group: +3.21 (SD 0.6) 
(p=0.04). 
Table 9: Baseline Auxology and Blood Pressure 
Characteristic Metformin Placebo Total 
N Mean (SD) 
 
N Mean (SD) N Mean (SD) 
BMI (kg/m2) 74 37.10 (6.4) 77 35.95 (6.3) 
 
151 36.51 (6.3) 
BMI-SDS 74 3.44 (0.6) 77 3.34 (0.5) 
 
151 3.39 (0.5) 
Waist circumference (cm) 
 
74 107.76 (14.2) 77 106.51 (14.1) 151 107.12 (14.14) 
Hip circumference (cm) 74 117.09 (14.9) 77 116.79 (14.5) 
 
151 116.94(14.6) 
Waist:hip ratio 
 
74 0.92 (0.1) 77 0.91 (0.1) 
 
151 0.92(0.1) 
Systolic blood pressure (mm/hg) 
 
73 119.19 (12.9) 74 117.04 (14) 147 118.11(13.5) 
Diastolic blood pressure (mm/hg) 
 
73 65.85 (8.9) 74 65.18 (8.5) 147 65.51(8.7) 
 
Baseline Biochemical Results  
The baseline biochemistry results for the participants in each group are shown in table 10 and there 
were no significant differences between the treatment groups at visit one. The baseline biochemical 
results were normally distributed (see figures 14 and 15). The mean fasting insulin was higher in the 
pubertal/post-pubertal group: 28.3 (15.9) mIU/l compared with 21.1 (8.8) mIU/l in the pre-pubertal 
group (p=0.01, 95% CI -0.9 to 0.4). The CRP in both groups was elevated: 5.06 mg/l in the metformin 
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group and 4.57mg/l in the placebo group.  The HDL was borderline in both groups at 1.07 mmol/l in 
the metformin group and 1mmol/l in the placebo group (normal <1 mmol/l). Fasting insulin was 
correlated with measures of adiposity including weight (r=0.3, p<0.001), BMI (r=0.3, p=0.005), BMI-
SDS (r=0.22, p=0.02) and waist circumference (r=0.3, p=0.002) (see figure 16).  
 
Figure 14: Normal distribution of fasting insulin 
 
 
Figure 15: Normal distribution of fasting glucose 
 
 
 
  
 
73 
 
Figure 16: Correlation of Fasting Insulin with BMI-SDS at visit one 
 
 
Table 10: Baseline Biochemistry at visit one 
 Metformin Placebo Total 
N Mean SD N Mean SD N Mean SD 
Fasting insulin (mIU/l) 55 29.00 16.7 61 25.17 11.9 116 26.99 14.4 
Fasting glucose (mmol/l) 60 4.83 0.5 62 4.75 0.5 122 4.79 0.5 
TSH (IU/l) 50 2.78 1.3 57 2.83 1.3 107 2.80 1.3 
T4 (pmol/l) 46 15.51 2.4 54 15.73 2.7 100 15.63 2.6 
Cholesterol (mmol/l) 65 4.23 0.8 64 4.15 0.8 129 4.19 0.8 
HDL (mmol/l) 62 1.07 0.2 63 1.00 0.2 125 1.04 0.2 
LDL (mmol/l) 51 2.38 0.7 50 2.35 0.6 101 2.36 0.7 
Triglycerides (mmol/l) 64 1.54 0.7 64 1.66 0.9 128 1.60 0.8 
ALT (U/l) 65 37.51 29.3 67 31.42 16.7 132 34.42 23.9 
Bilirubin (µmol/l) 52 7.42 2.9 56 7.82 5.1 108 7.63 4.2 
CRP (mg/l) 63 5.06 4.8 65 4.57 4.3 128 4.81 4.6 
Lactate (mmol/l) 54 1.45 0.3 54 1.42 0.4 108 1.44 0.4 
 
There were no significant differences in baseline biochemistry results between the ethnic groups 
(table 11).  
There were some significant differences in baseline biochemistry between the sexes (table 12):  
1. Fasting glucose was higher in males, 4.95 mmol/l vs 4.71mmol/l in females (p=0.008) 
2. 120 minute glucose was higher in females, 6.35 mmol/l vs 5.57 mmol/l (p=0.01) 
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3. 120 minute insulin was higher in females, 184.4 mIU/l vs 92.1 mIU/l (p=0.001) 
4. Mean ALT was higher in males, 44.77 vs 29.24 (p=0.004) 
5. Mean bilirubin was higher in males, 8.91 vs 7.01 (p=0.04) 
 
Table 11: Baseline biochemical characteristics at visit one by ethnicity 
 Ethnicity* 
 
N Mean SD P value Difference (95% CI) 
Fasting glucose (mmol/l) 1 93 4.81 0.5 0.3 0.10 
(-0.08 to 0.29) 2 29 4.71 0.4 
Fasting insulin (mIU/l) 1 84 26.92 13.4 0.5 1.90 
(-3.41 to 7.20) 2 31 25.02 12.3 
TSH (IU/l) 1 79 2.88 1.3 0.3 0.18 
(-0.28 to 0.83) 2 28 2.60 1.2 
T4 (pmol/l) 1 75 15.40 2.4 0.2 0.92 
(-2.24 to 0.39) 2 25 16.32 2.9 
Cholesterol (mmol/l) 1 101 4.18 0.8 0.7 0.06 
(-0.39 to 0.27) 2 28 4.24 0.7 
HDL (mmol/l) 1 97 1.03 0.2 0.2 0.05 
(-0.13 to 0.03) 2 28 1.08 0.2 
LDL (mmol/l) 1 76 2.34 0.7 0.5 0.11 
(-0.42 to 0.20) 2 25 2.45 0.7 
Triglycerides (mmol/l) 1 99 1.61 0.8 0.8 0.04 
(-0.28 to 0.36) 2 29 1.57 0.7 
ALT (IU/l) 1 103 34.29 25.1 0.9 0.57 
(-9.26 to 8.11) 2 29 34.86 19.2 
Bilirubin (µmol/l) 1 81 7.59 4.4 0.9 0.15 
(-1.79 to 1.49) 2 27 7.74 3.4 
CRP (mg/l) 1 96 4.99 5.0 0.3 0.71 
(-0.70 to 2.11) 2 32 4.28 2.8 
Lactate (mmol/l) 1 85 1.44 0.4 1.0 0 
(-0.19 to 0.18) 2 21 1.44 0.4 
*Ethnicity: 1= White British, 2= British Asian or Afro-Caribbean 
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Table 12: Baseline Characteristics by Sex 
Characteristic Sex 
 
N Mean SD Significance Difference (95% CI) 
Fasting glucose (mmol/l) female 83 4.71 0.4 0.008 0.24 
(-0.41 to -0.06) male 39 4.95 0.5 
120 minute glucose (mmol/l) female 62 6.35 1.5 0.01 0.78 
(0.19 -1.35) male 28 5.57 1.2 
Fasting Insulin (mIU/l) female 75 27.71 14.7 0.09 3.76 
(-0.05 to 8.11) male 40 23.95 8.8 
120 minute insulin (mIU/l) female 58 184.4 171.8 0.001 92.3 
(37 to 147.6) male 28 92.1 86.1 
TSH (IU/l) female 75 2.94 1.4 0.06 0.46 
(-0.02 to 0.93) male 32 2.48 1.0 
T4 (pmol/l) female 70 15.53 2.6 0.59 0.32 
(-1.45 to 0.83) male 30 15.85 2.6 
Cholesterol (mmol/l) female 87 4.18 0.8 0.80 0.04 
(-0.34 to 0.27) male 42 4.22 0.8 
HDL (mmol/l) female 86 1.06 0.2 0.12 0.06 
(-0.01 to 0.13) male 39 1.00 0.2 
LDL (mmol/l) female 68 2.34 0.7 0.62 0.07 
(-0.36 to 0.21) male 33 2.41 0.7 
Triglycerides (mmol/l) female 87 1.56 0.8 0.43 0.13 
(-0.43 to 0.19) male 41 1.69 0.8 
ALT (IU/l) female 88 29.24 15.6 0.004 15.53 
(-25.99 to -5.07) male 44 44.77 32.8 
Bilirubin (µmol/l) female 73 7.01 3.9 0.04 1.9 
(-3.66 to -0.14) male 35 8.91 4.4 
CRP (mg/l) female 85 4.97 4.2 0.60 0.03 
(-1.36 to 2.31) male 43 4.50 5.3 
Lactate (mmol/l) female 73 1.43 0.4 0.97 0 
(-0.15 to 0.15) male 35 1.43 0.3 
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Table 13: Main baseline characteristics by treatment group and sex 
  Metformin Placebo 
 Characteristic Sub-group Male  Female Male Female 
Ethnicity (N) 
  
  
White British 19 40 16 40 
British Asian 5 9 8 12 
Afro-Caribbean 1 0 0 1 
Family History T2D (N) 
  
  
Yes 15 32 11 31 
No 5 7 5 12 
Unk 5 10 8 10 
Acanthosis Nigricans 
(N) 
  
 
Yes 12 26 10 30 
No 5 13 7 9 
Unk 8 10 7 14 
Pubertal stage (N) 
  
  
Pre-pubertal 6 7 4 10 
Pubertal/post-
pubertal 
16 37 11 35 
Unk 3 5 9 8 
Age (mean, SD) 13.8 (2.3) 13.6 (2.3) 14.1 (2.20 13.4 (2.2) 
BMI-SDS (mean, SD) 3.3 (0.5) 3.5 (0.6) 3.3 (0.5) 3.3 (0.5) 
Fasting insulin (mean, SD) mIU/l 22.6 (8.5)* 30.9 (16)* 25.2 (9.2) 25.1 (13.2) 
Fasting glucose (mean, SD) mmol/l 5.0 (0.4) 4.8 (0.5) 4.9 (0.5) 4.7 (0.4) 
HOMA-IR (mean, SD) 5.2 (1.9) 6.6 (3.4) 5.7 (2.4) 5.3 (3.2) 
 
*p=0.02 (difference: 8.3, CI: 1.6 to 15) 
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Table 14: Main baseline characteristics by treatment group and ethnicity 
  Metformin Placebo 
 Characteristic Sub-group 
White 
British 
British 
Asian/AC 
White 
British 
British 
Asian/AC 
Sex 
  
Male 19 6 16 8 
Female 40 9 40 13 
Family History 
T2D 
  
  
Yes 35 12 28 14 
No 11 1 16 1 
Unknown 13 2 12 6 
Acanthosis 
Nigricans 
  
  
Yes 27 11 28 12 
No 17 1 15 1 
Unknown 15 3 13 8 
Pubertal stage 
  
  
Pre-pubertal 10 3 9 4 
Pubertal/post-
pubertal 42 11 36 10 
Unknown 7 1 11 6 
Age 13.8 (2.2) 13.3 (2.6) 13.8 (2.1) 13.3 (2.6) 
BMI-SDS (mean, SD) 3.5 (0.5)* 3.1 (0.7)* 3.3 (0.5) 3.3 (0.5) 
Fasting insulin (mean, SD) mIU/l 28.6 (14.8) 24.9 (12.2) 25.2 (11.7) 25.1 (12.7) 
Fasting glucose (mean, SD) mIU/l 4.9 (0.4) 4.8 (0.5) 4.8 (0.5) 4.7 (0.4) 
HOMA-IR (mean, SD) 6.2 (3.1) 5.7 (2.8) 5.5 (2.9) 5.3 (3.4) 
 
* p=0.02 (difference: 0.04, 95% CI: 0.08 to 0.8) 
 
Baseline Measures of Insulin Resistance/Sensitivity 
The MOCA participants were selected due to abnormalities in insulin glucose status. HOMA-IR was 
significantly raised (>2.5) in both groups, indicating IR at baseline in both groups. In addition, both 
groups had low QUICKI values at baseline, indicating that both groups had poor insulin sensitivity. 
There was a small, but significant, difference in QUICKI between the groups at baseline (p=0.04), 
indicating that the metformin group may have been less insulin sensitive at the start using this 
parameter of insulin resistance (see table 15). WBISI was also lower in the metformin group, but the 
difference did not achieve significance. HOMA-IR was correlated with 120 minute insulin (r=0.4, 
p=0.001), 120 minute glucose (r=0.3, p=0.009) and waist circumference (r=0.4, p<0.001). QUICKI 
negatively correlated with waist circumference (r=-0.3, p=0.007) and 120 minute insulin (r=-0.4, 
p=0.003). 
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Table 15: Baseline measures of insulin resistance 
Measure of Insulin Resistance/Sensitivity Metformin Placebo Total 
N Mean SD N Mean SD N Mean SD 
HOMA-IR 45 6.10 3.0 52 5.45 3.0 97 5.75 3.00 
QUICKI 43 0.237* 0.01 51 0.243* 0.02 94 0.24 0.01 
WBISI 35 1.62 0.6 34 2.12 1.8 69 1.87 1.35 
 
*p=0.04 (Difference: 0.006, 95% CI -0.01 to 0.0003) 
 
Baseline Insulin Glucose Status 
At baseline there were seventy participants (59%) with raised fasting insulin (N=116): thirty-two(64%) 
in the metformin group (n= 50) and thirty eight (58%) in the placebo group (n=66). There were fifty 
(59%) participants with raised 120 minute insulin (N=85): twenty-one (55%) in the metformin group 
(n=38) and twenty-nine (60%) in the placebo group (n=48). Raised fasting glucose (N=122) was only 
found in one participant in the metformin group and raised 120 minute glucose (N=90) was raised in 
eight (9%) participants: three (7%) in the metformin group (n=43) and five(11%) in the placebo group 
(n=47) (see table 51). There were no significant differences in numbers of participants with 
abnormalities between the groups at baseline. 
 
Baseline Characteristics according to Treatment Centre 
In order to ensure the participants at each centre were not significantly different, the baseline BMI-
SDS and fasting insulin were compared. The visit one BMI-SDS and fasting insulin at each centre were 
not significantly different (BMI-SDS: p=0.1, fasting insulin: p=0.3) (see tables 16 and 17). 
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Table 16: BMI-SDS at visit one in each treatment centre 
BMI-SDS Visit One 
 
Treatment Centre N Mean SD SE 95% CI Minimum Maximum 
Lower Upper 
Manchester 106 3.4 0.5 0.0 3.3 3.5 2.1 4.4 
Birmingham 4 2.9 1.0 0.5 1.3 4.5 1.9 4.3 
Coventry 5 3.0 0.6 0.3 2.2 3.7 2.1 3.9 
Hull 4 3.0 0.5 0.2 2.2 3.7 2.5 3.6 
Middlesborough 4 3.6 0.8 0.4 2.4 4.9 2.7 4.5 
Sheffield 28 3.4 0.5 0.1 3.2 3.6 2.4 4.4 
Total 151 3.4 0.5 0.0 3.3 3.5 1.9 4.5 
 
Table 17: Fasting insulin at visit one in each treatment centre 
Fasting Insulin Visit One 
 
Treatment Centre N Mean SD SE 95% CI Minimum Maximum 
Lower Upper 
Manchester 84 28.0 13.2 1.4 25.1 30.8 7.1 63.4 
Birmingham 4 27.0 6.9 3.4 16.1 37.9 19.3 35.8 
Coventry 4 22.6 5.4 2.7 14.0 31.2 15.9 28.4 
Hull 3 20.7 6.4 3.7 4.9 36.4 17.0 28.0 
Middlesborough 4 14.4 3.5 1.8 8.7 20.0 11.0 18.1 
Sheffield 16 23.0 15.5 3.9 14.8 31.3 4.1 68.8 
Total 115 26.4 13.1 1.2 24.0 28.8 4.1 68.8 
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Chapter 5: Results of Auxology and Blood Pressure  
 
The results will all be presented with the visit three data (six months) first, as this is the primary 
outcome. The visit two data will be presented with the secondary outcomes. 
 
Auxology and Blood Pressure Results at visit three (six months)  
Auxology measurements were obtained in fifty-five patients in each group at visit three (fifty-four in 
each group had waist-hip measurements recorded). There were no significant differences between 
the placebo and metformin groups in the auxology measurements and blood pressure at visit three 
(see table 18). 
 
Table 18: Auxology and Blood Pressure at visit three 
Visit three metformin placebo Significance 
N Mean SD N Mean SD 
BMI visit three (kg/m2) 55 36.85 6.3 55 36.16 6.5 NS 
BMI-SDS  55 3.35 0.7 55 3.31 0.5 NS 
Waist Circumference (cm) 54 108.27 14.2 54 105.85 13.6 NS 
Hip Circumference (cm) 54 118.64 14.7 54 116.51 15.1 NS 
Waist: Hip Ratio 54 0.91 0.1 54 0.91 0.1 NS 
Systolic BP (mm/hg) 55 120.62 14.4 55 117.78 13.2 NS 
Diastolic BP (mm/hg) 55 66.20 9.3 55 64.15 8.9 NS 
NS = not significant in a student t-test to compare means 
Primary Outcome: Change in BMI-SDS at visit three 
The primary outcome of reduction in BMI-SDS at visit three (six months) in the metformin group, 
compared to placebo was found to be significant. In regression analysis the BMI-SDS in the metformin 
group was significantly lower than in the placebo group, after adjustments for baseline BMI-SDS, 
pubertal status, sex and ethnicity (p=0.01, 95% CI: 0.02 to 0.19) (see table 19).  
A further analysis was performed using student t-tests to compare the change from baseline in BMI-
SDS and metformin was found to have a beneficial treatment effect over placebo with a mean 
change -0.09 compared with a mean change -0.03 in the placebo group (p=0.02) (see table 20). The 
changes in mean BMI-SDS at visit two and visit three are shown in figure 17. 
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Table 19: Regression analysis for BMI-SDS as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.10  0.01 0.02 0.19 
Pubertal Stage 0.0  0.33 -0.08 0.03 
Ethnicity 0.01  0.83 -0.08 0.11 
Sex 0.02  0.67 -0.07 0.11 
BMI-SDS Visit 1 1.03  0.00 0.95 1.11 
B=difference per unit change in measurement  
Secondary Outcomes: Change in BMI, Waist: Hip ratio and Blood Pressure at visit three 
BMI: Metformin was also found to have a beneficial treatment effect over placebo for BMI (-0.25 
kg/m2) compared with placebo (+0.21 kg/m2) at six months. In regression analysis with adjustments 
for pubertal status, sex, ethnicity and baseline visit one values, the BMI at visit three in the 
metformin group was significantly lower (table 20 and 21).  
Waist: Hip ratio: There were no significant difference between the groups for change in waist: hip 
ratio at visit three (see tables 20 and 26). 
Blood Pressure: There were no significant differences in the change at visit three for systolic or 
diastolic blood pressure between the placebo and metformin groups (see tables 20 and 26). 
Table 20: Change in BMI-SDS, BMI, Waist: Hip ratio, Systolic and Diastolic Blood Pressure at visit three  
 
 
Treatment group 
 
P value* Difference 
between 
groups* 
 
(95% CI) 
Metformin 
 
Change (SD) 
Placebo 
 
Change (SD) 
Change in BMI-SDS 
 
-0.09(0.2) -0.03(0.2) 0.02 0.06 
(-0.17 to -0.01) 
Change in BMI (kg/m2) 
 
-0.25(1.9) 0.21(2.1) <0.001 0.46 
(-1.87 to 0.49) 
Change in Waist: Hip 
 
-0.01(0.1) 0.01(0.1) 0.13 0.02 
(-0.04 to 0.03) 
Change in Systolic BP (mm/hg) 
 
1.43 (14.1) 0.74(17.4) 0.9 0.69 
(-6.34 to 5.8) 
Change in Diastolic BP (mm/hg) 
 
0.35 (10.3) -1.03 (7.2) 0.7 1.38 
(-4.1 to 2.7) 
*T-test results 
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Table 21: Regression analysis for BMI as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 1.07 0.01 0.29 1.86 
Pubertal Stage -0.05 0.84 -0.57 0.46 
Ethnicity 0.28 0.53 -0.60 1.16 
Sex -0.08 0.86 -0.91 0.76 
BMI Visit 1 0.97 0.00 0.91 1.03 
 
 
Auxology and blood Pressure results at visit two (three months) 
There were no significant differences between the placebo and metformin groups in all the auxology 
measurements and blood pressure at visit two (see table 22). 
 
Table 22: Auxology and Blood Pressure at visit two 
Visit two metformin placebo Significance 
N Mean SD N Mean SD 
BMI (kg/m2) 59 36.56 6.6 65 35.8 6.4 NS 
BMI-SDS  59 3.35 0.7 65 3.3 0.5 NS 
Waist Circumference (cm) 57 108.12 14.6 64 106.6 14.2 NS 
Hip Circumference (cm) 57 117.46 14.6 64 115.9 14.2 NS 
Waist: Hip Ratio  57 0.91 0.1 64 0.9 0.1 NS 
Systolic BP (mm/hg) 58 120.43 15.3 64 117.3 12.2 NS 
Diastolic BP (mm/hg) 58 68.21 9.8 64 66.0 8.9 NS 
NS = not significant in a student t-test to compare means 
 
Secondary Outcomes: Change in BMI-SDS, BMI, Waist: Hip ratio, Systolic and Diastolic Blood 
Pressure at visit two 
BMI-SDS: The effect of metformin to reduce BMI-SDS was detected at three months. In regression 
analysis, after adjusting for pubertal status, sex, ethnicity and baseline BMI-SDS values, the 
metformin treated group had a significantly lower BMI-SDS (p=0.01) (see table 23). 
The treatment effect of metformin (reduction in BMI-SDS) was also detected by student t-tests to 
compare mean change after three months. Metformin had a significant beneficial treatment effect 
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over placebo for BMI-SDS with a mean change of -0.09 compared with a -0.04 mean change in the 
placebo group (p=0.01) (see table 24).  
Table 23: Regression analysis for BMI-SDS as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group 0.08 0.01 0.03 0.13 
Pubertal Stage 0.00 0.93 -0.04 0.03 
Ethnicity 0.02 0.48 -0.04 0.08 
Sex 0.02 0.46 -0.03 0.08 
BMI-SDS visit one 1.04 0.00 0.99 1.09 
BMI: There was also a significant reduction in BMI at visit two in the metformin group detected by a 
student t-test to compare the mean change: mean change -0.54 kg/m2  in metformin group 
compared with a change of -0.17 kg/m2 (p= 0.003) in the placebo group. In regression analysis, 
adjusting for pubertal status, sex, ethnicity and baseline BMI values, the metformin treated group 
had a significantly lower BMI (p=0.01) at visit two (see tables 24 and 25).  
Waist: Hip Ratio: There was no significant difference in waist: hip ratio at three months using 
student t-tests to compare the means of change between the placebo and metformin groups or in 
regression analysis (see tables 24 and 26). 
Blood Pressure: There were no significant differences in the systolic and diastolic BP at visit two 
between the placebo or metformin groups using student t-tests to compare the means of the change 
or in regression analysis (see tables 24 and 26). 
Table 24: Change in BMI-SDS, BMI, Waist: Hip ratio, Systolic and Diastolic BP at visit two 
 
 
Treatment group 
 
P value* Difference 
between 
groups* 
 (95% CI) 
Metformin 
Mean change (SD) 
Placebo 
Mean change (SD) 
Change in BMI-SDS 
 
-0.09 (0.1) -0.04 (0.14) 0.01 0.05 
(-3.0 to -0.4) 
Change in BMI (kg/m2) 
 
-0.54 (1.3) -0.17 (1.4) 0.003 0.37 
(-1.2 to – 0.3) 
Change in waist:hip  
 
-0.01 (0.1) 0.01 (0.1) 0.34 0.02 
(-0.1 to 0.02) 
Change in Systolic BP 
 
1.24 (13.8) 0.23 (15.9) 0.43 1.01 
(-7.5 to 3.2) 
Change in Diastolic BP 
 
2.36 (11.2) 0.82 (9.0) 0.60 1.54 
(-4.7 to 2.6) 
*T-test results 
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Table 25: Regression analysis for BMI as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.69 0.01 0.19 1.19 
Pubertal Stage 0.09 0.62 -0.26 0.43 
Ethnicity 0.40 0.16 -0.16 0.97 
Sex -0.01 0.96 -0.54 0.51 
BMI visit one 1.01 0.00 0.97 1.05 
 
 
Table 26: Regression analysis results for BMI-SDS, BMI and Waist: Hip ratio, Systolic and Diastolic BP at visit 
two and visit three (controlling for sex, pubertal status, ethnicity and baseline visit one value) 
  Visit two P value(CI) Visit three P value (CI) 
BMI-SDS P=0.01 (0.03 to 0.13) P=0.01 (0.02 to 0.19) 
BMI P=0.01 (0.19 to 1.19) P=0.01 (0.29 to 1.86) 
Waist: Hip P=0.47 (-0.02 to 0.05) P=0.45 (-0.01 to 0.03) 
Systolic BP P=0.22 (-7.7 to 1.8) P=0.50 (-7 to 3.4) 
Diastolic BP P=0.24 (-5.3 to 1.3) P=0.36 (-4.6 to 1.7) 
 
Figure 17: BMI-SDS at visit one, visit two and visit three in the MOCA trial 
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Chapter 6: Results of Laboratory Investigations 
 
Laboratory results at visit two (three months) and visit three (six months) 
There were no significant differences between the placebo group and metformin group at visits two 
or three for all the biochemical tests using a student t-test to compare means between the groups 
(see table 27 and 28). 
 
Table 27: Biochemical results at visit two 
Visit two metformin placebo P value 
N Mean SD N Mean SD 
Fasting insulin (mIU/l) 42 27.83 18.3 39 28.56 14.5 NS 
Fasting Glucose (mmol/l) 41 4.80 0.5 52 4.84 0.4 NS 
Cholesterol Visit (mmol/l) 51 4.13 0.7 55 4.32 0.8 NS 
HDL (mmol/l) 48 1.07 0.2 54 1.07 0.3 NS 
LDL (mmol/l) 34 2.41 0.7 39 2.48 0.7 NS 
Triglycerides (mmol/l) 51 1.41 0.7 56 1.66 1.1 NS 
ALT (U/l) 51 37.47 22.5 55 31.20 19.4 NS 
Bilirubin (µmol/l) 35 7.51 3.3 41 8.29 4.3 NS 
CRP (mg/l) 36 4.78 4.2 40 4.02 3.3 NS 
Lactate (mmol/l) 42 1.36 0.4 42 1.32 0.3 NS 
 
Table 28: Biochemical results at visit three 
Visit three metformin placebo P value 
N Mean SD N Mean SD 
Fasting insulin (mIU/l) 33 28.35 15.9 35 28.94 20.8 NS 
Fasting Glucose (mmol/l) 44 4.79 0.5 40 4.76 0.4 NS 
Cholesterol Visit (mmol/l) 51 4.17 0.7 47 4.15 0.8 NS 
HDL (mmol/l) 49 1.12 0.3 44 1.12 0.3 NS 
LDL (mmol/l) 35 2.33 0.8 34 2.41 0.7 NS 
Triglycerides (mmol/l) 51 1.40 0.6 46 1.42 0.8 NS 
ALT (U/l) 50 32.80 19.3 48 31.52 21.8 NS 
Bilirubin (µmol/l) 33 7.15 4.1 36 7.92 3.9 NS 
CRP (mg/l) 45 4.80 3.7 45 5.06 6.4 NS 
Lactate (mmol/l) 39 1.40 0.4 36 1.42 0.4 NS 
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Insulin Glucose Status 
Fasting Insulin 
The mean fasting insulin results were not significantly different between the groups at visit one, 
visit two or visit three (see table 29). The trend in the mean fasting insulin was an overall reduction 
in the metformin group, but with a slight increase between visit two and three. Conversely there 
was an overall increase in fasting insulin in the placebo group. However the changes in fasting 
insulin between the visits were not significantly different between the groups (see table 30). 
In addition, the regression analyses for fasting insulin, at visits two and three, controlling for 
baseline values, pubertal stage, ethnicity, sex and treatment group were not significant (see tables 
31 and 32). In conclusion the fasting insulin levels did not vary significantly throughout the trial in 
either the metformin or placebo groups (see figure 18). 
 
Table 29: Fasting insulin at each visit 
 
Treatment Group N Mean SD P value Difference 
between groups 
(95% CI) 
Fasting Insulin visit one 
(mIU/l) 
metformin 55 29.00 16.7 0.16 3.83 
(-1.6 to 9.2) placebo 61 25.17 11.9 
Fasting Insulin visit two 
(mIU/l) 
metformin 42 27.83 18.3 0.84 0.73 
(-8.0 to 6.6) placebo 39 28.56 14.5 
Fasting Insulin visit three 
(mIU/l) 
metformin 33 28.35 15.9 0.90 0.59 
(-9.5 to 8.3) placebo 35 28.94 20.8 
T test results 
 
Table 30: Change in fasting insulin at visits two and three 
 
Treatment Group 
 
N Mean 
 
SD P value Difference  
(95% CI) 
Change in fasting insulin at visit two 
(mIU/l) 
metformin 42 -1.17 20.9 0.46 4.56 
(-5.4 to 11.7) placebo 39 3.39 15.8 
Change in fasting insulin at visit 
three (mIU/l) 
metformin 33 -0.65 18.5 0.13 4.42 
(-2 to 16.2) placebo 35 3.77 16.6 
T-test results 
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Table 31:  Regression analysis for fasting insulin as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group 3.55 0.45 -5.86 12.96 
Pubertal Stage -1.15 0.72 -7.61 5.31 
Ethnicity 5.01 0.35 -5.62 15.64 
Sex -6.67 0.17 -16.28 2.94 
Fasting insulin visit one 0.64 0.00 0.30 0.97 
 
Table 32: Regression analysis for fasting insulin as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group -1.37 0.69 -8.11 5.37 
Pubertal Stage -0.25 0.91 -4.79 4.28 
Ethnicity -5.24 0.15 -12.38 1.91 
Sex -3.64 0.28 -10.28 3.01 
Fasting insulin visit one 0.23 0.02 0.04 0.42 
 
Figure 18: Fasting insulin at visits one, two and three in both metformin and placebo groups 
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Fasting Glucose 
The mean fasting glucose results were not significantly different between the groups at visit one, 
visit two or visit three (see table 33 and figure 19). However the reduction in fasting glucose at visit 
two was significantly greater in the metformin group (-0.03 mmol/l) than in the placebo group, in 
which there was a mean increase in fasting glucose (+0.09 mmol/l) (see table 34). The regression 
analysis for fasting glucose at visit two, controlling for baseline values, pubertal stage, ethnicity, sex 
and treatment group was also significant and confirmed the difference between the groups (p=0.05) 
(see table 35).  
Although the reduction in fasting glucose was sustained at visit three, it did not achieve significance 
in statistical tests (see tables 34 and 36). 
 
Table 33: Fasting glucose at each visit 
 
 
Treatment Group N Mean SD P value Difference 
between groups  
(95% CI) 
Fasting Glucose visit one 
(mmol/l) 
metformin 60 4.83 0.4 0.32 0.08 
(-0.08 to 0.25) placebo 62 4.75 0.4 
Fasting Glucose visit two 
(mmol/l) 
metformin 41 4.80 0.5 0.68 0.04 
(-0.24 to 0.16) placebo 52 4.84 0.4 
Fasting Glucose visit three 
(mmol/l) 
metformin 44 4.79 0.4 0.71 0.03 
(-0.16 to 0.23) placebo 40 4.76 0.4 
T test results 
 
Table 34: Change in fasting glucose between visit two and visit three 
 
metformin placebo P value Difference  
(95% CI) N Mean SD N Mean SD 
Change in fasting glucose at 
visit two 
38 -0.03 0.4 48 +0.09 0.4 0.05  0.12  
(0.05 to 0.38) 
Change in fasting glucose at 
visit three 
40 -0.04 0.4 37 +0.01 0.4 0.13  0.05  
(-0.04 to 0.3) 
T test results 
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Table 35: Regression analysis of fasting glucose as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.08 0.37 -0.09 0.24 
Pubertal Stage -0.04 0.43 -0.15 0.06 
Ethnicity 0.08 0.39 -0.10 0.26 
Sex 0.14 0.14 -0.04 0.31 
Fasting Glucose visit one 0.46 0.00 0.28 0.65 
 
Table 36: Regression analysis for fasting glucose as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower  Upper 
Treatment Group 0.16 0.05 0.00 0.33 
Pubertal Stage -0.02 0.71 -0.12 0.08 
Ethnicity 0.02 0.85 -0.17 0.20 
Sex 0.03 0.77 -0.15 0.20 
Fasting glucose visit 1 0.61 0.00 0.43 0.78 
 
Figure 19: Fasting glucose at visits one, two and three in both the metformin and placebo groups 
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Prolonged Oral Glucose Tolerance Test Results 
Insulin 
The insulin results during the pOGTT at each time interval (0, 30, 60, 90, 120,150 and 180 mins) 
were higher in the metfomin group compared with the placebo group at all the time intervals other 
than 60 minutes at visit one, but they were not significantly different in statistical analysis except at 
150 minutes in visit three (see table 37).  
The peak insulin occurred at thirty minutes in the metformin group and at sixty minutes in the 
placebo group, however there was no significant difference in peak mean insulin results between the 
two groups in regression analysis (see figure 20 and table 38).  
The 120 minute insulin was not significantly different between the groups at visit one or three and in 
regression analysis there was no significant difference detected (see table 39). 
It must be noted that the numbers of children with results at each time interval varies due to 
difficulties in blood sampling or loss of the intravenous line. There were fourteen children in the 
metformin group and eleven in the placebo group that had the pOGTT with insulin results at both 
visit one and at visit three.  
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Table 37: Insulin results in the prolonged oral glucose tolerance test 
 
Visit 
 
Insulin time 
Treatment 
Group 
 
N Mean SD P value Difference  
(95% CI) 
Visit one Insulin 30mins metformin 38 238.72 196.7 0.11 57.29 
(-18.00 to 123.24) placebo 51 181.43 105.3 
Insulin 60mins  metformin 37 211.83 151.0 0.89 4.36 
(-89 to 52.04) placebo 48 216.19 196.9 
Insulin 90 mins  metformin 40 172.02 126.0 0.68 12.08 
(-52 to 56.28) placebo 47 159.94 146.7 
Insulin 120 mins metformin 37 169.70 176.0 0.43 27.44 
(-50.98 to 77.9) placebo 48 142.26 136.9 
Insulin 150 mins  metformin 37 127.92 115.2 0.23 28.33 
(-23.4 to 70.21) placebo 44 99.59 95.9 
Insulin180mins  metformin 39 84.45 100.0 0.16 28.91 
(-11.17 to 66.96) placebo 44 55.54 73.0 
Visit three Insulin 30mins  metformin 25 216.30 151.2 0.68 16.34 
(-70 to 144.42) placebo 19 199.96 108.9 
Insulin 60mins  metformin 25 204.6 151.5 0.57 21.85 
(-51 to 113.15) placebo 20 182.75 107.0 
Insulin 90mins  metformin 26 285.6 143.2 0.13 156.38 
(-13.5 to 138.87) placebo 20 129.22 101.3 
Insulin 120mins  metformin 23 277.70 171.9 0.18 158.42 
(-35.47 to 206.24) placebo 18 119.28 99.7 
Insulin 150mins  metformin 23 112.30 117.1 0.05 53.98 
(-2.68 to 134.20) placebo 19 58.32 44.5 
Insulin180mins  metformin 22 74.60 117.6 0.18 36.41 
(-38.36 to 161.27) placebo 18 38.19 37.4 
T Test results Peak values highlighted in bold 
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Figure 20: Visit one prolonged OGTT mean insulin results at each time interval 
 
 
Table 38: Regression analysis for peak insulin as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group 25.66 0.49 -48.45 99.77 
Pubertal Stage 4.63 0.85 -45.55 54.81 
Ethnicity 25.34 0.51 -51.91 102.59 
Sex 1.86 0.96 -68.67 72.38 
Peak Insulin visit 1 0.00 0.96 -0.17 0.18 
 
Table 39: Regression analysis for 120 minute insulin as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Pubertal Stage -0.10 1.00 -60.52 60.32 
Ethnicity -2.46 0.96 -102.24 97.31 
Treatment Group 6.18 0.89 -81.19 93.54 
Sex -31.11 0.47 -117.41 55.20 
Insulin 120mins 0.31 0.03 0.04 0.58 
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In the metformin group that attended both visit one and visit three (N=27) and in whom fasting 
bloods were obtained, there was no correlation between increasing BMI-SDS and increasing fasting 
insulin (p=0.91). There were eleven participants whose weight remained the same or increased but 
insulin reduced (lower right quadrant in figure 21).  There was only one participant whose weight 
increased and insulin also increased (upper right quadrant). There were nine whose weight 
decreased and insulin remained the same or increased (upper left quadrant) and there were eight in 
whom both BMI-SDS and insulin reduced (lower left quadrant). 
Conversely, in the placebo group (N=25) there was a significant correlation between increasing BMI-
SDS and increasing insulin, r= 0.154, p=0.05 (figure 22). There were only seven whose weight 
increased and insulin reduced, eleven in whom insulin and weight increased, two who had an 
increase in insulin and a reduction in BMI-SDS and five who had a reduction in both insulin and BMI-
SDS. 
 
Figure 21: Scatter plot of change in BMI-SDS vs. change in fasting insulin in the metformin group 
 
 
 
 
 
 
  
 
94 
 
Figure 22: Scatter plot of change in fasting insulin vs. change in BMI-SDS placebo group 
 
 
 
Key:  
Upper right quadrant: increase in BMI-SDS and increase in fasting insulin 
Upper left quadrant: decrease in BMI-SDS and increase in fasting insulin 
Lower right quadrant: increase in BMI-SDS and decrease in fasting insulin 
Lower left quadrant: decrease in BMI-SDS and decrease in fasting insulin 
 
Glucose 
The glucose results during the pOGTT at each time interval (0, 30, 60, 90, 120,150 and 180 mins) 
were not significantly different in statistical analysis (see table 40).  
The peak glucose occurred at thirty minutes in both the groups and there was no significant 
difference in mean peak glucose results between the two groups (see figure 23 and table 41).  
The 120 minute glucose was not significantly different between the groups at visit one or three and 
in regression analysis there was no significant difference detected (see table 42). 
It must be noted that the numbers of children with results at each time interval varies due to 
difficulties in blood sampling or loss of the intravenous line. There were nineteen children in the 
metformin group and fifteen in the placebo group that had the pOGTT with glucose results at both 
visit one and at visit three.  
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Table 40: Glucose at each time interval in the prolonged oral glucose tolerance test 
 
Visit 
 
Glucose time 
Treatment Group 
 
N Mean SD P value Difference (95% CI) 
Visit one Glucose 30 mins  metformin 46 8.14 1.2 0.07 0.48 
(-0.04 to 1.01) placebo 49 7.66 1.4 
Glucose 60mins  metformin 44 7.66 2.0 0.95 0.02 
(-0.78 to 0.82) placebo 48 7.64 1.8 
Glucose 90mins  metformin 46 6.65 1.9 0.55 0.21 
(-0.5 to 0.93) placebo 47 6.44 1.6 
Glucose 120mins  metformin 43 6.18 1.5 0.63 0.15 
(-0.46 to 0.75) placebo 47 6.03 1.4 
Glucose 150mins metformin 41 5.16 1.5 0.35 0.29 
(-0.89 to 0.32) placebo 48 5.45 1.3 
Glucose 180 mins  metformin 39 4.54 1.4 0.71 0.11 
(-0.72 to 0.49) placebo 41 4.65 1.3 
Visit three Glucose30mins  metformin 29 7.54 1.8 0.54 0.27 
(-0.59 to 1.12) placebo 26 7.27 1.4 
Glucose60mins  metformin 27 6.92 2.0 0.92 0.05 
(-0.96 to 1.07) placebo 25 6.87 1.7 
Glucose90mins metformin 29 6.32 1.5 0.42 0.31 
(-0.46 to 1.09) placebo 26 6.01 1.4 
Glucose120mins  metformin 28 5.87 1.3 0.67 0.16 
(-0.60 to 0.93) placebo 24 5.71 1.4 
Glucose 150mins metformin 28 5.07 1.1 0.62 0.16 
(-0.49 to 0.81) placebo 25 4.91 1.2 
Glucose 180 mins  metformin 28 4.37 1.6 0.64 0.17 
(-0.89 to 0.55) placebo 25 4.54 1.0 
T test results Peak values highlighted in bold 
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Figure 23: Mean glucose results at visits one and three for metformin and placebo 
 
 
Table 41: Regression analysis for peak glucose as the dependent variable at visit three 
Independent variables  B  P value 95% CI 
Lower  Upper  
Treatment Group 0.06 0.91 -0.93 1.05 
Pubertal Stage -0.33 0.35 -1.04 0.37 
Ethnicity 0.36 0.52 -0.75 1.47 
Sex 0.11 0.83 -0.92 1.15 
Peak glucose visit one 0.42 0.02 0.06 0.79 
 
Table 42: Regression analysis of 120 minute glucose as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower Upper 
Pubertal Stage -0.01 0.96 -0.58 0.56 
Ethnicity 0.29 0.50 -0.57 1.16 
Treatment Group -0.08 0.85 -0.90 0.75 
Sex 0.31 0.48 -0.57 1.19 
Glucose120mins visit one 0.39 0.01 0.12 0.66 
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Measures of Insulin Resistance/Sensitivity 
HOMA-IR 
The mean HOMA-IR at each visit were not significantly different between the metformin and placebo 
groups (see table 43). In addition to correlating with insulin and glucose (as expected), HOMA-IR 
positively correlated with weight (r=0.37, p<0.001), BMI (r=0.3, p=0.003) and BMI-SDS (r=0.22, 
p=0.03). HOMA-IR also negatively correlated with QUICKI (r=-0.9, p<0.001). 
Regression analysis for HOMA-IR at visit three and visit two, controlling for pubertal status, sex, 
ethnicity and baseline values did not show any significant difference between the groups (see tables 
44 and 45). 
 
Table 43: HOMA-IR at each visit 
 Treatment Group N Mean SD P value Difference between 
groups (95% CI) 
HOMA-IR visit one metformin 45 6.10 3.0 0.30 0.65 
(-0.60 to 0.85) placebo 52 5.45 3.0 
HOMA-IR visit two metformin 32 6.17 4.2 1.0 0 
(-1.84 to 1.84) placebo 37 6.17 3.3 
HOMA-IR visit three metformin 25 6.70 4.2 0.26 1.22 
(-0.93 to 3.39) placebo 28 5.48 3.5 
T test results 
 
Table 44: Regression analysis results for HOMA-IR as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group -1.12 0.40 -3.82 1.57 
Pubertal Stage -0.49 0.61 -2.41 1.43 
Ethnicity 0.12 0.94 -3.21 3.44 
Sex -0.81 0.56 -3.60 1.99 
HOMA-IR visit one 0.41 0.07 -0.04 0.85 
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Table 45: Regression analysis for HOMA-IR as the dependent variable at visit two 
Independent variables  B  P value 95% CI 
Lower  Upper  
Treatment Group 0.66 0.57 -1.63 2.95 
Pubertal Stage -0.44 0.54 -1.88 1.00 
Ethnicity 1.37 0.30 -1.28 4.02 
Sex 0.10 0.93 -2.16 2.35 
HOMA-IR visit one 0.37 0.04 0.02 0.72 
 
QUICKI 
The mean QUICKI at visit one was significantly lower in the metformin group (p=0.04) indicating 
that, using this parameter, this group was less insulin sensitive than the placebo group at the start 
(see table 46). As expected QUICKI correlated negatively with fasting insulin and glucose and QUICKI 
also negatively correlated with weight (r=-0.4, p<0.001), BMI (r=0.33, p=0.001) and BMI-SDS (r= -2.8, 
p=0.007). 
Regression analysis for QUICKI at visit three and visit two, controlling for pubertal status, sex, 
ethnicity and baseline values did not show any significant difference between the groups (see tables 
47 and 48). 
 
Table 46: QUICKI at visits one, two and three 
 Treatment Group N 
 
Mean SD P value Difference between 
groups (95% CI) 
QUICKI visit one metformin 45 0.237 0.01 0.04 0.003 
(-0.04 to 0.01) placebo 52 0.243 0.02 
QUICKI visit two metformin 32 0.242 0.01 0.57 0.002 
(-0.005 to 0.008) placebo 37 0.240 0.01 
QUICKI visit three metformin 25 0.240 0.01 0.55 0.002 
(-0.011 to 0.006) placebo 28 0.242 0.02 
T test results 
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Table 47: Regression analysis for QUICKI as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.00 0.89 -0.01 0.01 
Pubertal Stage 0.00 0.96 0.00 0.01 
Ethnicity 0.00 0.89 -0.01 0.02 
Sex 0.01 0.22 0.00 0.02 
QUICKI visit one 0.19 0.43 -0.29 0.66 
 
Table 48: Regression analysis for QUICKI as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.00 0.10 -0.01 0.00 
Pubertal Stage 0.00 0.27 0.00 0.01 
Ethnicity 0.00 0.68 -0.01 0.01 
Sex 0.00 0.92 0.00 0.01 
QUICKI visit one 0.30 0.02 0.06 0.55 
 
WBISI 
The WBISI at visits one and three were not significantly different (see table 49).  
Regression analysis for WBISI at visit three, controlling for pubertal status, sex, ethnicity and 
baseline values did not show any significant difference between the groups (see tables 50). 
 
Table 49: WBISI at visits one and three 
 Treatment Group N Mean SD P value Difference 
between groups 
(95% CI) 
WBISI visit one metformin 35 1.62 0.6 0.13  0.5 
(-1.2 to 0.16) placebo 34 2.12 1.8 
WBISI visit three metformin 16 1.51 0.7 0.18  0.58 
(-1.5 to 0.3) placebo 12 2.09 1.3 
T test results 
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Table 50: Regression analysis of WBISI as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group -0.60 0.23 -1.64 0.44 
Pubertal Stage 0.20 0.49 -0.41 0.81 
Ethnicity -0.27 0.59 -1.32 0.79 
Sex 0.37 0.39 -0.56 1.31 
WBISI visit one 0.22 0.09 -0.05 0.49 
 
Change in insulin glucose status 
The total number of participants with raised fasting insulin at visit two compared to visit one, 
decreased by 16% in the metformin group and increased by 14% in the placebo group. This decrease 
was most evident in the metformin-treated pre-pubertal group, where the number with raised 
fasting insulin decreased from 81% to 44% (see figure 24). The numbers of participants with 
abnormalities of glucose status (raised fasting glucose and 120 minute glucose) did not change 
significantly throughout the trial (see table 51). 
 
Figure 24: Change in fasting insulin status 
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Table 51: Changes in insulin glucose status  
  Metformin  
N/totalN(%) 
Placebo  
N/totalN(%) 
Total 
N/totalN(%)  
Raised Fasting insulin Visit one  
 
 
 
Pre-pubertal>15mIU/l  9/11(81%) 8/11(72%) 17/22 (77%) 
Pubertal/post-
pubertal>26 mIU/l  
23/44(56%) 30/50(60%) 53/94 (56%) 
Total   32/55(64%) 38/61(58%) 70/116(60%) 
Visit two  
 
Prepubertal>15 mIU/l 4/9 (44%) 7/11(63%) 11/20 (55%) 
Pubertal/postpubertal 
> 26 mIU/l  
16/33(32%) 21/28(75%) 37/61 (61%) 
Total  20/42(48%) 28/39(72%) 48/81(59%) 
Visit 
three 
 
Prepubertal>15 mIU/l  4/7 (57%) 8/9(89%) 12 /16(75%) 
Pubertal/postpubertal  
> 26 mIU/l  
14/26(54%) 16/26(62%) 30 /52(58%) 
Total  18/33(55%) 22/35(63%) 40/68 (59%) 
120 minute insulin >89 mIU/l  Visit one  21/38(55%) 29/48(60%) 50/86 (59%) 
Visit three  13/23(56%) 10/18(56%) 23/41 (56%) 
Fasting glucose ≥ 6.1 mmol/l Visit one  1/60 0/62 1/122 (<1%) 
Visit two  1/41 0/52 1/93 (<1%) 
Visit three  0/44 1/40 1/84 (<1%) 
120 minute glucose ≥ 7.8 and ≤ 
11.1 mmol/l  
Visit one  3/43(7%) 5/47(11%) 8/90 (9%) 
Visit three  2/28(7%) 1/24(4%) 3/52 (6%) 
 
 
CRP 
The CRP concentration was measured at baseline, visit two and visit three. All of the participants 
had a raised CRP at baseline. There were fifty-eight (45.7%) participants with CRP>1 to ≤3 mg/ml 
and sixty-nine (54.3%) with a CRP greater than 3mg/ml. There were no significant differences 
between the groups in numbers of participants in each category (see table 52). 
The baseline CRP was correlated with baseline BMI (r=0.23, p=0.01) and 120 minute insulin (r= 0.3, 
p=0.01) (see figure 25). 
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Figure 25: Correlation of CRP with BMI at baseline 
 
 
Table 52: Baseline CRP categories 
 
Treatment Group 
metformin placebo Total 
CRP Categories >1 to ≤3 mg/ml No 27 31 58 
% of Total 21.3% 24.4% 45.7% 
> 3mg/ml 
No 35 34 69 
% of Total 27.6% 26.8% 54.3% 
Total No 62 65 127 
% of Total 48.8% 51.2% 100.0% 
 
 
Visits two and three 
In the metformin group, there was a mean reduction in CRP (-0.26 mg/l) compared with a mean 
increase in the CRP in the placebo group (+0.49 mg/l), however this was not statistically significant 
(see table 53). 
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In addition, regression analysis, controlling for sex, pubertal stage, ethnicity and baseline CRP values 
did not discover any significant differences between treatment groups in CRP at visit three (p=0.96) 
or visit two (p=0.52)(see tables 54 and 55). Sex and baseline CRP were significant variables. 
 
Table 53: Change in CRP at visit three 
 
Treatment Group 
 
N Mean SD P value Difference  
(95% CI) 
Change in CRP metformin 43 -0.26 5.8 0.24 0.75 
(-9.9 to 4.2) placebo 44 +0.49 6.4 
T test results 
 
Table 54: Regression analysis for CRP as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.06 0.96 -5.75 7.63 
Sex -2.55 0.04 -12.37 1.60 
Pubertal Stage 0.77 0.31 -1.02 7.75 
Ethnicity 1.81 0.18 -1.43 13.94 
CRP visit 1 0.31 0.02 -0.22 1.27 
 
Table 55: Regression analysis of CRP as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group -0.45 0.52 -1.87 0.96 
Sex 0.20 0.79 -1.29 1.69 
Pubertal Stage 0.22 0.61 -0.66 1.11 
Ethnicity 0.42 0.59 -1.15 2.00 
CRP visit 1 0.71 0.00 0.51 0.92 
 
At visit three there were no significant differences between the groups in numbers of participants in 
each CRP category. Thirty seven (41.6%) of the participants were in the >1 to ≤ 3mg/ml category and 
fifty-two (58.4%) in the > 3 mg/ml category (see table 56).  
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Table 56: CRP Categories at visit three 
 
Treatment Group 
metformin placebo Total 
CRP Risk Categories visit three >1 to ≤3 mg/ml No 15 22 37 
% of Total 16.9% 24.7% 41.6% 
>3mg/ml Count 30 22 52 
% of Total 33.7% 24.7% 58.4% 
Total No 45 44 89 
% of Total 50.6% 49.4% 100.0% 
 
Fasting Lipids 
There were no significant changes in the fasting lipids at visit two or three in either the metformin 
and placebo groups. The results at visit three are presented here. T-tests for changes in the mean 
between visits one and three did not show any significant differences for cholesterol (p=0.63), HDL 
(p=0.94), LDL (p=0.55) and triglycerides (p=0.81) (see table 57). 
In addition, regression analysis, controlling for pubertal status, sex, ethnicity and baseline values did 
not show any significant difference between the groups for cholesterol (p=0.79, table 58), HDL 
(p=0.81, table 59), LDL (p=0.41, table 60) and triglycerides (p=0.46, table 61). 
 
Table 57: Changes in fasting lipids at visit three 
 
Treatment Group 
 
N Mean SD P value Difference 
(95% CI) 
Change in cholesterol metformin 47 -0.06 0.6 0.63 0.06 
(-0.17 to 0.29) placebo 42 0.00 0.5 
Change in HDL metformin 43 0.05 0.2 0.94 0.01 
(-0.11 to 1.10) placebo 39 0.04 0.2 
Change in LDL metformin 35 -0.05 0.6 0.55 0.08 
(-0.20 to 0.37) placebo 30 0.03 0.5 
Change in triglycerides metformin 47 -0.14 0.5 0.81 0.05 
(-0.24 to 0.30) placebo 41 -0.09 0.7 
T test results 
 
 
  
 
105 
 
Table 58: Regression analysis for Cholesterol as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group 0.03 0.79 -0.21 0.27 
Pubertal Stage -0.04 0.66 -0.20 0.12 
Ethnicity 0.00 0.98 -0.29 0.28 
Sex -0.13 0.29 -0.38 0.11 
Cholesterol visit one 0.79 0.00 0.64 0.94 
 
Table 59: Regression analysis for HDL as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.01 0.81 -0.10 0.12 
Pubertal Stage -0.04 0.28 -0.11 0.03 
Ethnicity 0.18 0.00 0.06 0.31 
Sex 0.07 0.20 -0.04 0.19 
HDL visit one 0.80 0.00 0.53 1.07 
 
Table 60: Regression analysis for LDL as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.13 0.41 -0.18 0.43 
Pubertal Stage -0.06 0.54 -0.25 0.13 
Ethnicity 0.00 0.99 -0.33 0.33 
Sex -0.30 0.06 -0.61 0.02 
LDL visit one 0.80 0.00 0.58 1.02 
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Table 61: Regression analysis for Triglycerides as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.09 0.46 -0.16 0.34 
Pubertal Stage -0.07 0.40 -0.24 0.10 
Ethnicity -0.21 0.15 -0.49 0.08 
Sex -0.01 0.93 -0.26 0.24 
Triglycerides visit one 0.64 0.00 0.49 0.79 
 
Liver Function Tests 
The liver function tests (bilirubin and ALT) did not alter significantly during the trial at visit two or 
visit three, in either the placebo or the metformin treated groups. 
At visit three, there was a reduction of bilirubin in the metformin group (-0.27 µmol/l) compared 
with an increase in the placebo group (+0.47µmol/l), but this was not significant (p=0.73) (see table 
62). 
The reduction in ALT was slightly higher in the metformin group (-4.71 U/l) compared with the 
placebo group (-0.22 U/l), but again this did not achieve significance (p=0.87) (see table 62). 
Furthermore, regression analysis for bilirubin and ALT at visit three, controlling for pubertal status, 
sex, ethnicity and baseline values did not show any significant changes (bilirubin: p=0.43 and ALT: 
p= 0.64) (see tables 63 and 65). 
In regression analysis for bilirubin and ALT at visit two there were also no significant changes (tables 
64 and 66). 
 
Table 62: Change in Bilirubin and ALT at visit three 
 
Treatment Group 
 
N Mean SD P value Difference (95% CI) 
Change in Bilirubin (µmol/l) metformin 33 -0.27 3.2 0.73 0.74 
(-1.50 to 2.14) placebo 35 0.47 4.2 
Change in  ALT (U/l) metformin 45 -4.71 15.3 0.87 4.59 
(-5.08 to 6.00) placebo 43 -0.22 10.5 
T test results 
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Table 63: Regression analysis for Bilirubin as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.81 0.34 -0.88 2.51 
Sex 0.28 0.75 -1.52 2.08 
Pubertal Stage -0.30 0.57 -1.36 0.75 
Ethnicity -1.63 0.09 -3.49 0.23 
Bilirubin visit one 0.53 0.00 0.35 0.72 
 
Table 64: Regression analysis for bilirubin as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group 0.43 0.46 -0.72 1.58 
Pubertal Stage 0.08 0.82 -0.63 0.79 
Ethnicity -1.14 0.08 -2.41 0.13 
Sex 0.06 0.93 -1.15 1.26 
Bilirubin visit one 0.70 0.00 0.57 0.83 
 
Table 65: Regression analysis for ALT as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 1.33 0.64 -4.27 6.93 
Sex 4.20 0.20 -2.32 10.72 
Pubertal Stage -2.35 0.21 -6.03 1.32 
Ethnicity -6.32 0.06 -12.95 0.32 
 ALT visit one 0.76 0.00 0.61 0.91 
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Table 66: Regression analysis for ALT at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group -5.09 0.11 -11.31 1.13 
Pubertal Stage -2.28 0.27 -6.36 1.80 
Ethnicity 1.06 0.77 -6.23 8.36 
Sex -1.40 0.69 -8.41 5.61 
ALT at visit one 0.81 0.00 0.63 0.99 
 
Lactate 
Lactate was measured at baseline, visit two and visit three as a safety measure. There was no 
significant change in the mean lactate at visit three between the placebo and metformin groups (see 
table 67). 
There was no significant change in lactate at visit two or visit three in regression analysis, 
controlling for sex, pubertal status, ethnicity and baseline lactate value (visit three, p=0.2) (visit 
two, p=0.5) (see tables 68 and 69). 
 
Table 67: Change in lactate at visit three 
 
Treatment Group 
 
N Mean SD P value Difference (95% CI) 
Change in lactate (mmol/l) metformin 38 -0.05 0.4 0.82 0.04 
(-0.15 to 0.19) placebo 35 -0.1 0.3 
T test results 
 
Table 68: Regression analysis for lactate as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 0.10 0.20 -0.06 0.26 
Sex 0.01 0.88 -0.15 0.18 
Pubertal Stage -0.15 0.00 -0.25 -0.05 
Ethnicity 0.06 0.49 -0.12 0.25 
Lactate visit one 0.49 0.00 0.29 0.70 
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Table 69: Regression analysis of lactate as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower  Upper 
Treatment Group -0.05 0.50 -0.20 0.10 
Sex 0.05 0.53 -0.10 0.20 
Pubertal Stage -0.02 0.63 -0.12 0.07 
Ethnicity 0.04 0.60 -0.12 0.21 
Lactate visit one 0.44 0.00 0.26 0.62 
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Chapter 7: Results of Adipokines 
 
Three adipokines were measured in the MOCA trial: resistin, adiponectin and leptin. The adipokines 
were not normally distributed and all concentrations were log transformed for analysis. 
The mean values for each adipokine were not significantly different between the two treatment 
groups at each visit (see table 70).  
 
Table 70: Baseline, visit two and visit three Resistin, Adiponectin and Leptin 
Visit Adipokine 
metformin placebo Significance 
N Mean SD N Mean SD 
Visit one Resistin (µg/l) 71 13.30 11.9 67 11.50 9.0 NS 
Adiponectin (mg/l) 72 11.63 18.4 68 8.96 13.3 NS 
Leptin (µg/l) 71 54.25 35.9 68 55.38 42.8 NS 
Visit two Resistin (µg/l) 57 15.00 12.6 54 11.85 7.7 NS 
Adiponectin (mg/l) 57 13.81 21.7 56 8.82 14.4 NS 
Leptin  (µg/l) 57 51.95 24.8 56 57.1 48.0 NS 
Visit three Resistin  (µg/l) 46 12.34 8.1 45 12.10 9.0 NS 
Adiponectin (mg/l) 48 12.39 19.7 45 9.90 14.6 NS 
Leptin (µg/l) 46 50.64 28.5 46 55.82 49.2 NS 
T test results NS = not significant 
 
Gender differences 
The baseline Leptin was significantly higher in females at 62.3 (42.5) µg/l than in males at 37.6 
(22.1) µg/l (p<0.001) (see table 71). 
 
Table 71: Sex differences in baseline adipokines 
Adipokine 
female male P value Difference (95% CI) 
N Mean SD N Mean SD 
Resistin (µg/l) 96 12.9 11.1 42 11.28 9.5 0.4 1.64 (-2.0 to 5.3) 
Adiponectin (mg/l) 98 10.1 14.2 42 10.84 20.1 0.8 0.73 (-7.6 to 6.1) 
Leptin (µg/l) 97 62.3 42.5 42 37.60 22.7 <0.001 24.70 (13.7 to 35.7) 
T test results 
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Ethnic differences 
All three adipokines were higher in the WB group, however the difference was only found to be 
significant for resistin with a mean resistin of 13.2 (11.6)µg/l in the WB group and 7.1 (8.9)µg/l in 
the BA/AC group, p=0.04 (see table 72). 
Table 72: Ethnic differences in baseline adipokines 
Adipokine 
White British British Asian / Afro-Caribbean P value Difference (95% CI) 
N Mean SD N Mean SD 
Resistin (µg/l) 104 13.22 11.6 34 9.97 6.5 0.04 3.25 (0.1 to 6.4) 
Adiponectin (mg/l) 105 11.41 17.8 35 7.10 8.9 0.06 4.31 (-0.2 to 8.9) 
Leptin (µg/l) 104 57.40 43.1 35 47.10 23.3 0.08 10.3 (-1.2 to 21.8) 
 
Resistin was positively correlated with weight (r=0.20, p=0.01), BMI (r=0.20, p=0.02), CRP (r=0.4, 
p<0.001) and adiponectin (r=0.24, p=0.04) at baseline (see figures 26 and 27). 
Adiponectin was negatively correlated with fasting insulin (r=-0.22, p=0.02), 120 minute insulin (r= -
0.3, p=0.02), fasting glucose (r= -0.25, p=0.006) and HOMA-IR (r= -0.26, p=0.01), and positively 
correlated with QUICKI (r= 0.30, p=0.004) and WBISI (r= 0.26, p=0.04) at baseline (see figure 28).  
 
Leptin was positively correlated with weight (r=0.30, p< 0.001), BMI (r=0.48, p<0.001), BMI-SDS (r= 
0.48, p<0.001), waist circumference (r=0.2, p=0.004), fasting insulin (r=0.2, p=0.04), 120 minute 
insulin (r=0.3, p=0.02) and CRP (r=0.3, p=0.02) at baseline (see figures 29 and 30). 
 
Figure 26: Correlation of Resistin with CRP at visit one 
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Figure 27: Correlation of Resistin with Adiponectin at visit one 
 
 
 
Figure 28: Correlation of Adiponectin with fasting glucose at visit one 
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Figure 29: Correlation of Leptin with BMI-SDS at visit one 
 
 
 
Figure 30: Correlation of Leptin with 120 minute insulin at visit one 
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Visit three 
There were reductions in resistin and leptin concentrations at visit three in the metformin group and 
increases in the placebo group, but the changes were not statistically significant (see tables 73, 74, 
76 and figures 31, 33). There was an increase in adiponectin but again the change was not 
statistically significant (see tables 73, 75 and figure 32).  
 
Table 73: Changes in Resistin, Adiponectin and Leptin at visit three 
Visit three 
metformin placebo P value Difference  
(95% CI) N Mean SD N Mean SD 
Change in resistin  (µg/l) 45 -0.96 8.1 42 +0.6 5.9 0.22 1.56  
(-1.2 to 4.9) 
Change in adiponectin (mg/l)  48 +0.76 15.6 42 +0.94 11.0 0.83 0.18  
(-6.2 to 5.0) 
Change in leptin (µg/l) 45 -3.61 64.4 43 +0.44 45.3 0.55 4.05 
(-30.6 to 16.5) 
T test results 
 
Table 74: Regression for Resistin as the dependent variable at visit three 
Independent variables B  P value 95% CI 
Lower  Upper  
Treatment Group 1.67 0.23 -1.09 4.44 
Pubertal Stage -1.24 0.19 -3.08 0.61 
Ethnicity -2.13 0.15 -5.05 0.79 
Sex -3.15 0.03 -5.97 -0.32 
Resistin visit one 0.61 0.00 0.47 0.74 
 
Table 75: Regression for Adiponectin as the dependent variable at visit three 
Independent variables B   P value 95% CI 
Lower Upper  
Treatment Group -3.29 0.27 -9.22 2.64 
Pubertal Stage 4.27 0.04 0.26 8.28 
Ethnicity 1.03 0.75 -5.30 7.36 
Sex -2.47 0.43 -8.70 3.77 
Adiponectin visit one 0.79 0.00 0.61 0.98 
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Table 76: Regression for Leptin as the dependent variable at visit three 
Independent variables B   P value 95% CI 
Lower  Upper  
Treatment Group -3.68 0.78 -29.60 22.24 
Pubertal Stage -4.51 0.62 -22.31 13.30 
Ethnicity -6.17 0.65 -33.21 20.86 
Sex -15.31 0.28 -43.22 12.59 
Leptin visit one 0.77 0.00 0.36 1.18 
 
Visit two 
In regression analysis there were no significant changes in any of the three adipokines at visit two 
(see tables 77, 78, 79). 
 
Table 77: Regression for Resistin as the dependent variable at visit two 
Independent variables  B  P value 95% CI 
Lower  Upper  
Treatment Group -1.19 0.44 -4.28 1.89 
Pubertal Stage -0.84 0.42 -2.89 1.21 
Ethnicity -3.01 0.08 -6.37 0.35 
Sex 0.56 0.73 -2.71 3.83 
Resistin visit one 0.67 0.00 0.53 0.81 
 
Table 78: Regression for Adiponectin as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group -1.75 0.42 -5.98 2.49 
Pubertal Stage 1.69 0.24 -1.17 4.55 
Ethnicity -1.27 0.59 -5.96 3.43 
Sex 0.13 0.96 -4.38 4.63 
Adiponectin visit one 0.88 0.00 0.76 1.00 
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Table 79: Regression for Leptin as the dependent variable at visit two 
Independent variables B  P value 95% CI 
Lower Upper  
Treatment Group 14.51 0.13 -4.48 33.51 
Pubertal Stage 3.17 0.63 -9.67 16.02 
Ethnicity -3.17 0.76 -23.94 17.60 
Sex -0.81 0.94 -21.79 20.16 
Leptin visit one 0.77 0.00 0.49 1.06 
 
 
Figure 31: Resistin at visit one, two and three 
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Figure 32: Adiponectin at visit one, two and three 
 
 
 
Figure 33: Leptin at visit one, two and three 
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Adiponectin: leptin ratio 
The mean value of the adiponectin: leptin (A/L) ratio in this cohort of obese children (n= 139) at 
baseline was 0.28 (0.6). There were no differences in the A/L ratio at baseline according to sex, 
ethnicity or treatment group (see table 80). 
 
Table 80: Adiponectin: leptin ratio at each visit 
 metformin placebo 
N Mean SD N Mean SD 
Adipinectin: leptin ratio visit one 71 0.30 0.7 68 0.26 0.5 
Adipinectin: leptin ratio visit two 57 0.34 0.6 56 0.23 0.5 
Adipinectin: leptin ratio visit three 46 0.28 0.4 45 0.29 0.5 
 
At baseline, the log A/L ratio showed significant correlations with: 
1. Measures of adiposity: BMI (r=-0.3, p=0.01), BMI-SDS (r=-0.23, p=0.07) and waist 
circumference (r=-0.3, p=0.04) (see figure 34); and 
2. Measures of insulin-glucose status: log fasting glucose (r=-0.21, p=0.02), log fasting insulin 
(r=-0.4, p<0.001), log HOMA-IR (r=-0.4, p<0.001), log QUICKI (positive correlation r=0.34, 
p=0.002) and log 120 minute insulin (-0.4, p<0.001) (see figure 35). 
 
At visit three there was no difference in the A/L ratio between the groups, using regression analysis 
and controlling for sex, ethnicity, pubertal status and baseline values (see table 81). 
However at visit two the A/L ratio had significantly increased in the metformin group (+ 0.04) 
compared with a reduction on the placebo group (-0.03), p=0.03 (see table 82).  
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Figure 34: Correlation of Adiponectin: leptin ratio with BMI-SDS at visit one 
 
 
 
Figure 35: Correlation of Adiponectin: leptin ratio and HOMA-IR at visit one 
 
 
 
 
  
 
120 
 
Table 81: Regression results for log Adiponectin: leptin ratio as the dependent variable at visit three 
Independent variables B 
 
P value 95% CI 
Lower Upper 
Treatment Group -0.22 0.21 -0.6 0.1 
Sex -0.09 0.63 -0.4 0.3 
Pubertal Stage 0.23 0.06 -0.1 0.5 
Ethnicity 0.04 0.83 -0.3 0.4 
Log adiponectin: leptin ratio visit one 0.82 0.00 0.6 1.0 
 
 
Table 82: Regression results for log Adiponectin: leptin ratio as the dependent variable at visit two 
 
Independent variables B 
 
P value 95% CI 
Lower  Upper  
Treatment Group -0.27 0.03 -0.52 -0.02 
Sex -0.01 0.93 -0.28 0.25 
Pubertal Stage 0.01 0.88 -0.15 0.18 
Ethnicity -0.16 0.24 -0.43 0.11 
Log adiponectin: leptin ratio visit one 0.78 0.00 0.66 0.90 
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Chapter 8: Safety and Adherence to Therapy 
 
There were no Suspected Unexpected Serious Adverse Reactions (SUSAR‟s) in the MOCA trial. There 
were no serious adverse events (SAE‟s) or serious adverse reactions (SAR‟s). 
There were twenty-eight adverse events, twenty in the metformin group and eight in the placebo 
group (see table 83). The commonest adverse events (diarrhoea, nausea and abdominal pain) were 
related to the gastro-intestinal tract and were to be expected, as possible side effects of metformin 
treatment. In all cases the symptoms settled with a reduction in the dose and a gradual increase 
back up to the required daily dose. 
Medication adherence and compliance to therapy were assessed at visit two and three by interview 
and review of medication diaries. Good adherence to therapy was reported and observed in most 
participants. However no formal pill counts were performed and the medication diaries were not 
formally analysed. Compliance with medication is difficult to assess particularly in this age group of 
participants and this is one of the limitations of any study done in adolescents. 
 Gastro-intestinal side effects were experienced by thirteen participants in the metformin group and 
two in the placebo group. Two patients in the metformin group withdrew from the trial due to 
recurrent diarrhoea and abdominal discomfort.  
 
Table 83: Adverse events 
Adverse event type Metformin Placebo  Total 
Diarrhoea 7 1 8 
Nausea 3 0 3 
Abdominal pain 2 1 3 
Vomited after polycal 1 2 3 
Fainted/unwell during cannulation 1 2 3 
Generally unwell 2 1 3 
Headaches 2 0 2 
Loss of appetite 1 0 1 
Possible urine infection 0 1 1 
Pneumonia 1 0 1 
Total 20 8 28 
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Chapter 9: Discussion 
 
Metformin reduces the risk of developing T2D in adult patients with obesity and insulin resistance. 
Children and adolescents have different characteristics and physiological responses to adults and 
therefore independent studies are required. It is unsatisfactory to accept evidence from adult 
studies and the studies of metformin efficacy in obese children and adolescents have been 
inconclusive and conflicting (see table 85). The MOCA trial was a prospective double-blind 
randomised placebo controlled trial to assess the role of metformin in obese non diabetic children 
and adolescents. 
 
Study Population 
The MOCA study population was representative of the obese children and adolescents who are 
currently referred to the Paediatric Endocrinology department in Manchester. These children have 
often experienced relentless weight-gain for many years, despite attempts at modifying their 
lifestyle. Entrenched unhealthy family lifestyle choices are undoubtedly a factor, but the 
physiological insulin resistance of puberty can compound the situation, resulting in severe insulin 
resistance at an early age. Attempts have often been made to interrupt this inexorable cycle by the 
child, family and health-workers, but they have frequently experienced failure and frustration which 
is partly due to the limited availability of treatment options. Specifically, the evidence to support 
pharmacological interventions in this group of patients remains deficient, hence the development of 
the MOCA trial. 
One hundred and fifty-one children and adolescents participated in the MOCA trial with equal 
randomisation: seventy-four in the metformin group and seventy-seven in the placebo group. The 
MOCA trial is the largest published study to date, followed by a study in one hundred and twenty 
obese children117.  
Clinical Characteristics 
The participants were mainly female, White British and pubertal or post-pubertal. There were only 
two Afro-Caribbean participants in the trial, however there was high British Asian representation at 
22.5%. There were no differences in baseline clinical or auxological characteristics between the 
metformin and placebo groups (ethnicity, sex, age, pubertal stage and auxology measurements). The 
participants were a significantly obese group with mean BMI of 36.5 (6.3) kg/m2 and a mean BMI-SDS 
3.4 (0.5) at the start. Ethnic differences were found with acanthosis nigricans and a family history of 
T2D being more common in the British Asian group, supporting evidence from the experience in a UK 
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specialist endocrine clinic (chapter 2). In addition the White British group were found to have a 
higher BMI-SDS than British Asian participants. 
Baseline Laboratory Tests 
Insulin Glucose Status 
The fasting insulin was positively correlated with weight, BMI, BMI-SDS and waist circumference, 
confirming its relationship with parameters of increasing adiposity in this cohort. Gender differences 
in glucose concentrations were found with the fasting glucose higher in males than females, and the 
120 minute glucose and insulin higher in females. These findings support adult data where impaired 
fasting glucose is known to be more common in men than women, and conversely impaired glucose 
tolerance after a glucose load is more common in women157. This may simply reflect the same 
glucose load being given to individuals with different weights i.e. higher weights in males or it may 
reflect a gender difference in the way that a glucose load is metabolised. However, in the MOCA 
study there was no significant difference in the baseline BMI or BMI-SDS between males and females, 
and so the difference in 120 minute insulin glucose status may reflect increased insulin resistance in 
females after a glucose load. A recent large population study in 6006 non diabetic adults also found 
that fasting glucose was significantly higher in males158.  
The measures of insulin resistance/sensitivity used in this study were HOMA-IR, QUICKI (based on 
fasting glucose and insulin values) and WBISI (based on a calculation using insulin and glucose values 
from the pOGTT). The baseline HOMA-IR was significantly elevated (>2.5) in both the metformin and 
placebo groups and both QUICKI and WBISI were low (<0.33 and <2.5 respectively), indicating 
reduced insulin sensitivity. In this cohort of obese children the indices based on fasting values were 
both associated with insulin-glucose status after a glucose load and a measure of adiposity: HOMA-IR 
was positively correlated with 120 minute insulin, 120 minute glucose and waist circumference; 
QUICKI was negatively correlated with 120 minute insulin and waist circumference. The practicality 
of assessing obese children in a non research setting must be considered and fasting bloods are far 
easier to obtain than OGTT or pOGTT blood samples. The correlation of fasting indices with glucose 
and insulin after a glucose load suggests that, in obese children, fasting bloods may give at least an 
indication of the peripheral insulin resistance associated with testing after a glucose load. 
 
CRP 
CRP is an inflammatory marker and it was elevated in all the trial participants at baseline and was 
positively correlated with baseline BMI and 120 minute insulin. In adult population studies a higher 
CRP is associated with coronary heart disease incidence and mortality, although the magnitude of 
this association is variable159. The Young Finn‟s study in 1617 subjects determined the correlation 
between childhood and adult CRP (r=0.29, p<0.0001). Childhood BMI, CRP and insulin were the 
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predictors of adult CRP160. BMI-SDS and body fatness (skin fold thickness) were also associated with 
CRP in a study of 835 young adults in whom childhood adiposity was associated with higher CRP161. 
The mechanism for the relationship between CRP and increased atherosclerosis and ischaemic heart 
disease is not entirely clear, but it is thought that the inflammatory response plays an important role 
in the development and evolution of atherosclerosis. In the group of participants in the MOCA study, 
the finding that CRP is both elevated and correlated with BMI and 120 minute insulin in childhood 
obesity is important. It confirms that childhood obesity is associated with changes in the 
inflammatory pathways and emphasises the need for intervention to prevent possible early 
development of coronary artery disease. 
 
Liver Function 
In the MOCA cohort, the ALT and bilirubin were significantly higher in the males than females. 
Previous adult population studies have found a difference between the sexes in liver function tests 
with males having higher ALT162. In a study of one hundred and twenty-seven obese adolescents, 
abnormal ALT was significantly more prevalent in boys (44%) than girls (7%)163. Reasons for the 
increase in ALT in boys may include a difference in the pattern of fat distribution in males with more 
accumulation in the intra-abdominal compartment or the influence of sex hormones, as they affect 
the distribution of both fat and muscle.  
 
Adipokines 
Adipose tissue may represent an important site for the production of pro-inflammatory cytokines and 
acute phase reactants. Three adipokines, previously related in the literature to obesity and insulin 
resistance, were studied in the MOCA trial: resistin, adiponectin and leptin.  
In this group of obese adolescents with abnormal insulin glucose status, the relationship of resistin 
with increasing adiposity (weight and BMI) and CRP is demonstrated. Resistin stimulates insulin 
resistance in rodents, but the function in human insulin glucose metabolism remains uncertain. 
There is evidence that Resistin has a role in inflammatory processes. Resistin is associated with 
inflammatory bowel disease164, coronary artery disease165, rheumatoid arthritis166 and correlates with 
severity of septic shock167. As there is evidence of some crossover between inflammatory pathways 
and insulin signalling (TNF-α and IL-6), resistin may represent a further link between inflammation 
and metabolic signalling pathways. The data from the MOCA trial suggests a potential role for 
resistin as a marker associated with inflammation in childhood obesity. Resistin was also significantly 
higher in the White British ethnic group and this difference has not been previously reported in 
obese adolescents. This may be explained by the increased BMI-SDS observed in the White British 
group. 
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Adiponectin has important beneficial biological actions including increasing insulin sensitivity which 
is relevant to the clinical development of T2D. In clinical and epidemiological studies low serum 
levels of adiponectin are associated with obesity, T2D and cardiovascular disease. In the MOCA 
cohort no association was found between adiponectin and measures of adiposity, but a robust 
relationship with insulin resistance/sensitivity was found (negative correlation with fasting glucose 
and HOMA-IR and positive correlation with QUICKI and WBISI).  
The relationship of Leptin concentration with increasing adiposity (weight, BMI, BMI-SDS) is 
confirmed in the participants in the MOCA trial. Leptin is well known to be increased in obese 
individuals and it is postulated that this may represent resistance to the actions of Leptin. Leptin 
concentrations were significantly higher in females (almost double) than males, supporting previous 
studies that have also reported two to three fold greater leptin concentrations in girls168,169. One 
study found that Leptin levels were correlated with subcutaneous adiposity, although the gender 
differences could not be fully accounted for by the differences in subcutaneous adiposity. The 
gender difference in Leptin concentration at baseline in the MOCA study may suggest that there are 
gender differences in the way that Leptin is synthesised, its bioactivity and clearance rates. 
The A/L ratio is proposed as an indicator of insulin resistance and this is confirmed by the results of 
the MOCA trial. The A/L ratio was low in this group of obese insulin resistant adolescents and it 
significantly correlated with measures of adiposity including BMI, BMI-SDS and waist circumference, 
and measures of insulin resistance including HOMA-IR and QUICKI.  
 
Primary Outcome 
The MOCA trial demonstrates a small but significant beneficial effect of metformin over placebo for 
BMI-SDS at six months with a mean reduction of 0.1 SD (3% of initial BMI-SDS) compared to a zero 
mean change in the placebo group. The reduction in BMI-SDS is similar to that in a previous study (-
0.12 in Srinivasen115) and supports the short-term use of metformin to stimulate and promote 
reduction in BMI-SDS in obese non-diabetic children and adolescents. Furthermore, the MOCA trial 
has demonstrated that metformin is effective in changing body composition, even without significant 
lifestyle change.  
The mechanism of action of metformin on body composition remains unclear. Many patients taking 
metformin report an anorectic effect and this may be an early factor when metformin is first 
started, which is then superseded by the metabolic actions of metformin. In the MOCA study the 
decline in BMI and BMI-SDS was detected at three months and sustained at six months, and a change 
in insulin glucose status (reduction in fasting glucose) was detected over the same time period, but 
then lost at six months. Longer term effects on body composition may result from the action of 
metformin to improve insulin sensitivity. The primary action of Metformin is to enhance hepatic 
glucose turnover by increasing glucose uptake and reducing glucose output. It may also act 
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peripherally to induce muscles to take up glucose from the bloodstream via the AMPK system and 
translocation of the glucose transporters GLUT-1 and GLUT-4. Studies in adults with T2D have shown 
weight loss attributed mainly to fat loss rather than lean body mass loss. Studies have demonstrated 
that metformin is increased in the gut mucosa and increases utilization of glucose in the gut in 
rodents, although the mechanism has not been identified170. There may be also be alterations in 
hepatic, adipose tissue or muscle metabolism that are not yet identified to explain the changes in 
adiposity, weight and BMI observed with metformin therapy.  
Indeed metformin has recently been shown to selectively increase levels of the gut hormone 
glucagon-like-peptide 1 (GLP-1) and Gastric Inhibitory Peptide (GIP) in mice171. Furthermore, the 
expression of genes encoding GLP-1 and GIP were enhanced, possibly via a different mechanism to 
activation of AMPK. The effects appeared to be mediated by the peroxisome proliferator-activated 
receptor-α (PPAR-α), as metformin failed to induce expression of the GLP-1 and GIP genes in PPAR-α 
knockout mice. GLP-1 and GIP are incretins (insulin secretagogues) and are involved in glucose 
homeostasis via several mechanisms including appetite regulation, gastrointestinal motility and 
insulin secretion via effects on the incretin receptor in the pancreas. Additional studies will be 
needed in humans to evaluate if metformin can increase incretin receptor expression and thus 
augment incretin action to increase insulin and reduce blood glucose. Metformin is now being used in 
combination with GLP-1 like analogues (Exenatide), which also increase pancreatic β cell function, 
in the treatment of adult T2D. 
Metformin is not a modern therapy and yet new insights into its biological actions and effectiveness 
are still being published in the literature. The metformin treatment effects in the MOCA trial are 
summarised below (table 84). 
 
Secondary Outcomes 
The MOCA trial also examined the beneficial effect of metformin over placebo at three months for 
BMI-SDS and it is apparent that the significant change in BMI-SDS in the metformin treated group 
occurred during the first three months of the trial and is then sustained at six months. Although this 
is a small reduction, in an individual it brings to an end the often inexorable rise in BMI-SDS that has 
often been an ingrained pattern for many years. The benefits in halting this rise could include an 
increase in an individual‟s self-esteem and their enthusiasm to then make further increased effort 
with changes in lifestyle. 
There was also a significant reduction in BMI (-0.25 kg/m2) at six months and three months (-0.54 
kg/m2) in the metformin group compared to placebo. Interestingly there was a slight increase in raw 
weight in both groups. However the increase in height in the metformin group was larger than the 
increase in the placebo group, resulting in the reduction in BMI in the metformin group. This 
emphasizes the need to use weight adjusted for height (BMI) in growing children and furthermore, 
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the use of age and sex adjusted BMI-SDS. Changes in weight alone are not necessarily an indication 
of success. 
Although the other secondary outcomes (laboratory investigations) at six months were not 
significantly different between the groups, there was a trend towards greater improvement in the 
metformin group. The lack of significance for the secondary outcomes (laboratory investigations) 
may reflect the smaller numbers of participants that completed the blood tests, compared to 
auxology. It may also be due to the short treatment time of six months, although a recent study in 
seventy-seven obese adolescents over forty-eight weeks, also did not find any significant changes in 
insulin or lipid indices172. In this study there was a significant reduction in BMI at the end of the 
treatment period that subsequently disappeared twelve to twenty-four weeks after the end of the 
trial.  The disappearance of this treatment effect on body composition suggests that either 
metformin treatment may be ineffective beyond the short-term. It also emphasises the requirement 
in obese patients to commit to long-term changes in their lifestyle in order to sustain any previous 
changes in body composition, induced by either drug therapy or lifestyle changes. A return to 
previous behaviours will inevitably result in disappearance of the beneficial effects.  
There was some evidence of change in the metabolic status of the participants after three months. 
Although the measures of insulin resistance/sensitivity did not change significantly in either group 
after six months, a reduction in fasting glucose (-0.03 mmol/l, p=0.05) was detected after three 
months in the metformin group. This beneficial change in fasting glucose status, demonstrated at 
three months and then lost at six months, may be explained by the decline in numbers of 
participants at six months, a change in adherence to therapy not admitted to by the participants or 
detected in the trial or a decline in the effectiveness of metformin. Nevertheless the improvement 
in fasting glucose at three months suggests that metformin treatment can have a beneficial effect 
on metabolic parameters over a short time period. 
In a sub-analysis, including children who attended both visit one and three and had fasting insulin 
taken at both visits (N=52), the positive correlation between fasting insulin and BMI-SDS seen at 
baseline was disrupted, but in the placebo group it was not. There were more children who had a 
reduction in fasting insulin, despite an increase in BMI-SDS, in the metformin group than the placebo 
group. Perhaps this suggests that with larger numbers attending both visits for blood tests, a 
significant effect of metformin on fasting insulin and insulin resistance/sensitivity may have been 
detected after six months. 
The trend over the six month treatment period was for CRP to decrease in the metformin group and 
increase in the placebo group, although statistical significance was not achieved. Studies in adults 
have found that lifestyle intervention is more effective to reduce CRP than metformin65. Further 
studies are needed to examine the effects of metformin intervention on CRP in obese children and 
adolescents. 
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There were no changes in fasting lipid concentrations detected in the MOCA trial and this is in 
conflict with a recently published trial compared six months metformin and lifestyle intervention 
with lifestyle alone in twenty-five obese adolescents aged 10-16 years173. A reduction in BMI (-
1.8kg/m2) and an improvement in plasma lipids were reported in the metformin group, but no 
improvement in HOMA-IR was detected.  
There have been discrepant results from trials of metformin as a treatment for NASH, although a 
recent study of metformin in sixty-three patients with NASH found an improvement in ALT after four 
months treatment174. In the MOCA trial, there was no significant effect on liver function.  
Disappointingly there were no significant changes detected in the adipokine concentrations at three 
or six months and this is in contrast to a previous study that have found a decline in leptin in girls 
and an increase in adiponectin associated with improved insulin sensitivity113. It is perhaps 
unsurprising that significant changes in adipokines were not found at six months as there were no 
significant improvement in measures of insulin resistance or sensitivity at six months either. Trends 
were observed in leptin and resistin concentrations with a reduction in the metformin treated group, 
compared with an increase in the placebo group.  
However there was a significant improvement in the A/L ratio after three months in the metformin 
group. This may indicate that A/L ratio is a more sensitive marker of IR than the measures relating 
to insulin and glucose (HOMA-IR and QUICKI), or that changes in the A/L ratio may preceed changes 
in insulin glucose status. The improvement in the A/L ratio was lost at six months and this may again 
be due to reduced compliance with medication, reduced numbers of participants or reduced 
effectiveness of metformin. The value of the A/L ratio as a predictive marker or herald of insulin 
resistance in obese children and adolescents needs to be further investigated. 
Importantly there were no significant changes in lactate or liver function over the course of the 
trial, supporting the safety profile of metformin as a treatment option for up to six months in obese 
children and adolescents. The results suggest that if lactate is normal at the start of treatment, 
there is no need to then monitor lactate during  a short-term treatment course of metformin (<six 
months). In addition there were no serious adverse events and most of the reported side effects of 
metformin settled with a temporary reduction in dose. 
 
Limitations to the study 
There were a number of limitations to the MOCA trial including the drop-out rate, smaller number of 
participants with blood results at both visit one and three, metformin dose and length of treatment, 
difficulty in assessing compliance with treatment and lack of a lifestyle modification arm to the 
trial. 
There was a relatively high drop-out rate in the MOCA trial, although this is comparable to the range 
of drop-out rates quoted in the other metformin trials in obese adolescents (see table 85) and 
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pharmacological intervention trials in adults to prevent T2D175. By visit three at the end of the trial 
just over a quarter of the participant had been lost to follow up, perhaps reflecting the difficulty in 
treating patients with these often intractable problems. The results were analysed on an intention 
to treat basis and analysis of those children who withdrew, compared to those that continued in the 
trial, did not reveal any selective attrition between the groups or significant differences in baseline 
BMI-SDS, thus concluding that the drop-out can be considered entirely random and unrelated to 
starting BMI-SDS or treatment group.  
The study was primarily powered to detect a change in BMI-SDS and there was good attendance from 
one-hundred and ten participants at visit three for auxology measurements. This supported the 
primary outcome of reduction in BMI-SDS, however a much smaller number of participants had the 
full set of blood tests at visit three. The pOGTT is a long test over three hours and requires an 
intravenous cannula. Difficulties with cannulation, small volume of blood obtained and loss of frozen 
samples has resulted in a much smaller than expected number of laboratory results at visit three. 
The number of fasting blood tests at visit three varied between seventy-three and one hundred and 
six depending on the test, however only forty-one participants had insulin measured at 120 minutes 
and only twenty-eight completed the full pOGTT at 180 minutes to allow calculation of the WBISI. 
This relatively small number of participants with blood results at six months may have influenced 
the lack of observed benefit in the laboratory values for the metformin group. However the results 
were analysed on an intention to treat basis in order to account for this.  
A dose of 1.5 g per day was safely used in the MOCA study which may be low compared to the doses 
needed in T2D and may account for the lack of improvement in insulin glucose status at six months. 
Other similar studies in children and adolescents have used a range of doses from 1g to 2g per day. 
In adults with T2D, a dose of 3g per day may be needed to maximise the metabolic effects176. The 
improvement in fasting glucose detected at three months may have been sustained with an increase 
in dose of metformin to 2g per day at this point. Length of treatment may also need to be increased 
in order to achieve sustainable improvements and longer studies (> twelve months) are required. 
However adherence to therapy in teenagers must also be considered and a short term treatment 
course of metformin for three months to kick start improvements in insulin sensitivity and body 
composition, may be a powerful clinical tool to halt increasing adiposity and empower further 
sustainable changes in lifestyle. Compliance in the MOCA trial was monitored with medication diaries 
and by interview at each visit, however formal pill counts were not performed.  
The lack of a lifestyle arm to the MOCA trial was undesirable, however at the time of starting the 
trial there was little evidence to support any particular lifestyle intervention in children or 
adolescents. In addition there were insufficient funds to develop a bespoke intervention for the 
trial. In 2007 a meta-analysis of randomised controlled trials for the treatment of obesity with 
lifestyle intervention concluded that lifestyle interventions were effective at decreasing participants 
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BMI in the short term and there was some evidence for long term positive effects177. Furthermore 
the control groups and patients on waiting lists for treatment of obesity were found to gain weight. 
Therefore without any treatment, it can be expected that patients will gain weight. These findings 
suggest that a treatment programme, such as metformin, that results in improvement or 
maintenance of BMI should be considered in obese children. 
Other similar trials to MOCA have used individual coaching and goal setting alongside treatment with 
metformin or placebo. In the MOCA trial all participants were given standard exercise and healthy 
diet advice at the start, but there were no further lifestyle interventions. Participants were 
discouraged from starting any additional weight loss programme during the trial. The benefit of this 
approach is that the treatment effect of metformin can be considered to be due to the drug alone, 
rather than any lifestyle intervention. Ideally there would have been a third arm to the study for a 
lifestyle intervention and this would be recommended in further studies. 
 
Conclusion 
Childhood obesity is now one of the most common global health problems affecting children in 
developed countries. The significance of this problem is the association between childhood obesity, 
T2D and cardiovascular disease, both in childhood and in adulthood. Treatment programmes that 
reduce obesity and improve insulin glucose status may prevent T2D and cardiovascular disease in this 
population. The two major strategies for management of obesity are lifestyle modification and 
pharmacological therapy. There are a number of small studies demonstrating the safety and efficacy 
of metformin in obese non-diabetic children and adolescents. The MOCA study is the largest double 
blind randomised placebo controlled trial of its kind and the results are important in contributing to 
the evidence regarding the use of metformin in obese non diabetic children and adolescents. 
The MOCA study demonstrates that metformin therapy for children and adolescents with insulin 
resistance associated with obesity is safe, well tolerated and has a beneficial treatment effect over 
placebo for BMI and BMI-SDS at three months which is sustained at six months. In this study the 
metabolic effects were not as evident as in previous studies, however improvements in fasting 
glucose and A/L ratio were detected at three months. In translating the results of the MOCA trial to 
the clinical setting, the MOCA trial provides evidence that a three month treatment course of 1.5 g 
metformin daily may be clinically useful to halt further gain in adiposity, improve fasting glucose 
and A/L ratio and provide a real stimulus for further lifestyle changes to achieve sustainable 
reduction in adiposity and the risks associated with obesity in childhood. 
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Key message: Metformin therapy for obese children with abnormal insulin glucose status is safe, 
well tolerated and has a small beneficial treatment effect over placebo for BMI, BMI-SDS, fasting 
glucose and A/L ratio at three months, with the changes in body composition sustained at six 
months. A three month course of metformin should be considered by Paediatricians to halt the 
inexorable rise in BMI-SDS in these children, improve insulin glucose status and act as catalyst 
and support for more radical change in lifestyle in the individual. 
 
 
 
Table 84: Metformin treatment effects: regression analysis results of primary and secondary outcomes  
 
*P values from regression analysis controlling for treatment group, sex, pubertal status, ethnicity 
and baseline values 
 
 
 
 
 
Visit one  Visit two Visit three Change 
visit two
Change 
visit three 
 Visit one Visit two Visit three Change 
visit two
Change 
visit three
P  value 
visit two
P  value 
visit three
BMI-SDS 3.44 3.35 3.35 -0.09 -0.09 3.34 3.3 3.31 -0.04 -0.03 0.01 0.01
BMI (kg/m2) 37.1 36.56 36.85 -0.54 -0.25 35.95 35.78 36.16 -0.17 0.21 0.01 0.01
Waist:hip ratio 0.92 0.91 0.91 -0.01 -0.01 0.91 0.92 0.91 0.01 0 0.47 0.45
Systolic blood pressure (mm/hg) 119.19 120.43 120.62 1.24 1.43 117.04 117.27 117.78 0.23 0.74 0.22 0.5
Diastolic blood pressure (mm/hg) 65.85 68.21 66.2 2.36 0.35 65.18 66 64.15 0.82 -1.03 0.24 0.36
Fasting insulin (mIU/l) 29 27.83 28.35 -1.17 -0.65 25.17 28.56 28.94 3.39 3.77 0.09 0.45
Fasting glucose (mmol/l) 4.83 4.8 4.79 -0.03 -0.04 4.75 4.84 4.76 0.09 0.01 0.05 0.37
120 minute insulin (mIU/l) 169.7 NA 277.7 NA 108 142.26 NA 119.28 NA -22.98 NA 0.89
120 min glucose (mmol/l) 6.18 NA 5.87 NA -0.31 6.03 NA 5.71 NA -0.32 NA 0.85
HOMA 6.1 6.17 6.7 0.07 0.6 5.45 6.17 5.48 0.72 0.03 0.57 0.4
QUICKI 0.237 0.242 0.24 0.005 0.003 0.243 0.24 0.242 -0.003 -0.001 0.1 0.89
WBISI 1.62 NA 1.51 NA -0.11 2.12 NA 2.09 NA -0.03 NA 0.23
Cholesterol (mmol/l) 4.23 4.13 4.17 -0.1 -0.06 4.15 4.32 4.15 0.17 0 0.09 0.79
HDL (mmol/l) 1.07 1.07 1.12 0 0.05 1 1.07 1.12 0.07 0.12 0.28 0.81
LDL (mmol/l) 2.38 2.41 2.33 0.03 -0.05 2.35 2.48 2.41 0.13 0.06 0.69 0.41
Triglycerides (mmol/l) 1.54 1.41 1.4 -0.13 -0.14 1.66 1.66 1.42 0 -0.24 0.55 0.46
ALT (U/l) 37.51 37.47 32.8 -0.04 -4.71 31.42 31.2 31.52 -0.22 0.1 0.11 0.64
Bilirubin (µmol/l) 7.42 7.51 7.15 0.09 -0.27 7.82 8.29 7.92 0.47 0.1 0.46 0.34
CRP (mg/l) 5.06 4.78 4.8 -0.28 -0.26 4.57 4.02 5.06 -0.55 0.49 0.52 0.78
Lactate (mmol/l) 1.45 1.36 1.4 -0.09 -0.05 1.42 1.32 1.42 -0.1 0 0.5 0.2
Resistin (µ/ml) 13.3 15 12.34 1.7 -0.96 11.5 11.85 12.1 0.35 0.6 0.44 0.23
Adiponectin (mg/l) 11.63 13.81 12.39 2.18 0.76 8.96 8.82 9.9 -0.14 0.94 0.42 0.27
Leptin (µ/ml) 54.25 51.95 50.64 -2.3 -3.61 55.38 57.1 55.82 1.72 0.44 0.13 0.78
A/L ratio 0.3 0.34 0.28 0.04 -0.02 0.26 0.23 0.29 -0.03 0.03 0.03 0.21
PlaceboMetformin P  value*
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Table 85: Summary of Metformin trials in obese non diabetic children and adolescents 
Trial Outcome No of 
participants 
Dropout % Dose of 
Metformin/ 
Lifestyle 
intervention 
Length of 
treatment 
Freemark 
113 
Reduction in BMI, fasting 
insulin, glucose and 
leptin(girls) 
29 10% 500mg bd 
No lifestyle 
intervention 
6 months 
Kay114 Reduction in weight, 
improved insulin sensitivity 
(fasting and 2 hr glucose: 
insulin), reduced leptin, 
cholesterol and 
triglycerides  
24  850mg bd 
Low calorie 
diet 
8 weeks 
Srinivasen115 Reduction in weight, BMI, 
waist circumference, 
fasting insulin 
28 14% total 1g bd 
Standard 
healthy 
eating and 
exercise 
advice 
6 months 
Love-
Osbourne116 
Reduction in weight in girls 85 20% 
metformin 
36% placebo 
850mg bd 
Individual 
lifestyle 
coaching 
6 months 
Wiegand117 No significant results 67  500mg bd 6 months 
Atabek118 Reduction in BMI, fasting 
and 120 min insulin, 
improvement in HOMA-IR 
and QUICKI  
120  
 
 500 mg bd 
Individual 
lifestyle 
coaching 
6 months 
Wilson172 Reduction in BMI 77 30% 1g bd 
extended 
release 
Individual 
lifestyle 
coaching 
48 weeks 
Clarson173 Reduction in BMI, improved 
fasting lipids 
25  Individual 
and group 
lifestyle 
coaching 
6 months 
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Appendices 
 
Appendix 1: Example Invitation letter 
 
Local NHS letter-head 
Local hospital address and telephone number 
Date 
 
Dear Parent or guardian and child’s name, 
   
Re:   Child’s name, DOB and address, 
   
This is a letter of invitation to inquire if you would like your child to take part in this medical trial at 
name of local hospital.  
We have attached a patient and parent information leaflet for your further information. Please 
return the attached slip in the stamped addressed envelope provided. 
 
Please do not hesitate to contact us earlier if you have any questions. 
 
Yours Sincerely, 
 
Name of local investigator  
 
Please detach slip and return in envelope provided 
 
Name of child:   
 
I would like my child to take part in the MOCA Trial    YES/NO 
 
I would like further information before making a decision   YES/NO 
 
If you would like to speak to one of the team directly please provide a day-time telephone number 
or mobile number below: 
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Appendix 2: Example Information sheets for parents, patients and GP’s 
 
Parent Information Sheet 
 
Trial of Metformin in Obese Children with Abnormal Insulin and Glucose Status: 
A Randomised Controlled Trial. 
 
Introduction 
 Your child is being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with your child and others if you wish. Ask us if there is 
anything that is not clear or you would like more information. Take time to decide whether or not 
you wish your child to take part. 
Thank-you for taking the time to read this sheet. 
What is the Purpose of the Study? 
Obesity is an increasing problem in society today. Obesity causes changes in insulin and glucose 
concentrations in the blood, which can ultimately result in type 2 diabetes. Type 2 diabetes is 
associated with increased risk of health problems later in life such as heart disease, high blood 
pressure, eye problems and kidney problems so prevention of type2 diabetes is very important. 
 Studies in obese adults have also shown that treatment with a drug called metformin can prevent or 
delay the progression to type 2 diabetes. 
 We would like to invite your child to help us test if metformin can be used in children to reduce 
their weight and reduce their high insulin levels. In the longer term we will follow up all the children 
in the study to see if they do develop type 2 diabetes.  
Why has my child been chosen? 
 Your child has been chosen for the trial as he/she was referred to the hospital with obesity and has 
already had an oral glucose tolerance test showing high levels of insulin and/or glucose in the blood.  
Does my child have to take part? 
 It is up to you and your child to decide whether or not to take part. If you do decide to allow your 
child to take part you will be given this information sheet to keep and asked to sign a consent form. 
If you decide to allow your child to take part you are free to withdraw your child at any time 
without giving a reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care your child receives. 
What will happen to my child if he/she takes part?  
The study is a randomised controlled double-blinded trial, lasting for 6 months and will involve 
approximately 140 patients. This is a randomised trial because sometimes we do not know which 
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way of treating patients is best and we need to make comparisons. The children will be put into two 
groups by a computer that has no information about the individual ie.by chance. Patients in one 
group will receive metformin and patients in the other group will receive a placebo so that we can 
compare. A placebo is a dummy treatment in the form of a pill that looks very similar to metformin 
but does not contain any active drug. Your child has a one in two chance of receiving metformin 
treatment The treatment is allocated by chance (randomised) and neither you nor your doctor will 
know which pill your child is taking (double-blinded), although the doctor could find out very quickly 
if necessary. 
On the first visit your child will have a full history and examination. You will be asked to bring your 
child first thing in the morning so that fasting blood samples can be taken and the oral glucose 
tolerance test can be repeated. A local anaesthetic cream will be applied before the blood tests if 
required. 
You will be given some written and oral advice about a healthy diet and exercise plan for your child. 
 Once your child has started the pills he/she will attend the outpatient department after 3 months 
and 6 months for weighing, measuring, and blood pressure measurement. Further fasting blood tests 
will be taken at 3 months. The oral glucose tolerance test will be repeated at 6 months together 
with the other blood tests. There will be a questionnaire in the form of a diary about your child‟s 
exercise activity and dietary intake over a 7 day period during the trial.  
We would be happy to pay your travel costs. 
What is the drug being tested? 
 Metformin is a standard drug treatment for type 2 diabetes in children and adults. It lowers blood 
sugar levels. In obese adults it has been shown to delay or prevent progression to type 2 diabetes. 
Your child will be asked to take one pill by mouth per day (500mg) in the morning for 2 weeks and 
then to take 2 pills in the morning and 1 pill in the evening for a total of 6 months (total dose 1.5g). 
What are the alternatives for treatment? 
 Your child needs to lose weight to reduce the risk of health problems now and in the future. Other 
ways to lose weight are diet and exercise or drugs that reduce the amount of fat absorbed by the 
body. These other drugs do have side effects and there are few studies of their use in children. 
What are the side effects of the drug given when taking part in the study? 
Like all medicines, metformin may cause side effects. These may include nausea, loss of appetite 
and abdominal pain. There is a small chance of low blood sugar and you will be informed of the signs 
to look for. In the event of an emergency you should contact your local hospital and tell them that 
your child is taking part in the study. We would check for any side effects at every visit. If your child 
has any problems let the doctor know at once. The telephone number of the doctors involved in the 
trial is given at the end of this leaflet .The regular blood tests and clinic visits are there for your 
child‟s safety. If your doctor is concerned at any time she would take your child out of the study. 
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Are there any possible benefits? 
 It is hoped that your child‟s insulin levels will improve and that your child will lose weight, however 
this cannot be guaranteed. The information that we get from the study will help us gain knowledge 
about the treatment of obesity and prevention of type 2 diabetes in the future. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the 
drug that is being studied. If this happens your research doctor will tell you about it and discuss with 
you whether you want your child to continue in the study. If you decide to withdraw your child the 
research doctor will make arrangements for your child‟s care to continue. If you decide to let your 
child continue in the study you will be asked to sign an updated consent form. 
 Also, on receiving new information your research doctor might consider it to be in your child‟s best 
interests to withdraw your child from the study. They will explain the reasons and arrange for your 
care to continue. 
What happens when the research study stops? 
Your child will offered continuing follow up in outpatients. Metformin treatment can be continued as 
part of your child‟s routine NHS care after the trial stops, if it is considered appropriate for your 
child‟s medical care. 
What if something goes wrong? 
If you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanism will be available to you. 
Will my child taking part in this study be kept confidential? 
 Your child‟s medical records will remain confidential. The records will be held securely for up to 20 
years and accessed only by researchers involved, from within the hospital trust. Any information 
about your child that leaves the hospital will have your child‟s name and address removed so that 
they cannot be recognised from it. 
With your permission, we would want to inform your GP that your child is taking part. 
What will happen to the results of the research study? 
We anticipate that the results of the study will be published in a medical journal the following year 
after the study has finished. Copies of published results will be made available to you. You will be 
informed which treatment arm of the study your child was in at the end of the trial. The results will 
be analysed in an anonymous form and any publication in a medical journal will not allow the 
identification of individuals. 
Who is organising and funding the research? 
The research is being organised by Dr. Catherine Hall (Consultant Paediatric  Endocrinologist) and 
Dr. Debbie Clough ( Paediatric Specialist Registrar) from Pendlebury Children‟s Hospital in 
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Manchester (Central Manchester Children‟s NHS Trust), but all the tests will be done at your local 
children‟s hospital. These doctors are doing the research as part of their jobs and will not receive 
any extra payment for doing it. 
 Funding for the research has been sought from charities that fund medical research and from 
pharmaceutical companies with an interest in childhood diabetes. 
What do I do now? 
The research doctor organising the trial will contact you in a few days. She can answer any questions 
and you can let her know if you are interested in allowing your child to take part. If you do decide to 
allow your child to take part in the study then you will be asked to sign a consent form. You will be 
given a copy of this leaflet and the consent form to keep for your information. 
Your child has also been given a leaflet to read with information about the trial. Please discuss this 
information with your child and the rest of the family, friends or GP if you wish.  
Ethical Committee Approval 
This study has been given ethical approval from the Salford and Trafford Local Research Ethics 
Committee and the local ethical research committee in your area. 
  
Patient Information Sheet for children aged 13-18 years 
 
Trial of Metformin in Obese Children with Abnormal Insulin and Glucose Status:  
A Randomised Controlled Trial 
 
Introduction 
We want to tell you about a project, which we are asking you to take part in. We have already 
spoken to your parents or carers about this and they have their own information sheet. It is 
important that you understand what this project is about and feel happy to take part.  
You were referred to hospital because you are overweight and you have already had some tests 
done. Some children and young people who are overweight have other problems with their health 
such as diabetes when the levels of sugar in the blood are high. The aim of this project is to 
establish whether taking a medication called metformin every day can help to you to lose weight 
and improve your blood test results. 
 What does the study involve? 
 If you agree to take part in this project you will come to the hospital with your parents for a 
morning. You will be examined by a doctor and have some tests done including a test when you have 
to take a sugary drink. You can have anaesthetic cream put on your skin before the blood tests so 
that there will only be a little pain when the blood is taken. 
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The project will last for 6 months and will involve about 140 children.You will take either a pill 
called metformin for 6 months or another pill called a placebo for 6 months. A placebo is a pill that 
looks exactly the same as metformin but does not contain any medicine. You have a one in two 
chance of receiving metformin. Neither you nor your doctor will know which pill you are taking at 
the time. You will take one pill in the morning before breakfast and one pill in the evening before 
your evening meal. You will be told about healthy food to eat and we will ask you to try and do 30 
minutes of exercise, like walking, every day. 
 You will come back to the hospital after 3 and 6 months to have blood tests and to be weighed, 
measured and have your blood pressure taken. The sugary drink test will be repeated at 6 months. 
What are the potential benefits? 
Taking part in this project may have no immediate direct benefit to you, but we are hoping that you 
will lose weight and that your blood test results will get better. This cannot be guaranteed as you 
may be allocated to take the placebo instead of metformin. 
What are the potential risks? 
 Metformin is a very safe medication but sometimes people get tummy aches or feel sick. We will 
check for these side effects when you come to hospital every month. There  
is a very small chance of a low blood sugar level and you will be told of the symptoms to look out 
for. If you have any problems please tell your parents and they will tell the doctor at once. 
Do I have to take part? 
No, any decision to take part in this project is entirely up to you and your parents. You do not have 
to give a reason if you do not want to take part. Your doctor will not be upset and your care will not 
be affected. If you take part but then either you or your parents change your mind you can be 
withdrawn from the project at any time. You do not have to give a reason and your future medical 
care will not be affected in any way. 
Confidentiality. 
Your medical records will be held in a secure place for up to 20 years and only looked at by your own 
doctor or doctors and nurses involved in the project. The results will be analysed without your 
name. This project might give us some important information that we may want to publish in a 
medical journal. Your personal details will never be published. With your parents and your 
permission we will inform your family doctor that you are taking part in the project. 
What do I do now? 
The research doctor organising the project will contact you and your parents in a few days. She can 
answer any questions and you can let her know if you are interested in taking part. Your parents will 
be asked to sign a consent form. 
 Thank you for thinking about taking part in this research project. Please discuss this information 
with your parents, family and friends if you wish. 
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GP Information Sheet 
 
Trial of Metformin in Obese Children with Abnormal Insulin and Glucose Status: 
 A Randomised Controlled Trial. 
 
Introduction 
 In the last decade there has been an emergence of type 2 diabetes in children. The increase in 
diagnosis parallels the increase in the global prevalence of obesity. Insulin resistance can now be 
recognised as a distinct clinical entity and is the underlying endocrinopathy of type 2 diabetes. 
Obesity is accompanied by insulin resistance and by resulting hyperinsulinaemia. Hyperglycaemia is a 
later manifestation of long standing insulin resistance. 
The relationship between obesity and disordered glucose metabolism has been demonstrated in 
childhood. A recent study by our group of 42 obese children in Manchester showed that 26% had 
impaired glucose tolerance and 7% were diabetic. 
Prevention of type 2 diabetes is clearly a priority and can be targeted at those who are obese and 
already at risk. There are 3 major adult randomised controlled trials that show lifestyle intervention 
can prevent or delay the progression to type 2 diabetes in obese children with impaired glucose 
tolerance (IGT). The Diabetes Prevention Program research Group in America has shown a 31% 
reduction in type 2 diabetes in obese patients with IGT who are treated with metformin. 
There are very few studies of treatment options or preventative strategies in children. Lifestyle 
intervention strategies such as dietary modification and exercise are of limited success due to poor 
compliance. 
 Metformin is a biguanide with a primary action to reduce hepatic glucose output and a secondary 
action to reduce peripheral insulin resistance. The drug is licensed for use in children with type 2 
diabetes and has been found to be both a safe and effective treatment. 
What is the trial? 
 We propose a prospective randomised double blind placebo controlled trial to study the effects of 
metformin in obese children and adolescents with fasting hyperinsulinaemia. 
 Obese children referred to the endocrine clinic with BMI> 98th centile will investigated with an oral 
glucose tolerance test and other routine blood tests. Children will then be recruited to the trial 
according to the inclusion and exclusion criteria. 
The children will be admitted as a daycase at your local children‟s hospital for baseline 
investigations and then randomised to receive either metformin or placebo. They will take the 
medication for 6 months and return to outpatients on at 3 and 6 months. Further blood tests will be 
taken at 3 months and all the initial investigations will be repeated after 6 months of medication. 
The trial is double blinded so that neither the patient nor the doctors will know what the child is 
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taking. However if there is an emergency we can find out immediately. The medication will all be 
provided by the hospital. 
What are the side effects of the treatment? 
Metformin has been shown to be a very safe drug with very few side effects. The most commonly 
reported problems are nausea and abdominal pains. There have been episodes of lactic acidosis in 
adults with intercurrent hypoxic illnesses or dehydration but this has not been reported in children. 
We will monitor lactate levels. There is also a very small risk of hypoglycaemia and the family will 
be told of the signs to look for and action to take. 
What are the benefits of the treatment? 
We hope that the patients who are treated with metformin will lose weight and that their 
hyperinsulinaemia will improve. In the longer term we hope to monitor for the development of type 
2 diabetes. 
 We also hope to develop protocols for the management of obesity in childhood. 
Ethical Committee Approval 
Ethical approval has been granted from the Salford and Trafford MREC and the local research ethics 
committee in your area. 
 
Patient Information Sheet for Children aged 8-12 years. 
 
Trial of Metformin in Obese Children with Abnormal Insulin and Glucose status:  
A Randomised ControlledTrial. 
 
We want to tell you about a project, which we are asking you to take part in. We have already 
spoken to your parents or carers about this and they have their own information sheet. It is 
important that you understand what this project is about and feel happy to take part. 
What is the project about? 
 Some children who are overweight have other problems with their health such as diabetes when the 
levels of sugar in the blood are high. We would like to find out if taking a pill every day could help 
you to lose weight and to make your blood test results better.  
What will I have to do? 
You will come into the hospital with your parents or carers for a morning to have some more blood 
tests and to have another test where you have to take a sugary drink. You will also be examined by a 
doctor. 
You will be told about healthy food to eat and we will ask you to try and do 30 minutes of exercise, 
like walking, every day. 
You will then be given a pill to take every day, in the morning and in the evening. 
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You will come back for more blood tests after 3 months of taking the pill and after 6 months you will 
come back in for the morning to have blood tests and to repeat the sugary drink test. 
Will it hurt? 
Before you have any blood tests done we will put some special cream on your hand so that there will 
only be a little pain when you have blood taken. 
Sometimes the pills can make people have tummy pains or to feel unwell. If you have any problems 
like this please tell your parents or carers straight away and they can tell the doctors. 
Do I have to take part? 
 No, you can talk about this project with your family and decide together if you want to take part. If 
you decide not to take part you will still be seen at the hospital and we will still look after your 
medical problems. Also you can stop taking part in the project at any point and you do not have to 
tell us why. 
Your notes will only be seen by the doctors and nurses involved in the project.  When we look at the 
results at the end of the project your name will not be looked at. We hope that we will be able to 
put the results of the project in a scientific journal but your name will never be put in the results. 
 What do I do now? 
The project doctor organising the trial will contact you and your parents in a few days. She can 
answer any questions and you can let her know if you are interested in taking part. Your parents will 
be asked to sign a consent form. 
Thank you for thinking about taking part in this project. Please discuss this information with your 
parents, family and friends if you wish. 
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Appendix 3: Example Consent Form 
Centre Number:                 Study Number:                  Patient Identification Number: 
CONSENT FORM 
 
Title of Project: Metformin in Obese Children with abnormal Glucose and Insulin Status: 
 A Randomised Controlled Trial 
Name of researcher:  Name of local investigator 
 
         Please initial box 
1. I confirm that I have read and understand the information sheet dated June 2004 (version 2) for 
the above study and had the opportunity to ask questions      
                
2. I understand that my child‟s participation is voluntary and that I am free to withdraw my child at 
any time, without giving any reason, without my child‟s medical care or legal rights being 
affected  
 
3. I understand that sections of any of my child‟s medical notes may be looked at by a responsible 
individual (doctor or nurse) from the research team based at Pendlebury Children‟s Hospital or 
from regulatory authorities where it is relevant to my child taking part.  
 
4. I agree for my child to take part in the above study  
 
______________________________________________________________________________________ 
Child‟s name and date of birth Date   Signature of assent 
 
Name of parent  Date   Signature 
 
Name of person taking consent Date   Signature 
 
______________________________________________________________________________________
Researcher  Date   Signature 
 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes 
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Appendix 4: Prolonged OGTT protocol 
 
Prolonged Glucose Tolerance Test for the MOCA Trial 
 
Indications 
As part on the MOCA trial, this test is performed at visit one (baseline) and visit three (six months). 
Consent to participate in the trial must have been elicited before commencing the test. 
This test can also be used for the diagnosis of diabetes mellitus or impaired glucose tolerance, 
specifically in patients in whom random and fasting levels of glucose are not diagnostic. 
Precautions/Preparation 
The diet over the preceeding 3 days should contain adequate carbohydrate (approx 60% of calories). 
The patient should be fasted overnight for 10-14 hours (plain water allowed) and should rest 
throughout the test. 
Protocol 
1. Prepare the glucose load. 
This is 1.76g/kg anhydrous glucose (maximum dose 75g) or 1.92g/kg glucose monohydrate 
(maximum dose 82.5g). 
Dissolve in 100-200ml water. 
In teenage patients on maximum dose the volume of water may be increased to 300ml. 
2. Insert an intravenous cannula and take a basal sample for glucose (t=0) and insulin. 
3. The child should drink the glucose load over a period of about 5 minutes. Record the time on 
the form. 
4. Take further blood samples for glucose and insulin every 30 minutes up to 180 minutes after 
finishing the glucose drink. 
Samples 
Glucose: 0.5 ml venous blood in a fluoride oxalate tube at 0 min, 30 min, 60 min, 90 min, 
120 min, 150 min and 180 min. 
Insulin: 1 ml in a lithium heparin, orange-capped tube at 0 min, 30 min, 60 min, 90 min, 120 
min, 150 min and 180 min. Samples must be placed in a mixture of water and ice and sent 
to the laboratory immediately. The lab must be contacted prior to sending the sample. 
If the sample is being sent to RMCH it should be centrifuged and plasma/serum separated 
and stored at -80°C. It will need to be transferred frozen on ice. 
Please inform the RMCH lab before sending the sample on 0161 922 2262. 
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Appendix 5: Instructions for taking MOCA trial medication 
 
Take 1 tablet (500mg) per day for one week, then 1 tablet (500mg) in the morning and 1 tablet 
(500mg) in the evening for one week, then 2 tablets (1g) in the morning and 1 tablet (500mg) in the 
evening thereafter.  
Take the tablets before your breakfast and evening meals. 
Avoid alcohol. 
There is a very small risk of a low blood sugar.  
If you have any of the following symptoms: sudden onset of shakiness, sweating, feeling sick, light-
headed or unexplained collapse then you need to have a sugary drink such as coca-cola, orange juice 
or milk with a biscuit and contact your doctor. 
 
Appendix 6: Medication diary example three months 
 
 
 
 
Appendix 7: Minutes of a Trial Steering Committee meeting 
 
MOCA Steering Committee Minutes     19th December 2009 
         
Attendees 
Henry Kitchener (HK) -Chair 
Catherine Hall (CH) 
Neil Wright 
Medication Diary 2009
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
am pm am pm am pm am pm am pm am pm am pm
January 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31
February 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28
March 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31
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Steve Roberts 
Debbie Kendall 
Julian Davis 
Lynne Webster 
 
Agenda 
 
1. Announcements and apologies 
The Trial Steering Committee was set up on behalf of the Trust to support the trial and assure 
CMMC, as sponsors, that the trial is on track and that it is being run well. 
 
2. Progress report 
Rationale, progress and bringing up to date. 
MOCA arose out of clinical experience, many obese children with lack of evidence regarding early 
intervention. (Freemark study). 2004 -protocol and funding run in Manchester, Sheffield, Leeds, Hull 
and Middleborough. The first WTCRF recruit was in Manchester, in 2005.  
RCT- of Metformin as a means of achieving weight loss in 8-18 yr olds. 
Aims – the primary outcome was a change in BMI at 6 months. What would be recommended to 
patients if the study showed a decrease? Nobody knows if stopping the medication will have a 
prolonged benefit, or if prospective metformin given how long a patient would have to be on the 
drug.  
Asked if 6m long enough? CH believed sufficient to show an effect, also an effective enough dose.  
The trial has become more important as metaformin is now being used in practice.  
Is the trial still a valid question scientifically in 2008? 
A meta analysis has been published on trials of metformin and the overall treatment effect was 
small.  Uncertainty, therefore, remains regarding its use.  The TMG feel strongly that MOCA remains 
important and this was accepted by the TSC. 
Tim Cole (Statistician) advice discussed regarding what is a clinically significant change? Is SDS most 
appropriate? It was agreed that 0.3 was an appropriate measure. 
Age relevance was discussed, as patients ranged from 8 to 18 years old, stratification was used 
looking at BMI, age, sex and puberty.  Power was originally calculated on whole group without 
stratification as researchers thought too many patients would then have to be involved. Stratified to 
stop bias. 
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Patient accrual 
114 recruited (randomised) out of a target of 140. About 2 patients per month.  
Randomised 114.  
Recruitment would be required for about another year, in the 2 major recruiting centres 
(Manchester and Sheffield) there have been funding/staff changes (in Manchester the Research 
Fellow has moved on).  Sheffield now has funding to recruit 50 eligible participants. Ethics 
applications have been completed for Coventry and Birmingham. 
The investigators are confident that by the end of 2009 recruitment will be completed.  
 
Attrition 
Analysis will be based on “Intention to treat”.  To date, 22% drop out rate (25 patients).  Sheffield - 
15 finished. Manchester - 53 finished, 20 withdrawn, 6 ongoing. 
Similar attrition expected in future recruitment. 
SR expressed concerns over drop-out rate regarding whether it is random or possible that those 
doing less well may drop out so the results would become biased. TSC felt that enhanced accrual 
would be required to compensate for attrition in loss to follow-up. 
Investigators explained that MCRN has adopted study so there is scope for a larger cohort of patients 
to be recruited. 
TSC recommended that BMI measurements should try to be obtained from drop out population. 
Researchers should encourage them to come back for BMI measurement only to improve data. 
Recording data- DK records data from CRF onto a database for all centres. Currently there is no data 
validation system.  Suggested that MCRN may support data validation as they have adopted study. 
 
3. Finance 
Flexibility and Sustainability Funding (FSF) available that would support DK for 1 day a week from 
Jan - June 2009.  
Child Growth Foundation – 3 day/week July 2009 – June 2010 (£38,000) 
Funding would support completing trial and trial analysis with writing up. 
Two options suggested- 140pts as originally perceived or 80 patients in trial with 0.25 BMI SDI.  
HK raised question as to whether employing DK would be the best use of the fund or whether it 
would be better to consider a Trial co-ordinator or data manager.  
 
Recommendations of TSC 
 With new centres about to start/reactivate it seems possible that the accrual target of 140 
may be reached by mid 2009.  In view of the 20-25% loss of primary outcome data through 
loss to follow-up, the TSC recommends that the Trial Management Group try to achieve 
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additional accrual to 165 by the end of 2009.  With follow-up, this would mean the trial 
would complete by mid 2010.  a substantial amendment should be sought from the Ethics 
committee to grant accrual to continue to 165. 
 The TSC recommends that consideration is given by the TMG on how efficiently to utilise the 
available resource- a non-clinical co-ordinator may be a better use of funds. 
 The TSC recommend to ensure as much BMI data as possible is collected (include drop outs –
making concerted effort) to improve data analysis. 
 The TSC request a progress report in June 09, with accrual and any problems encountered. 
 Next meeting in a years time, unless precipitated by the above report.  
 
The TMG remain very committed to MOCA and with recently obtained external funding and new 
centres, are confident it can be satisfactorily concluded.  The TSC accepts that the trial remains 
important and should be continued, not only to the original accrual target, but with an additional 
10-20% to allow for attrition.  The governance arrangements appear satisfactory. 
 
Appendix 8: E-mail from MHRA regarding trial re-start 
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Appendix 9: Standardised Exercise advice 
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Appendix 10: Standardised Healthy Eating Advice 
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